US20170100607A1 - Fibers in therapy and cosmetics - Google Patents
Fibers in therapy and cosmetics Download PDFInfo
- Publication number
- US20170100607A1 US20170100607A1 US15/389,655 US201615389655A US2017100607A1 US 20170100607 A1 US20170100607 A1 US 20170100607A1 US 201615389655 A US201615389655 A US 201615389655A US 2017100607 A1 US2017100607 A1 US 2017100607A1
- Authority
- US
- United States
- Prior art keywords
- materials
- fiber
- derivatives
- treatment
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000835 fiber Substances 0.000 title claims abstract description 234
- 239000002537 cosmetic Substances 0.000 title claims abstract description 53
- 238000002560 therapeutic procedure Methods 0.000 title description 11
- 238000011282 treatment Methods 0.000 claims abstract description 130
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 64
- 201000010099 disease Diseases 0.000 claims abstract description 60
- 238000011321 prophylaxis Methods 0.000 claims abstract description 48
- 238000003745 diagnosis Methods 0.000 claims abstract description 20
- 239000000463 material Substances 0.000 claims description 238
- 206010000496 acne Diseases 0.000 claims description 68
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 57
- 229910052751 metal Inorganic materials 0.000 claims description 46
- 239000002184 metal Substances 0.000 claims description 46
- 230000005855 radiation Effects 0.000 claims description 41
- 238000002347 injection Methods 0.000 claims description 33
- 239000007924 injection Substances 0.000 claims description 33
- 230000000903 blocking effect Effects 0.000 claims description 26
- 206010023126 Jaundice Diseases 0.000 claims description 24
- 238000002428 photodynamic therapy Methods 0.000 claims description 21
- 201000004624 Dermatitis Diseases 0.000 claims description 18
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 18
- 206010061218 Inflammation Diseases 0.000 claims description 15
- 230000005525 hole transport Effects 0.000 claims description 15
- 230000004054 inflammatory process Effects 0.000 claims description 15
- 201000004681 Psoriasis Diseases 0.000 claims description 14
- 208000017520 skin disease Diseases 0.000 claims description 14
- 208000035484 Cellulite Diseases 0.000 claims description 13
- 206010030113 Oedema Diseases 0.000 claims description 13
- 206010049752 Peau d'orange Diseases 0.000 claims description 13
- 230000036232 cellulite Effects 0.000 claims description 13
- 206010047642 Vitiligo Diseases 0.000 claims description 12
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 11
- 201000008937 atopic dermatitis Diseases 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 208000010668 atopic eczema Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 8
- 230000000926 neurological effect Effects 0.000 claims description 7
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 6
- 206010027476 Metastases Diseases 0.000 claims description 4
- 208000009621 actinic keratosis Diseases 0.000 claims description 4
- 208000006934 radiodermatitis Diseases 0.000 claims description 4
- 206010003139 Arsenical keratosis Diseases 0.000 claims description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 3
- 208000013165 Bowen disease Diseases 0.000 claims description 3
- 208000019337 Bowen disease of the skin Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 239000008204 material by function Substances 0.000 abstract description 74
- 238000002360 preparation method Methods 0.000 abstract description 17
- 239000010410 layer Substances 0.000 description 142
- -1 poly(p-phenylene vinylene) Polymers 0.000 description 83
- 210000003491 skin Anatomy 0.000 description 74
- 150000001875 compounds Chemical class 0.000 description 68
- 229920000642 polymer Polymers 0.000 description 65
- 239000000203 mixture Substances 0.000 description 59
- 238000001126 phototherapy Methods 0.000 description 31
- 125000003118 aryl group Chemical group 0.000 description 29
- 230000032683 aging Effects 0.000 description 28
- 239000003814 drug Substances 0.000 description 25
- 239000011505 plaster Substances 0.000 description 23
- 230000001225 therapeutic effect Effects 0.000 description 23
- 238000000151 deposition Methods 0.000 description 22
- 229940079593 drug Drugs 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 201000004700 rosacea Diseases 0.000 description 20
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 17
- 229920000547 conjugated polymer Polymers 0.000 description 17
- 230000006870 function Effects 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 208000027418 Wounds and injury Diseases 0.000 description 16
- 230000008021 deposition Effects 0.000 description 16
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 16
- 230000032258 transport Effects 0.000 description 16
- 239000002019 doping agent Substances 0.000 description 15
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
- 239000000758 substrate Substances 0.000 description 15
- 125000005259 triarylamine group Chemical group 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 14
- 206010052428 Wound Diseases 0.000 description 14
- 238000004768 lowest unoccupied molecular orbital Methods 0.000 description 14
- 229930192474 thiophene Natural products 0.000 description 14
- 241001303601 Rosacea Species 0.000 description 13
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Natural products C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 13
- 229920001577 copolymer Polymers 0.000 description 13
- 238000004770 highest occupied molecular orbital Methods 0.000 description 13
- 125000003983 fluorenyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 206010040954 Skin wrinkling Diseases 0.000 description 11
- 150000001454 anthracenes Chemical class 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000011229 interlayer Substances 0.000 description 11
- 239000011159 matrix material Substances 0.000 description 11
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 11
- 150000003384 small molecules Chemical class 0.000 description 11
- ICPSWZFVWAPUKF-UHFFFAOYSA-N 1,1'-spirobi[fluorene] Chemical class C1=CC=C2C=C3C4(C=5C(C6=CC=CC=C6C=5)=CC=C4)C=CC=C3C2=C1 ICPSWZFVWAPUKF-UHFFFAOYSA-N 0.000 description 10
- 150000004982 aromatic amines Chemical class 0.000 description 10
- 239000004020 conductor Substances 0.000 description 10
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 10
- PJULCNAVAGQLAT-UHFFFAOYSA-N indeno[2,1-a]fluorene Chemical class C1=CC=C2C=C3C4=CC5=CC=CC=C5C4=CC=C3C2=C1 PJULCNAVAGQLAT-UHFFFAOYSA-N 0.000 description 10
- 238000004659 sterilization and disinfection Methods 0.000 description 10
- DXBHBZVCASKNBY-UHFFFAOYSA-N 1,2-Benz(a)anthracene Chemical class C1=CC=C2C3=CC4=CC=CC=C4C=C3C=CC2=C1 DXBHBZVCASKNBY-UHFFFAOYSA-N 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 229910052782 aluminium Inorganic materials 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 150000001716 carbazoles Chemical class 0.000 description 9
- 239000000412 dendrimer Substances 0.000 description 9
- 229920000736 dendritic polymer Polymers 0.000 description 9
- 238000003618 dip coating Methods 0.000 description 9
- MILUBEOXRNEUHS-UHFFFAOYSA-N iridium(3+) Chemical compound [Ir+3] MILUBEOXRNEUHS-UHFFFAOYSA-N 0.000 description 9
- 150000002576 ketones Chemical class 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 8
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 230000007704 transition Effects 0.000 description 8
- TVIVIEFSHFOWTE-UHFFFAOYSA-K tri(quinolin-8-yloxy)alumane Chemical compound [Al+3].C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1 TVIVIEFSHFOWTE-UHFFFAOYSA-K 0.000 description 8
- 230000037303 wrinkles Effects 0.000 description 8
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000010949 copper Substances 0.000 description 7
- 210000001508 eye Anatomy 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 229910052741 iridium Inorganic materials 0.000 description 7
- 239000002346 layers by function Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 229910052763 palladium Inorganic materials 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 208000012672 seasonal affective disease Diseases 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 229910019655 synthetic inorganic crystalline material Inorganic materials 0.000 description 7
- 150000003577 thiophenes Chemical class 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- 150000003918 triazines Chemical class 0.000 description 7
- UWRZIZXBOLBCON-VOTSOKGWSA-N (e)-2-phenylethenamine Chemical compound N\C=C\C1=CC=CC=C1 UWRZIZXBOLBCON-VOTSOKGWSA-N 0.000 description 6
- POILWHVDKZOXJZ-ARJAWSKDSA-M (z)-4-oxopent-2-en-2-olate Chemical compound C\C([O-])=C\C(C)=O POILWHVDKZOXJZ-ARJAWSKDSA-M 0.000 description 6
- BGEBZHIAGXMEMV-UHFFFAOYSA-N 5-methoxypsoralen Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC BGEBZHIAGXMEMV-UHFFFAOYSA-N 0.000 description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 0 [1*]C1=C2N(C3=C(C)C(C)=C(C)C(C)=C3C)C3=N4C(=C([10*])C([9*])=C3[8*])C3=C(C([14*])=C([13*])C([12*])=C3[11*])[Pt]43C4=C([7*])C([6*])=C([5*])C([4*])=C4C(=N23)C([3*])=C1[2*] Chemical compound [1*]C1=C2N(C3=C(C)C(C)=C(C)C(C)=C3C)C3=N4C(=C([10*])C([9*])=C3[8*])C3=C(C([14*])=C([13*])C([12*])=C3[11*])[Pt]43C4=C([7*])C([6*])=C([5*])C([4*])=C4C(=N23)C([3*])=C1[2*] 0.000 description 6
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 150000004696 coordination complex Chemical class 0.000 description 6
- 229910052802 copper Inorganic materials 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000005401 electroluminescence Methods 0.000 description 6
- 238000005538 encapsulation Methods 0.000 description 6
- 239000010408 film Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 229910052697 platinum Inorganic materials 0.000 description 6
- 229920003227 poly(N-vinyl carbazole) Polymers 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- UWRZIZXBOLBCON-UHFFFAOYSA-N styrylamine group Chemical group C(=CC1=CC=CC=C1)N UWRZIZXBOLBCON-UHFFFAOYSA-N 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 229910052723 transition metal Inorganic materials 0.000 description 6
- 150000003624 transition metals Chemical class 0.000 description 6
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 5
- 208000002782 Acneiform Eruptions Diseases 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 208000004631 alopecia areata Diseases 0.000 description 5
- 125000005577 anthracene group Chemical group 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229910052792 caesium Inorganic materials 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 238000005286 illumination Methods 0.000 description 5
- 150000002460 imidazoles Chemical class 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 229910052762 osmium Inorganic materials 0.000 description 5
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical class N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 5
- 229920000553 poly(phenylenevinylene) Polymers 0.000 description 5
- 150000004032 porphyrins Chemical class 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- YYMBJDOZVAITBP-UHFFFAOYSA-N rubrene Chemical class C1=CC=CC=C1C(C1=C(C=2C=CC=CC=2)C2=CC=CC=C2C(C=2C=CC=CC=2)=C11)=C(C=CC=C2)C2=C1C1=CC=CC=C1 YYMBJDOZVAITBP-UHFFFAOYSA-N 0.000 description 5
- 239000004065 semiconductor Substances 0.000 description 5
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 5
- 125000005504 styryl group Chemical group 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 4
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 208000032544 Cicatrix Diseases 0.000 description 4
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 206010016936 Folliculitis Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 201000006346 Neonatal Jaundice Diseases 0.000 description 4
- 208000009675 Perioral Dermatitis Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 206010039580 Scar Diseases 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 150000001556 benzimidazoles Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- VPUGDVKSAQVFFS-UHFFFAOYSA-N coronene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3)C4=C4C3=CC=C(C=C3)C4=C2C3=C1 VPUGDVKSAQVFFS-UHFFFAOYSA-N 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- XNKVIGSNRYAOQZ-UHFFFAOYSA-N dibenzofluorene Chemical compound C12=CC=CC=C2C2=CC=CC=C2C2=C1CC1=CC=CC=C12 XNKVIGSNRYAOQZ-UHFFFAOYSA-N 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 210000004177 elastic tissue Anatomy 0.000 description 4
- 238000001194 electroluminescence spectrum Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000003822 epoxy resin Substances 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 4
- 150000008376 fluorenones Chemical class 0.000 description 4
- 239000011888 foil Substances 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- VVVPGLRKXQSQSZ-UHFFFAOYSA-N indolo[3,2-c]carbazole Chemical class C1=CC=CC2=NC3=C4C5=CC=CC=C5N=C4C=CC3=C21 VVVPGLRKXQSQSZ-UHFFFAOYSA-N 0.000 description 4
- 229960005544 indolocarbazole Drugs 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- 201000005962 mycosis fungoides Diseases 0.000 description 4
- 210000000282 nail Anatomy 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 4
- 150000004866 oxadiazoles Chemical class 0.000 description 4
- MPQXHAGKBWFSNV-UHFFFAOYSA-N oxidophosphanium Chemical class [PH3]=O MPQXHAGKBWFSNV-UHFFFAOYSA-N 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229960003540 oxyquinoline Drugs 0.000 description 4
- 150000002987 phenanthrenes Chemical class 0.000 description 4
- 150000005041 phenanthrolines Chemical class 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920000647 polyepoxide Polymers 0.000 description 4
- 229920000123 polythiophene Polymers 0.000 description 4
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229910052703 rhodium Inorganic materials 0.000 description 4
- 229910052709 silver Inorganic materials 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 150000003462 sulfoxides Chemical class 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 239000011787 zinc oxide Substances 0.000 description 4
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 3
- BUNGCZLFHHXKBX-UHFFFAOYSA-N 8-methoxypsoralen Natural products C1=CC(=O)OC2=C1C=C1CCOC1=C2OC BUNGCZLFHHXKBX-UHFFFAOYSA-N 0.000 description 3
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 3
- LTUJKAYZIMMJEP-UHFFFAOYSA-N 9-[4-(4-carbazol-9-yl-2-methylphenyl)-3-methylphenyl]carbazole Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1C1=CC=C(C=2C(=CC(=CC=2)N2C3=CC=CC=C3C3=CC=CC=C32)C)C(C)=C1 LTUJKAYZIMMJEP-UHFFFAOYSA-N 0.000 description 3
- ZYASLTYCYTYKFC-UHFFFAOYSA-N 9-methylidenefluorene Chemical compound C1=CC=C2C(=C)C3=CC=CC=C3C2=C1 ZYASLTYCYTYKFC-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229910052684 Cerium Inorganic materials 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 241000186427 Cutibacterium acnes Species 0.000 description 3
- 238000003775 Density Functional Theory Methods 0.000 description 3
- 206010051651 Dermatitis papillaris capillitii Diseases 0.000 description 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 206010023129 Jaundice cholestatic Diseases 0.000 description 3
- 206010023138 Jaundice neonatal Diseases 0.000 description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 3
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 3
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 206010054107 Nodule Diseases 0.000 description 3
- 201000005267 Obstructive Jaundice Diseases 0.000 description 3
- 206010033733 Papule Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 3
- NRCMAYZCPIVABH-UHFFFAOYSA-N Quinacridone Chemical compound N1C2=CC=CC=C2C(=O)C2=C1C=C1C(=O)C3=CC=CC=C3NC1=C2 NRCMAYZCPIVABH-UHFFFAOYSA-N 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 229910052768 actinide Inorganic materials 0.000 description 3
- 150000001255 actinides Chemical class 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 150000001342 alkaline earth metals Chemical class 0.000 description 3
- 229910045601 alloy Inorganic materials 0.000 description 3
- 239000000956 alloy Substances 0.000 description 3
- 150000008425 anthrones Chemical class 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 3
- 229960002045 bergapten Drugs 0.000 description 3
- KGZDKFWCIPZMRK-UHFFFAOYSA-N bergapten Natural products COC1C2=C(Cc3ccoc13)C=CC(=O)O2 KGZDKFWCIPZMRK-UHFFFAOYSA-N 0.000 description 3
- 235000010290 biphenyl Nutrition 0.000 description 3
- 239000004305 biphenyl Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical group [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 210000001953 common bile duct Anatomy 0.000 description 3
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 3
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 3
- 125000004986 diarylamino group Chemical group 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 210000004904 fingernail bed Anatomy 0.000 description 3
- 239000013305 flexible fiber Substances 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 3
- 150000007857 hydrazones Chemical class 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000007641 inkjet printing Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229960005280 isotretinoin Drugs 0.000 description 3
- 229910052747 lanthanoid Inorganic materials 0.000 description 3
- 150000002602 lanthanoids Chemical class 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 3
- 229960003987 melatonin Drugs 0.000 description 3
- 229910044991 metal oxide Inorganic materials 0.000 description 3
- 150000004706 metal oxides Chemical class 0.000 description 3
- 229960004469 methoxsalen Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000037230 mobility Effects 0.000 description 3
- 229910052750 molybdenum Inorganic materials 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 238000013021 overheating Methods 0.000 description 3
- 150000002916 oxazoles Chemical class 0.000 description 3
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 3
- CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 3
- 125000001791 phenazinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 3
- 150000004986 phenylenediamines Chemical class 0.000 description 3
- 229920000548 poly(silane) polymer Polymers 0.000 description 3
- 229920001721 polyimide Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 150000003220 pyrenes Chemical class 0.000 description 3
- 150000003222 pyridines Chemical class 0.000 description 3
- 229910052761 rare earth metal Inorganic materials 0.000 description 3
- 230000003716 rejuvenation Effects 0.000 description 3
- 229910052707 ruthenium Inorganic materials 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 208000014745 severe cutaneous adverse reaction Diseases 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 235000021286 stilbenes Nutrition 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 150000003518 tetracenes Chemical class 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 3
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 description 3
- 150000003852 triazoles Chemical class 0.000 description 3
- 125000006617 triphenylamine group Chemical class 0.000 description 3
- 229910052721 tungsten Inorganic materials 0.000 description 3
- 238000007738 vacuum evaporation Methods 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- YGLVWOUNCXBPJF-UHFFFAOYSA-N (2,3,4,5-tetraphenylcyclopenta-1,4-dien-1-yl)benzene Chemical compound C1=CC=CC=C1C1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 YGLVWOUNCXBPJF-UHFFFAOYSA-N 0.000 description 2
- JCXLYAWYOTYWKM-UHFFFAOYSA-N (2,3,4-triphenylcyclopenta-1,3-dien-1-yl)benzene Chemical compound C1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 JCXLYAWYOTYWKM-UHFFFAOYSA-N 0.000 description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 2
- 150000005045 1,10-phenanthrolines Chemical class 0.000 description 2
- OZKOMUDCMCEDTM-UHFFFAOYSA-N 1,7-phenanthroline Chemical group C1=CC=C2C3=NC=CC=C3C=CC2=N1 OZKOMUDCMCEDTM-UHFFFAOYSA-N 0.000 description 2
- UHXOHPVVEHBKKT-UHFFFAOYSA-N 1-(2,2-diphenylethenyl)-4-[4-(2,2-diphenylethenyl)phenyl]benzene Chemical group C=1C=C(C=2C=CC(C=C(C=3C=CC=CC=3)C=3C=CC=CC=3)=CC=2)C=CC=1C=C(C=1C=CC=CC=1)C1=CC=CC=C1 UHXOHPVVEHBKKT-UHFFFAOYSA-N 0.000 description 2
- VERMWGQSKPXSPZ-BUHFOSPRSA-N 1-[(e)-2-phenylethenyl]anthracene Chemical class C=1C=CC2=CC3=CC=CC=C3C=C2C=1\C=C\C1=CC=CC=C1 VERMWGQSKPXSPZ-BUHFOSPRSA-N 0.000 description 2
- IYZMXHQDXZKNCY-UHFFFAOYSA-N 1-n,1-n-diphenyl-4-n,4-n-bis[4-(n-phenylanilino)phenyl]benzene-1,4-diamine Chemical compound C1=CC=CC=C1N(C=1C=CC(=CC=1)N(C=1C=CC(=CC=1)N(C=1C=CC=CC=1)C=1C=CC=CC=1)C=1C=CC(=CC=1)N(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 IYZMXHQDXZKNCY-UHFFFAOYSA-N 0.000 description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 2
- XDFUNRTWHPWCKO-UHFFFAOYSA-N 4,5,9,10-tetrahydropyrene Chemical class C1CC2=CC=CC3=C2C2=C1C=CC=C2CC3 XDFUNRTWHPWCKO-UHFFFAOYSA-N 0.000 description 2
- WPCIUCNVWJNRCD-UHFFFAOYSA-N 4,5-dihydropyrene Chemical class C1=CC=C2CCC3=CC=CC4=CC=C1C2=C34 WPCIUCNVWJNRCD-UHFFFAOYSA-N 0.000 description 2
- AWXGSYPUMWKTBR-UHFFFAOYSA-N 4-carbazol-9-yl-n,n-bis(4-carbazol-9-ylphenyl)aniline Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1C1=CC=C(N(C=2C=CC(=CC=2)N2C3=CC=CC=C3C3=CC=CC=C32)C=2C=CC(=CC=2)N2C3=CC=CC=C3C3=CC=CC=C32)C=C1 AWXGSYPUMWKTBR-UHFFFAOYSA-N 0.000 description 2
- ZOKIJILZFXPFTO-UHFFFAOYSA-N 4-methyl-n-[4-[1-[4-(4-methyl-n-(4-methylphenyl)anilino)phenyl]cyclohexyl]phenyl]-n-(4-methylphenyl)aniline Chemical compound C1=CC(C)=CC=C1N(C=1C=CC(=CC=1)C1(CCCCC1)C=1C=CC(=CC=1)N(C=1C=CC(C)=CC=1)C=1C=CC(C)=CC=1)C1=CC=C(C)C=C1 ZOKIJILZFXPFTO-UHFFFAOYSA-N 0.000 description 2
- SCZWJXTUYYSKGF-UHFFFAOYSA-N 5,12-dimethylquinolino[2,3-b]acridine-7,14-dione Chemical compound CN1C2=CC=CC=C2C(=O)C2=C1C=C1C(=O)C3=CC=CC=C3N(C)C1=C2 SCZWJXTUYYSKGF-UHFFFAOYSA-N 0.000 description 2
- MZCJSUCRGWIKHH-UHFFFAOYSA-N 6,7-dihydrobenzo[d][1]benzoxepine Chemical class O1CCC2=CC=CC=C2C2=CC=CC=C21 MZCJSUCRGWIKHH-UHFFFAOYSA-N 0.000 description 2
- 150000004325 8-hydroxyquinolines Chemical class 0.000 description 2
- ZHBOFZNNPZNWGB-UHFFFAOYSA-N 9,10-bis(phenylethynyl)anthracene Chemical compound C1=CC=CC=C1C#CC(C1=CC=CC=C11)=C(C=CC=C2)C2=C1C#CC1=CC=CC=C1 ZHBOFZNNPZNWGB-UHFFFAOYSA-N 0.000 description 2
- BITWULPDIGXQDL-UHFFFAOYSA-N 9,10-bis[4-(2,2-diphenylethenyl)phenyl]anthracene Chemical compound C=1C=C(C=2C3=CC=CC=C3C(C=3C=CC(C=C(C=4C=CC=CC=4)C=4C=CC=CC=4)=CC=3)=C3C=CC=CC3=2)C=CC=1C=C(C=1C=CC=CC=1)C1=CC=CC=C1 BITWULPDIGXQDL-UHFFFAOYSA-N 0.000 description 2
- XXPBFNVKTVJZKF-UHFFFAOYSA-N 9,10-dihydrophenanthrene Chemical class C1=CC=C2CCC3=CC=CC=C3C2=C1 XXPBFNVKTVJZKF-UHFFFAOYSA-N 0.000 description 2
- FCNCGHJSNVOIKE-UHFFFAOYSA-N 9,10-diphenylanthracene Chemical compound C1=CC=CC=C1C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1C1=CC=CC=C1 FCNCGHJSNVOIKE-UHFFFAOYSA-N 0.000 description 2
- SNFCXVRWFNAHQX-UHFFFAOYSA-N 9,9'-spirobi[fluorene] Chemical class C12=CC=CC=C2C2=CC=CC=C2C21C1=CC=CC=C1C1=CC=CC=C21 SNFCXVRWFNAHQX-UHFFFAOYSA-N 0.000 description 2
- MZYDBGLUVPLRKR-UHFFFAOYSA-N 9-(3-carbazol-9-ylphenyl)carbazole Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1C1=CC(N2C3=CC=CC=C3C3=CC=CC=C32)=CC=C1 MZYDBGLUVPLRKR-UHFFFAOYSA-N 0.000 description 2
- ZHQCITRPEYURRL-UHFFFAOYSA-N 9-ethynyl-1-[4-(9-ethynylanthracen-1-yl)phenyl]anthracene Chemical compound C1=CC=C2C(C#C)=C3C(C4=CC=C(C=C4)C=4C=CC=C5C=C6C=CC=CC6=C(C=45)C#C)=CC=CC3=CC2=C1 ZHQCITRPEYURRL-UHFFFAOYSA-N 0.000 description 2
- 206010000507 Acne infantile Diseases 0.000 description 2
- GDALETGZDYOOGB-UHFFFAOYSA-N Acridone Natural products C1=C(O)C=C2N(C)C3=CC=CC=C3C(=O)C2=C1O GDALETGZDYOOGB-UHFFFAOYSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- HKMTVMBEALTRRR-UHFFFAOYSA-N Benzo[a]fluorene Chemical compound C1=CC=CC2=C3CC4=CC=CC=C4C3=CC=C21 HKMTVMBEALTRRR-UHFFFAOYSA-N 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical class C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 2
- 206010011684 Cutaneous tuberculosis Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000531123 GB virus C Species 0.000 description 2
- 229910052688 Gadolinium Inorganic materials 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000724675 Hepatitis E virus Species 0.000 description 2
- 208000037262 Hepatitis delta Diseases 0.000 description 2
- 241000724709 Hepatitis delta virus Species 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000837344 Homo sapiens T-cell leukemia translocation-altered gene protein Proteins 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- SXFPNMRWIWIAGS-UHFFFAOYSA-N Khellin Natural products COC1C2CCOC2C(OC)C3OC(C)CC(=O)C13 SXFPNMRWIWIAGS-UHFFFAOYSA-N 0.000 description 2
- FUJCRWPEOMXPAD-UHFFFAOYSA-N Li2O Inorganic materials [Li+].[Li+].[O-2] FUJCRWPEOMXPAD-UHFFFAOYSA-N 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010028836 Neck pain Diseases 0.000 description 2
- 206010029098 Neoplasm skin Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 229920000144 PEDOT:PSS Polymers 0.000 description 2
- 238000009193 PUVA therapy Methods 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 229920001609 Poly(3,4-ethylenedioxythiophene) Polymers 0.000 description 2
- 239000004642 Polyimide Substances 0.000 description 2
- 206010036087 Polymorphic light eruption Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 229910006069 SO3H Inorganic materials 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 2
- 102100028692 T-cell leukemia translocation-altered gene protein Human genes 0.000 description 2
- XBDYBAVJXHJMNQ-UHFFFAOYSA-N Tetrahydroanthracene Natural products C1=CC=C2C=C(CCCC3)C3=CC2=C1 XBDYBAVJXHJMNQ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 206010044725 Tuberculid Diseases 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 2
- 229910052769 Ytterbium Inorganic materials 0.000 description 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- FZEYVTFCMJSGMP-UHFFFAOYSA-N acridone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3NC2=C1 FZEYVTFCMJSGMP-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- HAQFCILFQVZOJC-UHFFFAOYSA-N anthracene-9,10-dione;methane Chemical class C.C.C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 HAQFCILFQVZOJC-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 229910052788 barium Inorganic materials 0.000 description 2
- 229910001632 barium fluoride Inorganic materials 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 239000005388 borosilicate glass Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000013626 chemical specie Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 2
- 229910052681 coesite Inorganic materials 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000002322 conducting polymer Substances 0.000 description 2
- 229920001940 conductive polymer Polymers 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 208000018631 connective tissue disease Diseases 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229910052906 cristobalite Inorganic materials 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 2
- 229960003843 cyproterone Drugs 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- CUIWZLHUNCCYBL-UHFFFAOYSA-N decacyclene Chemical compound C12=C([C]34)C=CC=C4C=CC=C3C2=C2C(=C34)C=C[CH]C4=CC=CC3=C2C2=C1C1=CC=CC3=CC=CC2=C31 CUIWZLHUNCCYBL-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 230000035618 desquamation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- BKMIWBZIQAAZBD-UHFFFAOYSA-N diindenoperylene Chemical compound C12=C3C4=CC=C2C2=CC=CC=C2C1=CC=C3C1=CC=C2C3=CC=CC=C3C3=CC=C4C1=C32 BKMIWBZIQAAZBD-UHFFFAOYSA-N 0.000 description 2
- XUCJHNOBJLKZNU-UHFFFAOYSA-M dilithium;hydroxide Chemical compound [Li+].[Li+].[OH-] XUCJHNOBJLKZNU-UHFFFAOYSA-M 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 208000011318 facial edema Diseases 0.000 description 2
- 238000007380 fibre production Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000002223 garnet Substances 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- YBMRDBCBODYGJE-UHFFFAOYSA-N germanium dioxide Chemical compound O=[Ge]=O YBMRDBCBODYGJE-UHFFFAOYSA-N 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- WIAWDMBHXUZQGV-UHFFFAOYSA-N heptacyclo[13.10.1.12,6.011,26.017,25.018,23.010,27]heptacosa-1(25),2,4,6(27),7,9,11,13,15(26),17,19,21,23-tridecaene Chemical group C=12C3=CC=CC2=CC=CC=1C1=CC=CC2=C1C3=C1C=C3C=CC=CC3=C1C2 WIAWDMBHXUZQGV-UHFFFAOYSA-N 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002706 hydrostatic effect Effects 0.000 description 2
- 208000036796 hyperbilirubinemia Diseases 0.000 description 2
- AMGQUBHHOARCQH-UHFFFAOYSA-N indium;oxotin Chemical compound [In].[Sn]=O AMGQUBHHOARCQH-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 2
- HSMPDPBYAYSOBC-UHFFFAOYSA-N khellin Chemical compound O1C(C)=CC(=O)C2=C1C(OC)=C1OC=CC1=C2OC HSMPDPBYAYSOBC-UHFFFAOYSA-N 0.000 description 2
- 229960002801 khellin Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 201000011486 lichen planus Diseases 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- IMKMFBIYHXBKRX-UHFFFAOYSA-M lithium;quinoline-2-carboxylate Chemical compound [Li+].C1=CC=CC2=NC(C(=O)[O-])=CC=C21 IMKMFBIYHXBKRX-UHFFFAOYSA-M 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229960004023 minocycline Drugs 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 229910000476 molybdenum oxide Inorganic materials 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229940127249 oral antibiotic Drugs 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- FVDOBFPYBSDRKH-UHFFFAOYSA-N perylene-3,4,9,10-tetracarboxylic acid Chemical compound C=12C3=CC=C(C(O)=O)C2=C(C(O)=O)C=CC=1C1=CC=C(C(O)=O)C2=C1C3=CC=C2C(=O)O FVDOBFPYBSDRKH-UHFFFAOYSA-N 0.000 description 2
- 150000002979 perylenes Chemical class 0.000 description 2
- 150000003004 phosphinoxides Chemical class 0.000 description 2
- 238000005240 physical vapour deposition Methods 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 229920000767 polyaniline Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920000128 polypyrrole Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000009290 primary effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 150000003216 pyrazines Chemical class 0.000 description 2
- 150000004892 pyridazines Chemical class 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- FYNROBRQIVCIQF-UHFFFAOYSA-N pyrrolo[3,2-b]pyrrole-5,6-dione Chemical compound C1=CN=C2C(=O)C(=O)N=C21 FYNROBRQIVCIQF-UHFFFAOYSA-N 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 150000003252 quinoxalines Chemical class 0.000 description 2
- 150000002910 rare earth metals Chemical class 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229910052702 rhenium Inorganic materials 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000007650 screen-printing Methods 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- MABNMNVCOAICNO-UHFFFAOYSA-N selenophene Chemical compound C=1C=C[se]C=1 MABNMNVCOAICNO-UHFFFAOYSA-N 0.000 description 2
- 150000004756 silanes Chemical class 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 235000014214 soft drink Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000004528 spin coating Methods 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 229910052682 stishovite Inorganic materials 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960002197 temoporfin Drugs 0.000 description 2
- 150000003512 tertiary amines Chemical group 0.000 description 2
- 150000003513 tertiary aromatic amines Chemical class 0.000 description 2
- IFLREYGFSNHWGE-UHFFFAOYSA-N tetracene Chemical compound C1=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C21 IFLREYGFSNHWGE-UHFFFAOYSA-N 0.000 description 2
- 229940040944 tetracyclines Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002207 thermal evaporation Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 210000002105 tongue Anatomy 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 229910052905 tridymite Inorganic materials 0.000 description 2
- FMHHVULEAZTJMA-UHFFFAOYSA-N trioxsalen Chemical compound CC1=CC(=O)OC2=C1C=C1C=C(C)OC1=C2C FMHHVULEAZTJMA-UHFFFAOYSA-N 0.000 description 2
- 229910001935 vanadium oxide Inorganic materials 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- 229960001296 zinc oxide Drugs 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- DMDOIBWPFWJPQJ-ONEGZZNKSA-N (e)-2,3-bis(sulfanyl)but-2-enedinitrile Chemical compound N#CC(/S)=C(\S)C#N DMDOIBWPFWJPQJ-ONEGZZNKSA-N 0.000 description 1
- PFNQVRZLDWYSCW-UHFFFAOYSA-N (fluoren-9-ylideneamino) n-naphthalen-1-ylcarbamate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1=NOC(=O)NC1=CC=CC2=CC=CC=C12 PFNQVRZLDWYSCW-UHFFFAOYSA-N 0.000 description 1
- NGQSLSMAEVWNPU-YTEMWHBBSA-N 1,2-bis[(e)-2-phenylethenyl]benzene Chemical compound C=1C=CC=CC=1/C=C/C1=CC=CC=C1\C=C\C1=CC=CC=C1 NGQSLSMAEVWNPU-YTEMWHBBSA-N 0.000 description 1
- 150000005072 1,3,4-oxadiazoles Chemical class 0.000 description 1
- 150000000182 1,3,5-triazines Chemical class 0.000 description 1
- KLCLIOISYBHYDZ-UHFFFAOYSA-N 1,4,4-triphenylbuta-1,3-dienylbenzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)=CC=C(C=1C=CC=CC=1)C1=CC=CC=C1 KLCLIOISYBHYDZ-UHFFFAOYSA-N 0.000 description 1
- 125000004958 1,4-naphthylene group Chemical group 0.000 description 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
- ZMLPKJYZRQZLDA-UHFFFAOYSA-N 1-(2-phenylethenyl)-4-[4-(2-phenylethenyl)phenyl]benzene Chemical group C=1C=CC=CC=1C=CC(C=C1)=CC=C1C(C=C1)=CC=C1C=CC1=CC=CC=C1 ZMLPKJYZRQZLDA-UHFFFAOYSA-N 0.000 description 1
- ILBBNQMSDGAAPF-UHFFFAOYSA-N 1-(6-hydroxy-6-methylcyclohexa-2,4-dien-1-yl)propan-1-one Chemical compound CCC(=O)C1C=CC=CC1(C)O ILBBNQMSDGAAPF-UHFFFAOYSA-N 0.000 description 1
- UVHXEHGUEKARKZ-UHFFFAOYSA-N 1-ethenylanthracene Chemical compound C1=CC=C2C=C3C(C=C)=CC=CC3=CC2=C1 UVHXEHGUEKARKZ-UHFFFAOYSA-N 0.000 description 1
- KMQPLEYEXDZOJF-UHFFFAOYSA-N 1-naphthalen-2-ylanthracene Chemical compound C1=CC=C2C=C3C(C4=CC5=CC=CC=C5C=C4)=CC=CC3=CC2=C1 KMQPLEYEXDZOJF-UHFFFAOYSA-N 0.000 description 1
- XNCMQRWVMWLODV-UHFFFAOYSA-N 1-phenylbenzimidazole Chemical compound C1=NC2=CC=CC=C2N1C1=CC=CC=C1 XNCMQRWVMWLODV-UHFFFAOYSA-N 0.000 description 1
- GUPMCMZMDAGSPF-UHFFFAOYSA-N 1-phenylbuta-1,3-dienylbenzene Chemical compound C=1C=CC=CC=1[C](C=C[CH2])C1=CC=CC=C1 GUPMCMZMDAGSPF-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LPHIYKWSEYTCLW-UHFFFAOYSA-N 1h-azaborole Chemical class N1B=CC=C1 LPHIYKWSEYTCLW-UHFFFAOYSA-N 0.000 description 1
- PLJDGKPRGUMSAA-UHFFFAOYSA-N 2,2',7,7'-tetraphenyl-1,1'-spirobi[fluorene] Chemical compound C12=CC=C(C=3C=CC=CC=3)C=C2C=C(C23C(=CC=C4C5=CC=C(C=C5C=C43)C=3C=CC=CC=3)C=3C=CC=CC=3)C1=CC=C2C1=CC=CC=C1 PLJDGKPRGUMSAA-UHFFFAOYSA-N 0.000 description 1
- SULWTXOWAFVWOY-PHEQNACWSA-N 2,3-bis[(E)-2-phenylethenyl]pyrazine Chemical class C=1C=CC=CC=1/C=C/C1=NC=CN=C1\C=C\C1=CC=CC=C1 SULWTXOWAFVWOY-PHEQNACWSA-N 0.000 description 1
- MVWPVABZQQJTPL-UHFFFAOYSA-N 2,3-diphenylcyclohexa-2,5-diene-1,4-dione Chemical class O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 MVWPVABZQQJTPL-UHFFFAOYSA-N 0.000 description 1
- BFTIPCRZWILUIY-UHFFFAOYSA-N 2,5,8,11-tetratert-butylperylene Chemical group CC(C)(C)C1=CC(C2=CC(C(C)(C)C)=CC=3C2=C2C=C(C=3)C(C)(C)C)=C3C2=CC(C(C)(C)C)=CC3=C1 BFTIPCRZWILUIY-UHFFFAOYSA-N 0.000 description 1
- STTGYIUESPWXOW-UHFFFAOYSA-N 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline Chemical compound C=12C=CC3=C(C=4C=CC=CC=4)C=C(C)N=C3C2=NC(C)=CC=1C1=CC=CC=C1 STTGYIUESPWXOW-UHFFFAOYSA-N 0.000 description 1
- CZBAIXSNXBGZRP-UHFFFAOYSA-N 2-(4-methylphenyl)-9,10-dinaphthalen-2-ylanthracene Chemical compound C1=CC(C)=CC=C1C1=CC=C(C(C=2C=C3C=CC=CC3=CC=2)=C2C(C=CC=C2)=C2C=3C=C4C=CC=CC4=CC=3)C2=C1 CZBAIXSNXBGZRP-UHFFFAOYSA-N 0.000 description 1
- PVFFUHAAOKXVTK-UHFFFAOYSA-N 2-(methylamino)-4-oxopentanoic acid Chemical compound CNC(C(O)=O)CC(C)=O PVFFUHAAOKXVTK-UHFFFAOYSA-N 0.000 description 1
- GEQBRULPNIVQPP-UHFFFAOYSA-N 2-[3,5-bis(1-phenylbenzimidazol-2-yl)phenyl]-1-phenylbenzimidazole Chemical compound C1=CC=CC=C1N1C2=CC=CC=C2N=C1C1=CC(C=2N(C3=CC=CC=C3N=2)C=2C=CC=CC=2)=CC(C=2N(C3=CC=CC=C3N=2)C=2C=CC=CC=2)=C1 GEQBRULPNIVQPP-UHFFFAOYSA-N 0.000 description 1
- FBOKUMMWVKWLCK-UHFFFAOYSA-N 2-carbazol-9-yl-n,n-bis(4-carbazol-9-ylphenyl)aniline Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1C1=CC=CC=C1N(C=1C=CC(=CC=1)N1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(N2C3=CC=CC=C3C3=CC=CC=C32)C=C1 FBOKUMMWVKWLCK-UHFFFAOYSA-N 0.000 description 1
- KXGFMDJXCMQABM-UHFFFAOYSA-N 2-methoxy-6-methylphenol Chemical compound [CH]OC1=CC=CC([CH])=C1O KXGFMDJXCMQABM-UHFFFAOYSA-N 0.000 description 1
- VLRSADZEDXVUPG-UHFFFAOYSA-N 2-naphthalen-1-ylpyridine Chemical class N1=CC=CC=C1C1=CC=CC2=CC=CC=C12 VLRSADZEDXVUPG-UHFFFAOYSA-N 0.000 description 1
- VQGHOUODWALEFC-UHFFFAOYSA-N 2-phenylpyridine Chemical compound C1=CC=CC=C1C1=CC=CC=N1 VQGHOUODWALEFC-UHFFFAOYSA-N 0.000 description 1
- 150000005360 2-phenylpyridines Chemical class 0.000 description 1
- FSEXLNMNADBYJU-UHFFFAOYSA-N 2-phenylquinoline Chemical class C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=N1 FSEXLNMNADBYJU-UHFFFAOYSA-N 0.000 description 1
- KYGSXEYUWRFVNY-UHFFFAOYSA-N 2-pyran-2-ylidenepropanedinitrile Chemical compound N#CC(C#N)=C1OC=CC=C1 KYGSXEYUWRFVNY-UHFFFAOYSA-N 0.000 description 1
- QLPKTAFPRRIFQX-UHFFFAOYSA-N 2-thiophen-2-ylpyridine Chemical class C1=CSC(C=2N=CC=CC=2)=C1 QLPKTAFPRRIFQX-UHFFFAOYSA-N 0.000 description 1
- DMEVMYSQZPJFOK-UHFFFAOYSA-N 3,4,5,6,9,10-hexazatetracyclo[12.4.0.02,7.08,13]octadeca-1(18),2(7),3,5,8(13),9,11,14,16-nonaene Chemical group N1=NN=C2C3=CC=CC=C3C3=CC=NN=C3C2=N1 DMEVMYSQZPJFOK-UHFFFAOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- XNBNKCLBGTWWSD-UHFFFAOYSA-N 3-[8,13,18-tris(2-carboxyethyl)-3,7,12,17-tetramethyl-21,24-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(C)C(=CC=3C(=C(CCC(O)=O)C(=C4)N=3)C)N2)CCC(O)=O)=C(CCC(O)=O)C(C)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 XNBNKCLBGTWWSD-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- OGGKVJMNFFSDEV-UHFFFAOYSA-N 3-methyl-n-[4-[4-(n-(3-methylphenyl)anilino)phenyl]phenyl]-n-phenylaniline Chemical compound CC1=CC=CC(N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=C(C)C=CC=2)=C1 OGGKVJMNFFSDEV-UHFFFAOYSA-N 0.000 description 1
- DHDHJYNTEFLIHY-UHFFFAOYSA-N 4,7-diphenyl-1,10-phenanthroline Chemical compound C1=CC=CC=C1C1=CC=NC2=C1C=CC1=C(C=3C=CC=CC=3)C=CN=C21 DHDHJYNTEFLIHY-UHFFFAOYSA-N 0.000 description 1
- WPUSEOSICYGUEW-UHFFFAOYSA-N 4-[4-(4-methoxy-n-(4-methoxyphenyl)anilino)phenyl]-n,n-bis(4-methoxyphenyl)aniline Chemical compound C1=CC(OC)=CC=C1N(C=1C=CC(=CC=1)C=1C=CC(=CC=1)N(C=1C=CC(OC)=CC=1)C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 WPUSEOSICYGUEW-UHFFFAOYSA-N 0.000 description 1
- AZFHXIBNMPIGOD-UHFFFAOYSA-N 4-hydroxypent-3-en-2-one iridium Chemical compound [Ir].CC(O)=CC(C)=O.CC(O)=CC(C)=O.CC(O)=CC(C)=O AZFHXIBNMPIGOD-UHFFFAOYSA-N 0.000 description 1
- LQYYDWJDEVKDGB-XPWSMXQVSA-N 4-methyl-n-[4-[(e)-2-[4-[(e)-2-[4-(4-methyl-n-(4-methylphenyl)anilino)phenyl]ethenyl]phenyl]ethenyl]phenyl]-n-(4-methylphenyl)aniline Chemical compound C1=CC(C)=CC=C1N(C=1C=CC(\C=C\C=2C=CC(\C=C\C=3C=CC(=CC=3)N(C=3C=CC(C)=CC=3)C=3C=CC(C)=CC=3)=CC=2)=CC=1)C1=CC=C(C)C=C1 LQYYDWJDEVKDGB-XPWSMXQVSA-N 0.000 description 1
- HPMDJLFQPKZBGR-UHFFFAOYSA-N 4-methyl-n-[4-[1-[4-(4-methyl-n-(4-methylphenyl)anilino)phenyl]-3-phenylpropyl]phenyl]-n-(4-methylphenyl)aniline Chemical compound C1=CC(C)=CC=C1N(C=1C=CC(=CC=1)C(CCC=1C=CC=CC=1)C=1C=CC(=CC=1)N(C=1C=CC(C)=CC=1)C=1C=CC(C)=CC=1)C1=CC=C(C)C=C1 HPMDJLFQPKZBGR-UHFFFAOYSA-N 0.000 description 1
- UUSGRTCQLNWCHP-UHFFFAOYSA-N 4-tert-butyl-2-(3-phenylphenyl)pyridine Chemical compound CC(C)(C)C1=CC=NC(C=2C=C(C=CC=2)C=2C=CC=CC=2)=C1 UUSGRTCQLNWCHP-UHFFFAOYSA-N 0.000 description 1
- 229950010481 5-aminolevulinic acid hydrochloride Drugs 0.000 description 1
- CVXXPNSMZIRFAA-UHFFFAOYSA-N 9-(3-carbazol-9-yl-5-phenylphenyl)carbazole Chemical group C1=CC=CC=C1C1=CC(N2C3=CC=CC=C3C3=CC=CC=C32)=CC(N2C3=CC=CC=C3C3=CC=CC=C32)=C1 CVXXPNSMZIRFAA-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- VESMRDNBVZOIEN-UHFFFAOYSA-N 9h-carbazole-1,2-diamine Chemical compound C1=CC=C2C3=CC=C(N)C(N)=C3NC2=C1 VESMRDNBVZOIEN-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000501 Acne conglobata Diseases 0.000 description 1
- 206010000502 Acne cosmetica Diseases 0.000 description 1
- 206010049141 Acne fulminans Diseases 0.000 description 1
- 206010000518 Acne varioliformis Diseases 0.000 description 1
- 208000007815 Acquired Hyperostosis Syndrome Diseases 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229910001316 Ag alloy Inorganic materials 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 206010001766 Alopecia totalis Diseases 0.000 description 1
- 206010001767 Alopecia universalis Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010056375 Bile duct obstruction Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 208000021130 Bilirubin encephalopathy Diseases 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- VDLROYDWAIXTDF-UHFFFAOYSA-N C#CC#CCOC1=C(OCC#CC#C)C=C2C(=C1)C1=C(C=C(OC#CC#CC)C(OC#CC#CC)=C1)C21C2=CC(C)=CC=C2C2=C1C=C(C)C=C2.CC1=CC=C(C)C2=NSN=C12.CC1=CC=C(C2=CC=C(C3=CC=C(C4=CC=C(C5=CC=C(C6=CC=C(C7=CC=C(C8=CC=C(C9=CC=C(C%10=CC=C(C%11=CC=C(C%12=CC=C(C%13=CC=C(C%14=CC=C(C%15=CC=C(C)S%15)C%15=NSN=C%14%15)S%13)S%12)C%12=NSN=C%11%12)S%10)S9)C9=NSN=C89)S7)S6)C6=NSN=C56)S4)S3)C3=NSN=C23)S1.CC1=CC=C(N(C2=CC=C(C3=CC=C(N(C4=CC=C(C5=CC=C(N(C6=CC=C(C7=CC=C(N(C8=CC=C(C9=CC=C(N(C%10=CC=C(C%11=CC=C(N(C%12=CC=C(C%13=CC=C(N(C%14=CC=C(C%15=CC=C(N(C%16=CC=C(C%17=CC=C(N(C%18=CC=C(C%19=CC=C(N(C%20=CC=C(C%21=CC=C(N(C%22=CC=C(C%23=CC=C(N(C%24=CC=C(C%25=CC=C(N(C%26=CC=C(C%27=CC=C(N(C%28=CC=C(C%29=CC=C(N(C%30=CC=C(C%31=CC=C(N(C%32=CC=C(C%33=CC=C(N(C%34=CC=C(C%35=CC=C(N(C%36=CC=C(C%37=CC=C(N(C%38=CC=C(C%39=CC=C(N(C%40=CC=C(C)C=C%40)C%40=CC=C(C(C)(C)C)C=C%40)C=C%39)C=C%38)C%38=CC=C(C(C)(C)C)C=C%38)C=C%37)C=C%36)C%36=CC=C(C(C)(C)C)C=C%36)C=C%35)C=C%34)C%34=CC=C(C(C)(C)C)C=C%34)C=C%33)C=C%32)C%32=CC=C(C(C)(C)C)C=C%32)C=C%31)C=C%30)C%30=CC=C(C(C)(C)C)C=C%30)C=C%29)C=C%28)C%28=CC=C(C(C)(C)C)C=C%28)C=C%27)C=C%26)C%26=CC=C(C(C)(C)C)C=C%26)C=C%25)C=C%24)C%24=CC=C(C(C)(C)C)C=C%24)C=C%23)C=C%22)C%22=CC=C(C(C)(C)C)C=C%22)C=C%21)C=C%20)C%20=CC=C(C(C)(C)C)C=C%20)C=C%19)C=C%18)C%18=CC=C(C(C)(C)C)C=C%18)C=C%17)C=C%16)C%16=CC=C(C(C)(C)C)C=C%16)C=C%15)C=C%14)C%14=CC=C(C(C)(C)C)C=C%14)C=C%13)C=C%12)C%12=CC=C(C(C)(C)C)C=C%12)C=C%11)C=C%10)C%10=CC=C(C(C)(C)C)C=C%10)C=C9)C=C8)C8=CC=C(C(C)(C)C)C=C8)C=C7)C=C6)C6=CC=C(C(C)(C)C)C=C6)C=C5)C=C4)C4=CC=C(C(C)(C)C)C=C4)C=C3)C=C2)C2=CC=C(C(C)(C)C)C=C2)C=C1 Chemical compound C#CC#CCOC1=C(OCC#CC#C)C=C2C(=C1)C1=C(C=C(OC#CC#CC)C(OC#CC#CC)=C1)C21C2=CC(C)=CC=C2C2=C1C=C(C)C=C2.CC1=CC=C(C)C2=NSN=C12.CC1=CC=C(C2=CC=C(C3=CC=C(C4=CC=C(C5=CC=C(C6=CC=C(C7=CC=C(C8=CC=C(C9=CC=C(C%10=CC=C(C%11=CC=C(C%12=CC=C(C%13=CC=C(C%14=CC=C(C%15=CC=C(C)S%15)C%15=NSN=C%14%15)S%13)S%12)C%12=NSN=C%11%12)S%10)S9)C9=NSN=C89)S7)S6)C6=NSN=C56)S4)S3)C3=NSN=C23)S1.CC1=CC=C(N(C2=CC=C(C3=CC=C(N(C4=CC=C(C5=CC=C(N(C6=CC=C(C7=CC=C(N(C8=CC=C(C9=CC=C(N(C%10=CC=C(C%11=CC=C(N(C%12=CC=C(C%13=CC=C(N(C%14=CC=C(C%15=CC=C(N(C%16=CC=C(C%17=CC=C(N(C%18=CC=C(C%19=CC=C(N(C%20=CC=C(C%21=CC=C(N(C%22=CC=C(C%23=CC=C(N(C%24=CC=C(C%25=CC=C(N(C%26=CC=C(C%27=CC=C(N(C%28=CC=C(C%29=CC=C(N(C%30=CC=C(C%31=CC=C(N(C%32=CC=C(C%33=CC=C(N(C%34=CC=C(C%35=CC=C(N(C%36=CC=C(C%37=CC=C(N(C%38=CC=C(C%39=CC=C(N(C%40=CC=C(C)C=C%40)C%40=CC=C(C(C)(C)C)C=C%40)C=C%39)C=C%38)C%38=CC=C(C(C)(C)C)C=C%38)C=C%37)C=C%36)C%36=CC=C(C(C)(C)C)C=C%36)C=C%35)C=C%34)C%34=CC=C(C(C)(C)C)C=C%34)C=C%33)C=C%32)C%32=CC=C(C(C)(C)C)C=C%32)C=C%31)C=C%30)C%30=CC=C(C(C)(C)C)C=C%30)C=C%29)C=C%28)C%28=CC=C(C(C)(C)C)C=C%28)C=C%27)C=C%26)C%26=CC=C(C(C)(C)C)C=C%26)C=C%25)C=C%24)C%24=CC=C(C(C)(C)C)C=C%24)C=C%23)C=C%22)C%22=CC=C(C(C)(C)C)C=C%22)C=C%21)C=C%20)C%20=CC=C(C(C)(C)C)C=C%20)C=C%19)C=C%18)C%18=CC=C(C(C)(C)C)C=C%18)C=C%17)C=C%16)C%16=CC=C(C(C)(C)C)C=C%16)C=C%15)C=C%14)C%14=CC=C(C(C)(C)C)C=C%14)C=C%13)C=C%12)C%12=CC=C(C(C)(C)C)C=C%12)C=C%11)C=C%10)C%10=CC=C(C(C)(C)C)C=C%10)C=C9)C=C8)C8=CC=C(C(C)(C)C)C=C8)C=C7)C=C6)C6=CC=C(C(C)(C)C)C=C6)C=C5)C=C4)C4=CC=C(C(C)(C)C)C=C4)C=C3)C=C2)C2=CC=C(C(C)(C)C)C=C2)C=C1 VDLROYDWAIXTDF-UHFFFAOYSA-N 0.000 description 1
- KZUWPJHDSCPXFY-UHFFFAOYSA-N C.C.C.CCN(C)CC Chemical compound C.C.C.CCN(C)CC KZUWPJHDSCPXFY-UHFFFAOYSA-N 0.000 description 1
- YWCQLVVCCUTULG-UHFFFAOYSA-N C1=CC(C2=CC=C(N3C4=C(C=CC=C4)C4=C3C=CC=C4)C=C2)=CC(C2=CC(C3=CC=C(N4C5=C(C=CC=C5)C5=C4C=CC=C5)C=C3)=CC=C2)=C1.C1=CC=C(C2=CC(C3=CC=C(C4=CC=C(N5C6=C(C=CC=C6)C6=C5/C=C\C=C/6)C=C4)C=C3)=NC(C3=CC=CC=C3)=N2)C=C1.C1=CC=C(C2=CC(C3=CC=CC(C4=CC=C(N5C6=C(C=CC=C6)C6=C5C=CC=C6)C=C4)=C3)=CC(C3=CC=C(N4C5=C(C=CC=C5)C5=C4C=CC=C5)C=C3)=C2)C=C1.C1=CC=C(C2=CC(C3=CC=CC(C4=CC=C(N5C6=C(C=CC=C6)C6=C5C=CC=C6)C=C4)=C3)=NC(C3=CC=CC=C3)=N2)C=C1 Chemical compound C1=CC(C2=CC=C(N3C4=C(C=CC=C4)C4=C3C=CC=C4)C=C2)=CC(C2=CC(C3=CC=C(N4C5=C(C=CC=C5)C5=C4C=CC=C5)C=C3)=CC=C2)=C1.C1=CC=C(C2=CC(C3=CC=C(C4=CC=C(N5C6=C(C=CC=C6)C6=C5/C=C\C=C/6)C=C4)C=C3)=NC(C3=CC=CC=C3)=N2)C=C1.C1=CC=C(C2=CC(C3=CC=CC(C4=CC=C(N5C6=C(C=CC=C6)C6=C5C=CC=C6)C=C4)=C3)=CC(C3=CC=C(N4C5=C(C=CC=C5)C5=C4C=CC=C5)C=C3)=C2)C=C1.C1=CC=C(C2=CC(C3=CC=CC(C4=CC=C(N5C6=C(C=CC=C6)C6=C5C=CC=C6)C=C4)=C3)=NC(C3=CC=CC=C3)=N2)C=C1 YWCQLVVCCUTULG-UHFFFAOYSA-N 0.000 description 1
- CJGUQZGGEUNPFQ-UHFFFAOYSA-L C1=CC=C(/C2=N/C3=C(C=CC=C3)S2)C(O[Zn]OC2=C(C3=NC4=C(C=CC=C4)S3)C=CC=C2)=C1 Chemical compound C1=CC=C(/C2=N/C3=C(C=CC=C3)S2)C(O[Zn]OC2=C(C3=NC4=C(C=CC=C4)S3)C=CC=C2)=C1 CJGUQZGGEUNPFQ-UHFFFAOYSA-L 0.000 description 1
- VQDSTPDCRCUOOD-UHFFFAOYSA-L C1=CC=C(C2=C3/C=C\C4=C(C5=CC=CC=C5)C=CN=C4C3=NC=C2)C=C1.C1=CC=C(C2=NN=C(C3=CC=CC=C3)N2C2=C3C=CC=CC3=CC=C2)C=C1.C1=CC=C(N2C(C3=CC(/C4=N/C5=C(C=CC=C5)N4C4=CC=CC=C4)=CC(/C4=N/C5=C(C=CC=C5)N4C4=CC=CC=C4)=C3)=NC3=C2C=CC=C3)C=C1.CC(C)(C)C1=CC=C(C2=NN=C(C3=CC=CC(C4=NN=C(C5=CC=C(C(C)(C)C)C=C5)O4)=C3)O2)C=C1.CC1=CC(C2=CC=CC=C2)=C2/C=C\C3=C(C4=CC=CC=C4)C=C(C)N=C3C2=N1.[Be](OC1=C2C(=CC=C1)C=CC1=CC=CN=C12)O/C1=C/C=C\C2=CC=C3C=CC=NC3=C21 Chemical compound C1=CC=C(C2=C3/C=C\C4=C(C5=CC=CC=C5)C=CN=C4C3=NC=C2)C=C1.C1=CC=C(C2=NN=C(C3=CC=CC=C3)N2C2=C3C=CC=CC3=CC=C2)C=C1.C1=CC=C(N2C(C3=CC(/C4=N/C5=C(C=CC=C5)N4C4=CC=CC=C4)=CC(/C4=N/C5=C(C=CC=C5)N4C4=CC=CC=C4)=C3)=NC3=C2C=CC=C3)C=C1.CC(C)(C)C1=CC=C(C2=NN=C(C3=CC=CC(C4=NN=C(C5=CC=C(C(C)(C)C)C=C5)O4)=C3)O2)C=C1.CC1=CC(C2=CC=CC=C2)=C2/C=C\C3=C(C4=CC=CC=C4)C=C(C)N=C3C2=N1.[Be](OC1=C2C(=CC=C1)C=CC1=CC=CN=C12)O/C1=C/C=C\C2=CC=C3C=CC=NC3=C21 VQDSTPDCRCUOOD-UHFFFAOYSA-L 0.000 description 1
- WKGBJWLKOAQXFX-GHTABSBJSA-N C1=CC=C(C2=C3C=CC(N(C4=CC=CC=C4)C4=CC=CC=C4)=CC3=C(C3=CC=CC=C3)C3=CC=C(N(C4=CC=CC=C4)C4=CC=CC=C4)C=C32)C=C1.C1=CC=C2C=C(N(C3=CC=C(/C=C/C4=CC=C(N(C5=CC6=CC=CC=C6C=C5)C5=CC6=C(C=CC=C6)C=C5)C=C4)C=C3)C3=CC=C4C=CC=CC4=C3)C=CC2=C1.C[Si](C)(C)C1=CC=C(/C=C/C2=CC=C(N(C3=CC=C(/C=C/C4=CC=C([Si](C)(C)C)C=C4)C=C3)C3=CC=C(/C=C/C4=CC=C([Si](C)(C)C)C=C4)C=C3)C=C2)C=C1 Chemical compound C1=CC=C(C2=C3C=CC(N(C4=CC=CC=C4)C4=CC=CC=C4)=CC3=C(C3=CC=CC=C3)C3=CC=C(N(C4=CC=CC=C4)C4=CC=CC=C4)C=C32)C=C1.C1=CC=C2C=C(N(C3=CC=C(/C=C/C4=CC=C(N(C5=CC6=CC=CC=C6C=C5)C5=CC6=C(C=CC=C6)C=C5)C=C4)C=C3)C3=CC=C4C=CC=CC4=C3)C=CC2=C1.C[Si](C)(C)C1=CC=C(/C=C/C2=CC=C(N(C3=CC=C(/C=C/C4=CC=C([Si](C)(C)C)C=C4)C=C3)C3=CC=C(/C=C/C4=CC=C([Si](C)(C)C)C=C4)C=C3)C=C2)C=C1 WKGBJWLKOAQXFX-GHTABSBJSA-N 0.000 description 1
- ZUWPWCOLKFVHFM-UHFFFAOYSA-N C1=CC=C(C2=CC(C3=CC=C(N4C5=C(C=CC=C5)C5=C4C=CC=C5)C=C3)=CC(C3=CC(C4=CC=C(N5C6=C(C=CC=C6)C6=C5C=CC=C6)C=C4)=CC(C4=CC=CC=C4)=C3)=C2)C=C1 Chemical compound C1=CC=C(C2=CC(C3=CC=C(N4C5=C(C=CC=C5)C5=C4C=CC=C5)C=C3)=CC(C3=CC(C4=CC=C(N5C6=C(C=CC=C6)C6=C5C=CC=C6)C=C4)=CC(C4=CC=CC=C4)=C3)=C2)C=C1 ZUWPWCOLKFVHFM-UHFFFAOYSA-N 0.000 description 1
- WRBAFYDUAFUGCW-UHFFFAOYSA-N C1=CC=C(C2=CC(C3=CC=CC=C3)=NC(N3C4=C(C=CC=C4)C4=C3C3=C(C=C4)C4=C(/C=C\C=C/4)N3C3=CC=CC=C3)=N2)C=C1.C1=CC=C(C2=CC(N3C4=C(C=CC=C4)C4=C3C3=C(C=C4)C4=C(/C=C\C=C/4)N3C3=CC=CC=C3)=CC(C3=CC=CC=C3)=N2)C=C1.C1=CC=C(C2=NC(C3=CC=CC=C3)=NC(N3C4=C(C=CC=C4)C4=C3C3=C(C=C4)C4=C(/C=C\C=C/4)N3C3=CC=CC=C3)=N2)C=C1.CC1(C)C2=C(C=CC=C2)C2=C1C=C1C(=C2)N(C2=NC(C3=CC=CC=C3)=NC(C3=CC=CC=C3)=N2)C2=C1/C=C\C=C/2 Chemical compound C1=CC=C(C2=CC(C3=CC=CC=C3)=NC(N3C4=C(C=CC=C4)C4=C3C3=C(C=C4)C4=C(/C=C\C=C/4)N3C3=CC=CC=C3)=N2)C=C1.C1=CC=C(C2=CC(N3C4=C(C=CC=C4)C4=C3C3=C(C=C4)C4=C(/C=C\C=C/4)N3C3=CC=CC=C3)=CC(C3=CC=CC=C3)=N2)C=C1.C1=CC=C(C2=NC(C3=CC=CC=C3)=NC(N3C4=C(C=CC=C4)C4=C3C3=C(C=C4)C4=C(/C=C\C=C/4)N3C3=CC=CC=C3)=N2)C=C1.CC1(C)C2=C(C=CC=C2)C2=C1C=C1C(=C2)N(C2=NC(C3=CC=CC=C3)=NC(C3=CC=CC=C3)=N2)C2=C1/C=C\C=C/2 WRBAFYDUAFUGCW-UHFFFAOYSA-N 0.000 description 1
- DCQPIBMJCKKHDZ-UHFFFAOYSA-N C1=CC=C(C2=CC(C3=CC=CC=C3)=NC(N3C4=C(C=CC=C4)C4=C3C=C3C(=C4)N(C4=CC=CC=C4)C4=C3C=CC=C4)=N2)C=C1.C1=CC=C(C2=CC(N3C4=C(C=CC=C4)C4=C3C=C3C(=C4)N(C4=CC=CC=C4)C4=C3C=CC=C4)=CC(C3=CC=CC=C3)=N2)C=C1.C1=CC=C(C2=NC(C3=CC=CC=C3)=NC(N3C4=C(C=CC=C4)C4=C3C=C3C(=C4)N(C4=CC=CC=C4)C4=C3C=CC=C4)=N2)C=C1 Chemical compound C1=CC=C(C2=CC(C3=CC=CC=C3)=NC(N3C4=C(C=CC=C4)C4=C3C=C3C(=C4)N(C4=CC=CC=C4)C4=C3C=CC=C4)=N2)C=C1.C1=CC=C(C2=CC(N3C4=C(C=CC=C4)C4=C3C=C3C(=C4)N(C4=CC=CC=C4)C4=C3C=CC=C4)=CC(C3=CC=CC=C3)=N2)C=C1.C1=CC=C(C2=NC(C3=CC=CC=C3)=NC(N3C4=C(C=CC=C4)C4=C3C=C3C(=C4)N(C4=CC=CC=C4)C4=C3C=CC=C4)=N2)C=C1 DCQPIBMJCKKHDZ-UHFFFAOYSA-N 0.000 description 1
- SBIHFZWWHPXEFQ-UHFFFAOYSA-N C1=CC=C(C2=CC=C(C3=C4C=CC=CC4=C(C4=C(C5=CC=CC=C5)C=C(C5=CC=CC=C5)C=C4)C4=CC5=CC=CC=C5C=C43)C(C3=CC=CC=C3)=C2)C=C1 Chemical compound C1=CC=C(C2=CC=C(C3=C4C=CC=CC4=C(C4=C(C5=CC=CC=C5)C=C(C5=CC=CC=C5)C=C4)C4=CC5=CC=CC=C5C=C43)C(C3=CC=CC=C3)=C2)C=C1 SBIHFZWWHPXEFQ-UHFFFAOYSA-N 0.000 description 1
- FWMZJCIYQWSXOR-UHFFFAOYSA-N C1=CC=C(C2=CC=C(C3=C4C=CC=CC4=C(C4=CC=C(C5=CC=CC=C5)C=C4)/C4=C/C5=CC=CC=C5/C=C\34)C=C2)C=C1.C1=CC=C2C(=C1)C(C1=CC=C(C3=C4/C=C\C=C/C4=CC=C3)C=C1)=C1C=CC=CC1=C2C1=CC=C2C=CC=CC2=C1.CC1=CC=C(C2=CC3=C(C4=CC5=CC=CC=C5C=C4)C4=CC=CC=C4C(C4=CC=C5C=CC=CC5=C4)=C3C=C2)C=C1 Chemical compound C1=CC=C(C2=CC=C(C3=C4C=CC=CC4=C(C4=CC=C(C5=CC=CC=C5)C=C4)/C4=C/C5=CC=CC=C5/C=C\34)C=C2)C=C1.C1=CC=C2C(=C1)C(C1=CC=C(C3=C4/C=C\C=C/C4=CC=C3)C=C1)=C1C=CC=CC1=C2C1=CC=C2C=CC=CC2=C1.CC1=CC=C(C2=CC3=C(C4=CC5=CC=CC=C5C=C4)C4=CC=CC=C4C(C4=CC=C5C=CC=CC5=C4)=C3C=C2)C=C1 FWMZJCIYQWSXOR-UHFFFAOYSA-N 0.000 description 1
- IUMRTLIGEIHHCE-UHFFFAOYSA-N C1=CC=C(C2=CC=C(C3=CC=C(N(C4=CC=CC=C4)C4=CC=C(C5=CC=C(N(C6=CC=C(C7=CC=CC=C7)C=C6)C6=CC=C(C7=CC=CC=C7)C=C6)C=C5)C=C4)C=C3)C=C2)C=C1.C1=CC=C(C2=CC=C(N(C3=CC=C(C4=CC=CC=C4)C=C3)C3=CC=C(C4=CC=C(N(C5=CC=C(C6=CC=CC=C6)C=C5)C5=CC=C(C6=CC=CC=C6)C=C5)C=C4)C=C3)C=C2)C=C1.C1=CC=C(N(C2=CC=CC=C2)C2=C3C=CC=CC3=C(N(C3=CC=CC=C3)C3=CC=CC=C3)C3=CC=CC=C32)C=C1.C1=CC=C(N(C2=CC=CC=C2)C2=CC=C3C4=CC=C(N(C5=CC=CC=C5)C5=CC=CC=C5)C=C4C4(C3=C2)C2=CC(N(C3=CC=CC=C3)C3=CC=CC=C3)=CC=C2C2=CC=C(N(C3=CC=CC=C3)C3=CC=CC=C3)C=C24)C=C1.CC1(C)C2=C(C=CC=C2)C2=C1C=C(N(C1=CC=C(C3=CC=CC=C3)C=C1)C1=CC=C(C3=CC=C4C(=C3)C3=C(C=CC=C3)N4C3=CC=CC=C3)C=C1)C=C2.CC1(C)C2=CC3=C(C=C2C2=C1C=C(N(C1=CC=CC=C1)C1=CC=CC=C1)C=C2)C(C)(C)C1=C3/C=C\C(N(C2=CC=CC=C2)C2=CC=CC=C2)=C/1 Chemical compound C1=CC=C(C2=CC=C(C3=CC=C(N(C4=CC=CC=C4)C4=CC=C(C5=CC=C(N(C6=CC=C(C7=CC=CC=C7)C=C6)C6=CC=C(C7=CC=CC=C7)C=C6)C=C5)C=C4)C=C3)C=C2)C=C1.C1=CC=C(C2=CC=C(N(C3=CC=C(C4=CC=CC=C4)C=C3)C3=CC=C(C4=CC=C(N(C5=CC=C(C6=CC=CC=C6)C=C5)C5=CC=C(C6=CC=CC=C6)C=C5)C=C4)C=C3)C=C2)C=C1.C1=CC=C(N(C2=CC=CC=C2)C2=C3C=CC=CC3=C(N(C3=CC=CC=C3)C3=CC=CC=C3)C3=CC=CC=C32)C=C1.C1=CC=C(N(C2=CC=CC=C2)C2=CC=C3C4=CC=C(N(C5=CC=CC=C5)C5=CC=CC=C5)C=C4C4(C3=C2)C2=CC(N(C3=CC=CC=C3)C3=CC=CC=C3)=CC=C2C2=CC=C(N(C3=CC=CC=C3)C3=CC=CC=C3)C=C24)C=C1.CC1(C)C2=C(C=CC=C2)C2=C1C=C(N(C1=CC=C(C3=CC=CC=C3)C=C1)C1=CC=C(C3=CC=C4C(=C3)C3=C(C=CC=C3)N4C3=CC=CC=C3)C=C1)C=C2.CC1(C)C2=CC3=C(C=C2C2=C1C=C(N(C1=CC=CC=C1)C1=CC=CC=C1)C=C2)C(C)(C)C1=C3/C=C\C(N(C2=CC=CC=C2)C2=CC=CC=C2)=C/1 IUMRTLIGEIHHCE-UHFFFAOYSA-N 0.000 description 1
- WGPZILQLUGIWMJ-UHFFFAOYSA-N C1=CC=C(C2=CC=C(C3=NN=C(C4=CC=C(C5=CC=C(C6=NN=C(C7=CC=C(C8=CC=CC=C8)C=C7)O6)C=C5)C=C4)O3)C=C2)C=C1.C1=CC=C(C2=CC=C(C3=NN=C(C4=CC=C(OC5=CC=C(C6=NN=C(C7=CC=C(C8=CC=CC=C8)C=C7)O6)C=C5)C=C4)O3)C=C2)C=C1.CC(C)(C)C1=CC=C(C2=CC=C(C3=NN=C(C4=CC=C(C5=CC=C(C6=NN=C(C7=CC=C(C8=CC=C(C(C)(C)C)C=C8)C=C7)O6)C=C5)C=C4)O3)C=C2)C=C1 Chemical compound C1=CC=C(C2=CC=C(C3=NN=C(C4=CC=C(C5=CC=C(C6=NN=C(C7=CC=C(C8=CC=CC=C8)C=C7)O6)C=C5)C=C4)O3)C=C2)C=C1.C1=CC=C(C2=CC=C(C3=NN=C(C4=CC=C(OC5=CC=C(C6=NN=C(C7=CC=C(C8=CC=CC=C8)C=C7)O6)C=C5)C=C4)O3)C=C2)C=C1.CC(C)(C)C1=CC=C(C2=CC=C(C3=NN=C(C4=CC=C(C5=CC=C(C6=NN=C(C7=CC=C(C8=CC=C(C(C)(C)C)C=C8)C=C7)O6)C=C5)C=C4)O3)C=C2)C=C1 WGPZILQLUGIWMJ-UHFFFAOYSA-N 0.000 description 1
- RWIVEXBBQMOCQF-UHFFFAOYSA-N C1=CC=C(C2=NC3=C(C=CC(C4=C5C=CC=CC5=C(C5=CC6=CC=CC=C6C=C5)C5=CC=CC=C54)=C3)N2C2=CC=CC=C2)C=C1.C1=CC=C(N2C(C3=CC=C(C4=C5C=CC=CC5=C(C5=CC6=CC=CC=C6C=C5)C5=CC=CC=C54)C=C3)=NC3=C2C=CC=C3)C=C1 Chemical compound C1=CC=C(C2=NC3=C(C=CC(C4=C5C=CC=CC5=C(C5=CC6=CC=CC=C6C=C5)C5=CC=CC=C54)=C3)N2C2=CC=CC=C2)C=C1.C1=CC=C(N2C(C3=CC=C(C4=C5C=CC=CC5=C(C5=CC6=CC=CC=C6C=C5)C5=CC=CC=C54)C=C3)=NC3=C2C=CC=C3)C=C1 RWIVEXBBQMOCQF-UHFFFAOYSA-N 0.000 description 1
- RLAJVTUOQDCOTI-UHFFFAOYSA-N C1=CC=C(C2=NC3=C(C=CC=C3)N2C2=CC=C(C3=C4\C=CC=C\C4=C(C4=CC=C5C=CC=CC5=C4)\C4=C\C=C/C=C\34)C=C2)C=C1.C1=CC=C(N2C(C3=CC=C(C4=C5\C=CC=C\C5=C(C5=CC=C6C=CC=CC6=C5)\C5=C\C=C/C=C\45)C=C3)=NC3=C2C=CC=C3)C=C1.C1=CC=C(N2C(C3=CC=C(C4=CC5=C(C6=CC=C7C=CC=CC7=C6)/C6=C/C=C/C=C6/C(C6=CC7=CC=CC=C7C=C6)=C\5C=C4)C=C3)=NC3=C2C=CC=C3)C=C1 Chemical compound C1=CC=C(C2=NC3=C(C=CC=C3)N2C2=CC=C(C3=C4\C=CC=C\C4=C(C4=CC=C5C=CC=CC5=C4)\C4=C\C=C/C=C\34)C=C2)C=C1.C1=CC=C(N2C(C3=CC=C(C4=C5\C=CC=C\C5=C(C5=CC=C6C=CC=CC6=C5)\C5=C\C=C/C=C\45)C=C3)=NC3=C2C=CC=C3)C=C1.C1=CC=C(N2C(C3=CC=C(C4=CC5=C(C6=CC=C7C=CC=CC7=C6)/C6=C/C=C/C=C6/C(C6=CC7=CC=CC=C7C=C6)=C\5C=C4)C=C3)=NC3=C2C=CC=C3)C=C1 RLAJVTUOQDCOTI-UHFFFAOYSA-N 0.000 description 1
- UHKWUANHBUDYEF-UHFFFAOYSA-N C1=CC=C(N(C2=CC=CC=C2)C2=C3C=CC=CC3=C(N(C3=CC=CC=C3)C3=CC=CC=C3)C3=CC=CC=C32)C=C1.C1=CC=C(N(C2=CC=CC=C2)C2=CC=C3C(=C2)C(C2=CC4=CC=CC=C4C=C2)=C2C=CC(N(C4=CC=CC=C4)C4=CC=CC=C4)=CC2=C3C2=CC=C3C=CC=CC3=C2)C=C1.CC1=CC=C(N(C2=CC=C(C)C(C)=C2)C2=CC3=C(C=C(N(C4=CC=C(C)C(C)=C4)C4=CC(C)=C(C)C=C4)C4=CCCC=C43)C3=CC=CC=C32)C=C1C Chemical compound C1=CC=C(N(C2=CC=CC=C2)C2=C3C=CC=CC3=C(N(C3=CC=CC=C3)C3=CC=CC=C3)C3=CC=CC=C32)C=C1.C1=CC=C(N(C2=CC=CC=C2)C2=CC=C3C(=C2)C(C2=CC4=CC=CC=C4C=C2)=C2C=CC(N(C4=CC=CC=C4)C4=CC=CC=C4)=CC2=C3C2=CC=C3C=CC=CC3=C2)C=C1.CC1=CC=C(N(C2=CC=C(C)C(C)=C2)C2=CC3=C(C=C(N(C4=CC=C(C)C(C)=C4)C4=CC(C)=C(C)C=C4)C4=CCCC=C43)C3=CC=CC=C32)C=C1C UHKWUANHBUDYEF-UHFFFAOYSA-N 0.000 description 1
- DFUMCLSFCZWILE-UHFFFAOYSA-N C1=CC=C(N(C2=CC=CC=C2)C2=CC=C(C3=CC=C(N(C4=CC=CC=C4)C4=CC=C(C5=CC=C(N(C6=CC=CC=C6)C6=CC=C(C7=CC=C(N(C8=CC=CC=C8)C8=CC=CC=C8)C=C7)C=C6)C=C5)C=C4)C=C3)C=C2)C=C1.C1=CC=C(N(C2=CC=CC=C2)C2=CC=C(N(C3=CC=C(C4=CC=C(N(C5=CC=C(N(C6=CC=CC=C6)C6=CC=CC=C6)C=C5)/C5=C/C=C\C6=CC=CC=C65)C=C4)C=C3)/C3=C/C=C\C4=CC=CC=C43)C=C2)C=C1.C1=CC=C(N(C2=CC=CC=C2)C2=CC=C(N(C3=CC=CC=C3)C3=CC=C(C4=CC=C(N(C5=CC=CC=C5)C5=CC=C(N(C6=CC=CC=C6)C6=CC=CC=C6)C=C5)C=C4)C=C3)C=C2)C=C1.C1=CC=C(N2C3=C(C=CC=C3)C3=C2/C=C\C(N(C2=CC=CC=C2)C2=CC=C(C4=CC=C(N(C5=CC=CC=C5)C5=C/C=C6C(=C/5)/C5=C(C=CC=C5)N/6C5=CC=CC=C5)C=C4)C=C2)=C/3)C=C1 Chemical compound C1=CC=C(N(C2=CC=CC=C2)C2=CC=C(C3=CC=C(N(C4=CC=CC=C4)C4=CC=C(C5=CC=C(N(C6=CC=CC=C6)C6=CC=C(C7=CC=C(N(C8=CC=CC=C8)C8=CC=CC=C8)C=C7)C=C6)C=C5)C=C4)C=C3)C=C2)C=C1.C1=CC=C(N(C2=CC=CC=C2)C2=CC=C(N(C3=CC=C(C4=CC=C(N(C5=CC=C(N(C6=CC=CC=C6)C6=CC=CC=C6)C=C5)/C5=C/C=C\C6=CC=CC=C65)C=C4)C=C3)/C3=C/C=C\C4=CC=CC=C43)C=C2)C=C1.C1=CC=C(N(C2=CC=CC=C2)C2=CC=C(N(C3=CC=CC=C3)C3=CC=C(C4=CC=C(N(C5=CC=CC=C5)C5=CC=C(N(C6=CC=CC=C6)C6=CC=CC=C6)C=C5)C=C4)C=C3)C=C2)C=C1.C1=CC=C(N2C3=C(C=CC=C3)C3=C2/C=C\C(N(C2=CC=CC=C2)C2=CC=C(C4=CC=C(N(C5=CC=CC=C5)C5=C/C=C6C(=C/5)/C5=C(C=CC=C5)N/6C5=CC=CC=C5)C=C4)C=C2)=C/3)C=C1 DFUMCLSFCZWILE-UHFFFAOYSA-N 0.000 description 1
- FRXRPYQQTQNOMZ-UHFFFAOYSA-N C1=CC=C([Si](C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=C([Si](C3=CC=CC=C3)(C3=CC=CC=C3)C3=CC=CC=C3)C=C2)C=C1.C1=CC=C2C(=C1)CC1=CC=CC=C1[Si]21C2=CC=CC=C2CC2=CC=CC=C21.CC1=C([Si](C2=CC=CC=C2)(C2=CC=CC=C2)C2=C(C)C=CC=C2)C=CC=C1.CC1=CC(C)=C(B(C2=CC=C([Si](C3=CC=CC=C3)(C3=CC=CC=C3)C3=CC=C(B(C4=C(C)C=C(C)C=C4C)C4=C(C)C=C(C)C=C4C)C=C3)C=C2)C2=C(C)C=C(C)C=C2C)C(C)=C1.O=P(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=C([Si](C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=C(P(=O)(C3=CC=CC=C3)C3=CC=CC=C3)C=C2)C=C1 Chemical compound C1=CC=C([Si](C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=C([Si](C3=CC=CC=C3)(C3=CC=CC=C3)C3=CC=CC=C3)C=C2)C=C1.C1=CC=C2C(=C1)CC1=CC=CC=C1[Si]21C2=CC=CC=C2CC2=CC=CC=C21.CC1=C([Si](C2=CC=CC=C2)(C2=CC=CC=C2)C2=C(C)C=CC=C2)C=CC=C1.CC1=CC(C)=C(B(C2=CC=C([Si](C3=CC=CC=C3)(C3=CC=CC=C3)C3=CC=C(B(C4=C(C)C=C(C)C=C4C)C4=C(C)C=C(C)C=C4C)C=C3)C=C2)C2=C(C)C=C(C)C=C2C)C(C)=C1.O=P(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=C([Si](C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=C(P(=O)(C3=CC=CC=C3)C3=CC=CC=C3)C=C2)C=C1 FRXRPYQQTQNOMZ-UHFFFAOYSA-N 0.000 description 1
- WGVIMAFLEHSXRZ-UHFFFAOYSA-N C1=CC=C([Si]2(C3=CC=CC=C3)C3=C(C=CC=C3)[Si](C3=CC=CC=C3)(C3=CC=CC=C3)C3=C2C=CC=C3)C=C1 Chemical compound C1=CC=C([Si]2(C3=CC=CC=C3)C3=C(C=CC=C3)[Si](C3=CC=CC=C3)(C3=CC=CC=C3)C3=C2C=CC=C3)C=C1 WGVIMAFLEHSXRZ-UHFFFAOYSA-N 0.000 description 1
- XJLMHSONFLKODQ-NPDUFXBMSA-M C1=CC=C2C(=C1)C1=CC=CC3=C1C1N(/C=C\N21)[Ir]3.CC1=CC(C)=O[Ir]2(O1)C1=C(C=CC=C1)C1=N2C2=CC=CC=C2C=C1 Chemical compound C1=CC=C2C(=C1)C1=CC=CC3=C1C1N(/C=C\N21)[Ir]3.CC1=CC(C)=O[Ir]2(O1)C1=C(C=CC=C1)C1=N2C2=CC=CC=C2C=C1 XJLMHSONFLKODQ-NPDUFXBMSA-M 0.000 description 1
- CWESXQZFTFXSKW-UHFFFAOYSA-N C1=CC=C2C=C(C3=C4C=CC=CC4=C(C4=C5C=CC=CC5=CC=C4)C4=CC=CC=C43)C=CC2=C1.C1=CC=C2C=C(C3=CC4=C(C5=CC6=CC=CC=C6C=C5)C5=CC=CC=C5C(C5=CC=C6C=CC=CC6=C5)=C4C=C3)C=CC2=C1.CC1=C(C2=C3C=CC=CC3=C(C3=C(C)C=CC4=CC=CC=C43)C3=C2C=CC=C3)C2=CC=CC=C2C=C1 Chemical compound C1=CC=C2C=C(C3=C4C=CC=CC4=C(C4=C5C=CC=CC5=CC=C4)C4=CC=CC=C43)C=CC2=C1.C1=CC=C2C=C(C3=CC4=C(C5=CC6=CC=CC=C6C=C5)C5=CC=CC=C5C(C5=CC=C6C=CC=CC6=C5)=C4C=C3)C=CC2=C1.CC1=C(C2=C3C=CC=CC3=C(C3=C(C)C=CC4=CC=CC=C43)C3=C2C=CC=C3)C2=CC=CC=C2C=C1 CWESXQZFTFXSKW-UHFFFAOYSA-N 0.000 description 1
- 125000003184 C60 fullerene group Chemical group 0.000 description 1
- JYVICDASHSPMKJ-UHFFFAOYSA-N CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC1=CC=C(N(C2=CC=CC=C2)C2=CC=C(C)C=C2)C=C1.CC1=CC=C(N(C2=CC=CC=C2)C2=CC=C(C3=CC=C(N(C4=CC=CC=C4)C4=CC=C(C)C=C4)C=C3)C=C2)C=C1.CC1=CC=C(N(C2=CC=CC=C2)C2=CC=C(N(C3=CC=CC=C3)C3=CC=C(C)C=C3)C=C2)C=C1 Chemical compound CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC1=CC=C(N(C2=CC=CC=C2)C2=CC=C(C)C=C2)C=C1.CC1=CC=C(N(C2=CC=CC=C2)C2=CC=C(C3=CC=C(N(C4=CC=CC=C4)C4=CC=C(C)C=C4)C=C3)C=C2)C=C1.CC1=CC=C(N(C2=CC=CC=C2)C2=CC=C(N(C3=CC=CC=C3)C3=CC=C(C)C=C3)C=C2)C=C1 JYVICDASHSPMKJ-UHFFFAOYSA-N 0.000 description 1
- PLLYJSMIQGDIGY-UHFFFAOYSA-N CC.CC.CC.CC.CC1([Y])C2=C(C=CC=C2)C2=C1C1=C(C=C2)C2=C(/C=C\C=C/2)C1(C1=CC=CC=C1)C1=CC=CC=C1.CC1([Y])C2=CC3=C(C=C2C2=C1C=CC=C2)C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=C3/C=C\C=C/1 Chemical compound CC.CC.CC.CC.CC1([Y])C2=C(C=CC=C2)C2=C1C1=C(C=C2)C2=C(/C=C\C=C/2)C1(C1=CC=CC=C1)C1=CC=CC=C1.CC1([Y])C2=CC3=C(C=C2C2=C1C=CC=C2)C(C1=CC=CC=C1)(C1=CC=CC=C1)C1=C3/C=C\C=C/1 PLLYJSMIQGDIGY-UHFFFAOYSA-N 0.000 description 1
- FKEKYNKNIUUMCG-COWOPEBESA-N CC1=CC=C(N(C2=CC=C(C3=CC=C(N(C4=CC=C(C)C=C4)C4=CC=C(C(C)(C)C)C=C4)C=C3)C=C2)C2=CC=C(C(C)(C)C)C=C2)C=C1.CCC(C)COC1=C(OCC(C)CC)C=C2C(=C1)C1=C(C=C(C)C=C1)C21C2=C(C=CC(C)=C2)C2=C\C=C(C)/C=C\21.CCC(C)COC1=CC2=C(C=C1OCC(C)C)C1=C(C=C(OCC(C)CC)C(OCC(C)C)=C1)C21C2=C(C=CC(C)=C2)C2=C1/C=C(C)\C=C/2.CCC(C)COC1=CC2=C(C=C1OCC(C)CC)C1(C3=C2C=C(OCC(C)CC)C(OCC(C)CC)=C3)C2=C(C=CC(/C=C/C3=CC=C(C)C=C3)=C2)C2=C1/C=C(/C=C/C1=CC=C(C)C=C1)\C=C/2 Chemical compound CC1=CC=C(N(C2=CC=C(C3=CC=C(N(C4=CC=C(C)C=C4)C4=CC=C(C(C)(C)C)C=C4)C=C3)C=C2)C2=CC=C(C(C)(C)C)C=C2)C=C1.CCC(C)COC1=C(OCC(C)CC)C=C2C(=C1)C1=C(C=C(C)C=C1)C21C2=C(C=CC(C)=C2)C2=C\C=C(C)/C=C\21.CCC(C)COC1=CC2=C(C=C1OCC(C)C)C1=C(C=C(OCC(C)CC)C(OCC(C)C)=C1)C21C2=C(C=CC(C)=C2)C2=C1/C=C(C)\C=C/2.CCC(C)COC1=CC2=C(C=C1OCC(C)CC)C1(C3=C2C=C(OCC(C)CC)C(OCC(C)CC)=C3)C2=C(C=CC(/C=C/C3=CC=C(C)C=C3)=C2)C2=C1/C=C(/C=C/C1=CC=C(C)C=C1)\C=C/2 FKEKYNKNIUUMCG-COWOPEBESA-N 0.000 description 1
- VSEIDZLLWQQJGK-CHOZPQDDSA-N CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O Chemical compound CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O VSEIDZLLWQQJGK-CHOZPQDDSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010072578 Chronic actinic dermatitis Diseases 0.000 description 1
- 241000202285 Claravis Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 206010010317 Congenital absence of bile ducts Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 208000001819 Crigler-Najjar Syndrome Diseases 0.000 description 1
- KOPBYBDAPCDYFK-UHFFFAOYSA-N Cs2O Inorganic materials [O-2].[Cs+].[Cs+] KOPBYBDAPCDYFK-UHFFFAOYSA-N 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 206010065701 Dermatillomania Diseases 0.000 description 1
- 206010012432 Dermatitis acneiform Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 229910052692 Dysprosium Inorganic materials 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241001635598 Enicostema Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000011275 Epicondylitis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000242711 Fasciola hepatica Species 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 208000000901 Focal Epithelial Hyperplasia Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000025499 G6PD deficiency Diseases 0.000 description 1
- 208000009139 Gilbert Disease Diseases 0.000 description 1
- 208000022412 Gilbert syndrome Diseases 0.000 description 1
- 208000034619 Gingival inflammation Diseases 0.000 description 1
- 206010018444 Glucose-6-phosphate dehydrogenase deficiency Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019771 Hepatitis F Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 241001662043 Icterus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 206010066295 Keratosis pilaris Diseases 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 206010024380 Leukoderma Diseases 0.000 description 1
- 208000005995 Lichenoid Eruptions Diseases 0.000 description 1
- YHBTXTFFTYXOFV-UHFFFAOYSA-N Liquid thiophthene Chemical compound C1=CSC2=C1C=CS2 YHBTXTFFTYXOFV-UHFFFAOYSA-N 0.000 description 1
- 206010056301 Lupus miliaris disseminatus faciei Diseases 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- 206010068773 Mechanical urticaria Diseases 0.000 description 1
- 229910000861 Mg alloy Inorganic materials 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 208000000996 Mirizzi syndrome Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 208000014879 Morbihan disease Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000006098 Neonatal Hyperbilirubinemia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010072139 Ocular rosacea Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033635 Pancreatic pseudocyst Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 208000009077 Pigmented Nevus Diseases 0.000 description 1
- 208000000766 Pityriasis Lichenoides Diseases 0.000 description 1
- 208000010332 Plantar Fasciitis Diseases 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000004697 Polyetherimide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000265 Polyparaphenylene Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000006311 Pyoderma Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 208000003493 Rhinophyma Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 201000004854 SAPHO syndrome Diseases 0.000 description 1
- 229910018096 ScF3 Inorganic materials 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 229910052581 Si3N4 Inorganic materials 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 206010041509 Spherocytic anaemia Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229910004299 TbF3 Inorganic materials 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046752 Urticaria Pigmentosa Diseases 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 208000012544 Viral Skin disease Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229910009520 YbF3 Inorganic materials 0.000 description 1
- 239000005083 Zinc sulfide Substances 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- GENZLHCFIPDZNJ-UHFFFAOYSA-N [In+3].[O-2].[Mg+2] Chemical compound [In+3].[O-2].[Mg+2] GENZLHCFIPDZNJ-UHFFFAOYSA-N 0.000 description 1
- XHCLAFWTIXFWPH-UHFFFAOYSA-N [O-2].[O-2].[O-2].[O-2].[O-2].[V+5].[V+5] Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[V+5].[V+5] XHCLAFWTIXFWPH-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- LBGCRGLFTKVXDZ-UHFFFAOYSA-M ac1mc2aw Chemical compound [Al+3].[Cl-].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 LBGCRGLFTKVXDZ-UHFFFAOYSA-M 0.000 description 1
- CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 1
- 150000001251 acridines Chemical class 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 125000006193 alkinyl group Chemical group 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 208000032775 alopecia universalis congenita Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- JYMITAMFTJDTAE-UHFFFAOYSA-N aluminum zinc oxygen(2-) Chemical compound [O-2].[Al+3].[Zn+2] JYMITAMFTJDTAE-UHFFFAOYSA-N 0.000 description 1
- TVIVIEFSHFOWTE-UHFFFAOYSA-N aluminum;quinolin-8-ol Chemical compound [Al+3].C1=CN=C2C(O)=CC=CC2=C1.C1=CN=C2C(O)=CC=CC2=C1.C1=CN=C2C(O)=CC=CC2=C1 TVIVIEFSHFOWTE-UHFFFAOYSA-N 0.000 description 1
- IUFDZNVMARBLOJ-UHFFFAOYSA-K aluminum;quinoline-2-carboxylate Chemical compound [Al+3].C1=CC=CC2=NC(C(=O)[O-])=CC=C21.C1=CC=CC2=NC(C(=O)[O-])=CC=C21.C1=CC=CC2=NC(C(=O)[O-])=CC=C21 IUFDZNVMARBLOJ-UHFFFAOYSA-K 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229940022824 amnesteem Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000010405 anode material Substances 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- YUENFNPLGJCNRB-UHFFFAOYSA-N anthracen-1-amine Chemical compound C1=CC=C2C=C3C(N)=CC=CC3=CC2=C1 YUENFNPLGJCNRB-UHFFFAOYSA-N 0.000 description 1
- VVLCNWYWKSWJTG-UHFFFAOYSA-N anthracene-1,2-diamine Chemical compound C1=CC=CC2=CC3=C(N)C(N)=CC=C3C=C21 VVLCNWYWKSWJTG-UHFFFAOYSA-N 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000040 apocrine gland Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000005284 basis set Methods 0.000 description 1
- WZJYKHNJTSNBHV-UHFFFAOYSA-N benzo[h]quinoline Chemical class C1=CN=C2C3=CC=CC=C3C=CC2=C1 WZJYKHNJTSNBHV-UHFFFAOYSA-N 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- JZKFIPKXQBZXMW-UHFFFAOYSA-L beryllium difluoride Chemical compound F[Be]F JZKFIPKXQBZXMW-UHFFFAOYSA-L 0.000 description 1
- 229910001633 beryllium fluoride Inorganic materials 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 201000005271 biliary atresia Diseases 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- JRXXLCKWQFKACW-UHFFFAOYSA-N biphenylacetylene Chemical compound C1=CC=CC=C1C#CC1=CC=CC=C1 JRXXLCKWQFKACW-UHFFFAOYSA-N 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- UORVGPXVDQYIDP-BJUDXGSMSA-N borane Chemical class [10BH3] UORVGPXVDQYIDP-BJUDXGSMSA-N 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 206010006060 bowenoid papulosis Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000013547 bright light therapy Methods 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Inorganic materials [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000005606 carbostyryl group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000541 cathodic arc deposition Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
- 229910019990 cerium-doped yttrium aluminum garnet Inorganic materials 0.000 description 1
- 239000002800 charge carrier Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- OQENBJBTQPIZKA-UHFFFAOYSA-N chrysen-1-amine Chemical class C1=CC2=C3C=CC=CC3=CC=C2C2=C1C(N)=CC=C2 OQENBJBTQPIZKA-UHFFFAOYSA-N 0.000 description 1
- ILSGDBURWYKYHE-UHFFFAOYSA-N chrysene-1,2-diamine Chemical class C1=CC=CC2=CC=C3C4=CC=C(N)C(N)=C4C=CC3=C21 ILSGDBURWYKYHE-UHFFFAOYSA-N 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 229940031301 claravis Drugs 0.000 description 1
- 229940060799 clarus Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 238000009225 cognitive behavioral therapy Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- XCJYREBRNVKWGJ-UHFFFAOYSA-N copper(II) phthalocyanine Chemical compound [Cu+2].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 XCJYREBRNVKWGJ-UHFFFAOYSA-N 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229910052593 corundum Inorganic materials 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- AFYCEAFSNDLKSX-UHFFFAOYSA-N coumarin 460 Chemical compound CC1=CC(=O)OC2=CC(N(CC)CC)=CC=C21 AFYCEAFSNDLKSX-UHFFFAOYSA-N 0.000 description 1
- VBVAVBCYMYWNOU-UHFFFAOYSA-N coumarin 6 Chemical compound C1=CC=C2SC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 VBVAVBCYMYWNOU-UHFFFAOYSA-N 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002484 cyclic voltammetry Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical class C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 201000000409 dermatographia Diseases 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical class N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
- AKUNKIJLSDQFLS-UHFFFAOYSA-M dicesium;hydroxide Chemical compound [OH-].[Cs+].[Cs+] AKUNKIJLSDQFLS-UHFFFAOYSA-M 0.000 description 1
- 239000003989 dielectric material Substances 0.000 description 1
- 229940002658 differin Drugs 0.000 description 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 description 1
- VDQVEACBQKUUSU-UHFFFAOYSA-M disodium;sulfanide Chemical compound [Na+].[Na+].[SH-] VDQVEACBQKUUSU-UHFFFAOYSA-M 0.000 description 1
- 208000018211 dissecting cellulitis of the scalp Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- HKNRNTYTYUWGLN-UHFFFAOYSA-N dithieno[3,2-a:2',3'-d]thiophene Chemical compound C1=CSC2=C1SC1=C2C=CS1 HKNRNTYTYUWGLN-UHFFFAOYSA-N 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 description 1
- 229960004845 drospirenone Drugs 0.000 description 1
- 229960000925 efaproxiral Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 201000004306 epidermodysplasia verruciformis Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229920000840 ethylene tetrafluoroethylene copolymer Polymers 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 208000020157 familial dermatographia Diseases 0.000 description 1
- 208000006275 fascioliasis Diseases 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000005357 flat glass Substances 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical class O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004773 frontier orbital Methods 0.000 description 1
- 229920001002 functional polymer Polymers 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 208000008605 glucosephosphate dehydrogenase deficiency Diseases 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229960003569 hematoporphyrin Drugs 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 229940083761 high-ceiling diuretics pyrazolone derivative Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001329 hyperkeratotic effect Effects 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 208000012116 immunodeficiency-related disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- SWGQKRKXZZPKJA-UHFFFAOYSA-N indeno[2,1-a]fluorene-1,2-diamine Chemical class C1=CC=C2C=C3C4=CC5=C(N)C(N)=CC=C5C4=CC=C3C2=C1 SWGQKRKXZZPKJA-UHFFFAOYSA-N 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229910052809 inorganic oxide Inorganic materials 0.000 description 1
- 229910052909 inorganic silicate Inorganic materials 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 210000001613 integumentary system Anatomy 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002503 iridium Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 208000006663 kernicterus Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000005355 lead glass Substances 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- PQXKHYXIUOZZFA-UHFFFAOYSA-M lithium fluoride Inorganic materials [Li+].[F-] PQXKHYXIUOZZFA-UHFFFAOYSA-M 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- AHEVKYYGXVEWNO-UEPZRUIBSA-N lymecycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(=O)NCNCCCC[C@H](N)C(O)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O AHEVKYYGXVEWNO-UEPZRUIBSA-N 0.000 description 1
- 229960004196 lymecycline Drugs 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000030179 maculopapular cutaneous mastocytosis Diseases 0.000 description 1
- 229910001635 magnesium fluoride Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 208000028138 melanocytic neoplasm Diseases 0.000 description 1
- 201000002699 melanoma in congenital melanocytic nevus Diseases 0.000 description 1
- ABCGFHPGHXSVKI-UHFFFAOYSA-O meso-tetrakis(n-methyl-4-pyridyl)porphine(4+) Chemical compound C1=C[N+](C)=CC=C1C(C1=CC=C(N1)C(C=1C=C[N+](C)=CC=1)=C1C=CC(=N1)C(C=1C=C[N+](C)=CC=1)=C1C=CC(N1)=C1C=2C=C[N+](C)=CC=2)=C2N=C1C=C2 ABCGFHPGHXSVKI-UHFFFAOYSA-O 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 229910052976 metal sulfide Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- YUUAYBAIHCDHHD-UHFFFAOYSA-N methyl 5-aminolevulinate Chemical compound COC(=O)CCC(=O)CN YUUAYBAIHCDHHD-UHFFFAOYSA-N 0.000 description 1
- 229960005033 methyl aminolevulinate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 201000010241 mucinoses Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- IBHBKWKFFTZAHE-UHFFFAOYSA-N n-[4-[4-(n-naphthalen-1-ylanilino)phenyl]phenyl]-n-phenylnaphthalen-1-amine Chemical group C1=CC=CC=C1N(C=1C2=CC=CC=C2C=CC=1)C1=CC=C(C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C3=CC=CC=C3C=CC=2)C=C1 IBHBKWKFFTZAHE-UHFFFAOYSA-N 0.000 description 1
- RYZPDEZIQWOVPJ-UHFFFAOYSA-N n-naphthalen-1-yl-n-[4-[4-[naphthalen-1-yl(naphthalen-2-yl)amino]phenyl]phenyl]naphthalen-2-amine Chemical group C1=CC=C2C(N(C=3C=CC(=CC=3)C=3C=CC(=CC=3)N(C=3C=C4C=CC=CC4=CC=3)C=3C4=CC=CC=C4C=CC=3)C3=CC4=CC=CC=C4C=C3)=CC=CC2=C1 RYZPDEZIQWOVPJ-UHFFFAOYSA-N 0.000 description 1
- 125000006608 n-octyloxy group Chemical group 0.000 description 1
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- LKKPNUDVOYAOBB-UHFFFAOYSA-N naphthalocyanine Chemical class N1C(N=C2C3=CC4=CC=CC=C4C=C3C(N=C3C4=CC5=CC=CC=C5C=C4C(=N4)N3)=N2)=C(C=C2C(C=CC=C2)=C2)C2=C1N=C1C2=CC3=CC=CC=C3C=C2C4=N1 LKKPNUDVOYAOBB-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910000480 nickel oxide Inorganic materials 0.000 description 1
- USPVIMZDBBWXGM-UHFFFAOYSA-N nickel;oxotungsten Chemical compound [Ni].[W]=O USPVIMZDBBWXGM-UHFFFAOYSA-N 0.000 description 1
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 1
- 150000004767 nitrides Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 150000007978 oxazole derivatives Chemical class 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- PQQKPALAQIIWST-UHFFFAOYSA-N oxomolybdenum Chemical compound [Mo]=O PQQKPALAQIIWST-UHFFFAOYSA-N 0.000 description 1
- GNRSAWUEBMWBQH-UHFFFAOYSA-N oxonickel Chemical compound [Ni]=O GNRSAWUEBMWBQH-UHFFFAOYSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- YRZZLAGRKZIJJI-UHFFFAOYSA-N oxyvanadium phthalocyanine Chemical compound [V+2]=O.C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 YRZZLAGRKZIJJI-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 206010033898 parapsoriasis Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- 230000002215 photochemotherapeutic effect Effects 0.000 description 1
- 238000000103 photoluminescence spectrum Methods 0.000 description 1
- 125000005543 phthalimide group Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229920002493 poly(chlorotrifluoroethylene) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920005668 polycarbonate resin Polymers 0.000 description 1
- 239000004431 polycarbonate resin Substances 0.000 description 1
- 239000005023 polychlorotrifluoroethylene (PCTFE) polymer Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001225 polyester resin Polymers 0.000 description 1
- 239000004645 polyester resin Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 229920001601 polyetherimide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002098 polyfluorene Polymers 0.000 description 1
- 239000009719 polyimide resin Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920002620 polyvinyl fluoride Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 238000004549 pulsed laser deposition Methods 0.000 description 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
- 150000003219 pyrazolines Chemical class 0.000 description 1
- BUAWIRPPAOOHKD-UHFFFAOYSA-N pyrene-1,2-diamine Chemical class C1=CC=C2C=CC3=C(N)C(N)=CC4=CC=C1C2=C43 BUAWIRPPAOOHKD-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- WVIICGIFSIBFOG-UHFFFAOYSA-N pyrylium Chemical compound C1=CC=[O+]C=C1 WVIICGIFSIBFOG-UHFFFAOYSA-N 0.000 description 1
- 230000005610 quantum mechanics Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 150000002909 rare earth metal compounds Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229940002683 retin-a Drugs 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007761 roller coating Methods 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052706 scandium Inorganic materials 0.000 description 1
- OEKDNFRQVZLFBZ-UHFFFAOYSA-K scandium fluoride Chemical compound F[Sc](F)F OEKDNFRQVZLFBZ-UHFFFAOYSA-K 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 150000003346 selenoethers Chemical class 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000005266 side chain polymer Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 150000003967 siloles Chemical class 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000010944 silver (metal) Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- JACPFCQFVIAGDN-UHFFFAOYSA-M sipc iv Chemical compound [OH-].[Si+4].CN(C)CCC[Si](C)(C)[O-].C=1C=CC=C(C(N=C2[N-]C(C3=CC=CC=C32)=N2)=N3)C=1C3=CC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 JACPFCQFVIAGDN-UHFFFAOYSA-M 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000005361 soda-lime glass Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Inorganic materials [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 1
- VPQBLCVGUWPDHV-UHFFFAOYSA-N sodium selenide Chemical compound [Na+].[Na+].[Se-2] VPQBLCVGUWPDHV-UHFFFAOYSA-N 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 206010041307 solar urticaria Diseases 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940034345 sotret Drugs 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 229920006301 statistical copolymer Polymers 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000001629 stilbenes Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- 229910001637 strontium fluoride Inorganic materials 0.000 description 1
- FVRNDBHWWSPNOM-UHFFFAOYSA-L strontium fluoride Chemical compound [F-].[F-].[Sr+2] FVRNDBHWWSPNOM-UHFFFAOYSA-L 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 description 1
- 229950010924 talaporfin Drugs 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 229940036234 tazorac Drugs 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 150000004867 thiadiazoles Chemical class 0.000 description 1
- 150000003557 thiazoles Chemical class 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- NMFKEMBATXKZSP-UHFFFAOYSA-N thieno[3,2-b]thiophene Chemical compound S1C=CC2=C1C=CS2.S1C=CC2=C1C=CS2 NMFKEMBATXKZSP-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000004882 thiopyrans Chemical class 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 229910001887 tin oxide Inorganic materials 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000013306 transparent fiber Substances 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- LKNRQYTYDPPUOX-UHFFFAOYSA-K trifluoroterbium Chemical compound F[Tb](F)F LKNRQYTYDPPUOX-UHFFFAOYSA-K 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 238000004402 ultra-violet photoelectron spectroscopy Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 1
- 229960003895 verteporfin Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 150000003732 xanthenes Chemical class 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
- 229910001845 yogo sapphire Inorganic materials 0.000 description 1
- 229910019901 yttrium aluminum garnet Inorganic materials 0.000 description 1
- YVTHLONGBIQYBO-UHFFFAOYSA-N zinc indium(3+) oxygen(2-) Chemical compound [O--].[Zn++].[In+3] YVTHLONGBIQYBO-UHFFFAOYSA-N 0.000 description 1
- 229910052984 zinc sulfide Inorganic materials 0.000 description 1
- 229940063789 zinc sulfide Drugs 0.000 description 1
- DRDVZXDWVBGGMH-UHFFFAOYSA-N zinc;sulfide Chemical compound [S-2].[Zn+2] DRDVZXDWVBGGMH-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0616—Skin treatment other than tanning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
- A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0618—Psychological treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0621—Hyperbilirubinemia, jaundice treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
-
- H01L51/5004—
-
- H01L51/5287—
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
- H10K50/00—Organic light-emitting devices
- H10K50/10—OLEDs or polymer light-emitting diodes [PLED]
- H10K50/11—OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
- H10K50/00—Organic light-emitting devices
- H10K50/10—OLEDs or polymer light-emitting diodes [PLED]
- H10K50/14—Carrier transporting layers
- H10K50/15—Hole transporting layers
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
- H10K50/00—Organic light-emitting devices
- H10K50/10—OLEDs or polymer light-emitting diodes [PLED]
- H10K50/14—Carrier transporting layers
- H10K50/16—Electron transporting layers
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
- H10K50/00—Organic light-emitting devices
- H10K50/10—OLEDs or polymer light-emitting diodes [PLED]
- H10K50/17—Carrier injection layers
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
- H10K50/00—Organic light-emitting devices
- H10K50/10—OLEDs or polymer light-emitting diodes [PLED]
- H10K50/17—Carrier injection layers
- H10K50/171—Electron injection layers
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
- H10K50/00—Organic light-emitting devices
- H10K50/10—OLEDs or polymer light-emitting diodes [PLED]
- H10K50/18—Carrier blocking layers
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
- H10K50/00—Organic light-emitting devices
- H10K50/10—OLEDs or polymer light-emitting diodes [PLED]
- H10K50/182—OLED comprising a fiber structure
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
- H10K85/00—Organic materials used in the body or electrodes of devices covered by this subclass
- H10K85/10—Organic polymers or oligomers
- H10K85/111—Organic polymers or oligomers comprising aromatic, heteroaromatic, or aryl chains, e.g. polyaniline, polyphenylene or polyphenylene vinylene
- H10K85/113—Heteroaromatic compounds comprising sulfur or selene, e.g. polythiophene
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
- H10K85/00—Organic materials used in the body or electrodes of devices covered by this subclass
- H10K85/10—Organic polymers or oligomers
- H10K85/111—Organic polymers or oligomers comprising aromatic, heteroaromatic, or aryl chains, e.g. polyaniline, polyphenylene or polyphenylene vinylene
- H10K85/115—Polyfluorene; Derivatives thereof
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
- H10K85/00—Organic materials used in the body or electrodes of devices covered by this subclass
- H10K85/10—Organic polymers or oligomers
- H10K85/151—Copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/063—Radiation therapy using light comprising light transmitting means, e.g. optical fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0645—Applicators worn by the patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
- A61N2005/0653—Organic light emitting diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
- A61N2005/0663—Coloured light
-
- H01L2251/552—
-
- H01L51/0043—
-
- H01L51/5012—
-
- H01L51/5056—
-
- H01L51/5072—
-
- H01L51/5088—
-
- H01L51/5092—
-
- H01L51/5096—
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
- H10K2101/00—Properties of the organic materials covered by group H10K85/00
- H10K2101/30—Highest occupied molecular orbital [HOMO], lowest unoccupied molecular orbital [LUMO] or Fermi energy values
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
- H10K2101/00—Properties of the organic materials covered by group H10K85/00
- H10K2101/40—Interrelation of parameters between multiple constituent active layers or sublayers, e.g. HOMO values in adjacent layers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E10/00—Energy generation through renewable energy sources
- Y02E10/50—Photovoltaic [PV] energy
- Y02E10/549—Organic PV cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49826—Assembling or joining
Definitions
- Organic light emitting diodes have many advantages over their inorganic counterpart (light emitting diodes—LEDs) in that they are intrinsically flexible, and can be coated on large area by, for example, printing technologies, such as ink jet printing and screen printing. Furthermore they allow more homogenous irradiation as compared to LEDs.
- LEDs light emitting diodes
- Vogle Klaus and Kallert Heiko disclosed in EP 018180773 a device for the treatment of skin.
- the device comprises an potentially flexible organic light emitting diode (OLED) as light source.
- OLED organic light emitting diode
- the device can be integrated in clothes or plaster.
- FIG. 3 illustrates parallel arrangement of light emitting fibers in a device which emits light with n different wavelengths or ranges of wavelengths.
- FIG. 9 illustrates electroluminescence (EL) spectrum of fiber OLED using PB 1 as EML (emissive layer).
- the term functional material refers to an organic functional material.
- the term also refers to organic conductors, semiconductors, organic fluorescent compounds, organic phosphorescent compounds, organo-metallic complexes of transition metals, rare earths, lanthanides and actinides.
- emissive materials preferably refers to electroluminescent emitter materials as outlined elsewhere within the present invention.
- the molecular weight of the small molecule is preferably below 4000 g/mol, particularly preferably below 3000 g/mol, and very particularly preferably below 2000/mol.
- the polymers of the present invention preferably have 10 to 10000, particularly preferably 20 to 5000 and very particularly preferably 50 to 2000 repeat units. Oligomers according to this invention have preferably 2 to 9 repeat units.
- the branching index of the polymers and oligomers is between 0 (linear polymer without branching) and 1 (completely branched dendrimer).
- dendrimer as used herein is defined according to M. Fischer et al. in Angew. Chem., Int. Ed. 1999, 38, 885).
- a blend is a mixture comprising at least one polymeric dendrimeric, or oligomeric component.
- Organic functional materials according to the present invention are often characterized by their molecular frontier orbitals, i.e. the highest occupied molecular orbital (HOMO) (sometimes also referred to as valence band) and the lowest unoccupied molecular orbital (LUMO)(sometimes also referred to as conduction band).
- HOMO highest occupied molecular orbital
- LUMO lowest unoccupied molecular orbital
- the organic functional materials can be selected from exciton blocking materials (ExBM).
- An ExBM refers to a material which, if deposited adjacent to an emissive layer in a multilayer structure, prevents the excitons from diffusing through. ExBM should have either a higher triplet level or singlet level as compared to the emissive layer or other adjacent layer.
- dopant as employed herein is also used for the term emitter or emitter material.
- Arylamine dendrimers can also be used (JP Heisei 8 (1996) 193191), as can phthalocyanine derivatives, naphthalocyanine derivatives, or butadiene derivatives, are also suitable.
- Suitable materials for hole-transporting layers are phenylenediamine derivatives (U.S. Pat. No. 3,615,404), arylamine derivatives (U.S. Pat. No. 3,567,450), amino-substituted chalcone derivatives (U.S. Pat. No. 3,526,501), styrylanthracene derivatives (JP A 56-46234), polycyclic aromatic compounds (EP 1009041), polyarylalkane derivatives (U.S. Pat. No. 3,615,402), fluorenone derivatives (JP A 54-110837), hydrazone derivatives (U.S. Pat. No.
- aromatic tertiary amines containing at least two tertiary amine units (U.S. Pat. No. 4,720,432 and U.S. Pat. No. 5,061,569), such as, for example, 4,4′-bis[N-(1-naphthyl)-N-phenylamino]biphenyl (NPD) (U.S. Pat. No.
- EIMs which comprises at least one organic compound selected from metal complexes of 8-hydroxyquinoline, heterocyclic organic compounds, fluorenones, fluorenylidene methane, perylenetetracarboxylic acid, anthraquinone dimethanes, diphenoquinones, anthrones, anthraquinonediethylene-diamines, isomers and derivates thereof can be used according to the invention.
- EBM any EBM known to one skilled in the art can be employed according to the present invention.
- transition-metal complexes such as, for example, Ir(ppz) 3 (US 2003/0175553) can be employed as materials for an electron-blocking layer.
- N-substituted carbazole compounds such as, for example, TCTA, or heterocycles, such as, for example, BCP, are also suitable.
- derivatives of arylamine and styrylamine for example 4,4′-bis[N-(1-naphthyl)-N-(2-naphthyl)amino]biphenyl (TNB).
- Blue fluorescent emitters are preferably polyaromatic compounds, such as, for example, 9,10-di(2-naphthylanthracene) and other anthracene derivatives, derivatives of tetracene, xanthene, perylene, such as, for example, 2,5,8,11-tetra-t-butylperylene, phenylene, for example 4,4′-(bis(9-ethyl-3-carbazovinylene)-1,1′-biphenyl, fluorene, arylpyrenes (US 2006/0222886), arylenevinylenes (U.S. Pat. No. 5,121,029, U.S. Pat. No.
- Preferred fluorescent dopants according to the present invention are selected from the class of the monostyrylamines, the distyrylamines, the tristyrylamines, the tetrastyrylamines, the styrylphosphines, the styryl ethers and the arylamines.
- dopants from the class of the styrylamines are substituted or unsubstituted tristilbene-amines or the dopants described in WO 2006/000388, WO 2006/058737, WO 2006/000389, WO 2007/065549 and WO 2007/115610.
- Distyrylbenzene and distyrylbiphenyl derivatives are described in U.S. Pat. No. 5,121,029. Further styrylamines are found in US 2007/0122656 A1.
- the phosphorescent emitter may be a metal complex, preferably with the formula M(L) z , wherein M is a metal atom, L is in each occurrence independently of one another an organic ligand that is bonded to or coordinated with M via one, two or more positions, and z is an integer ⁇ 1, preferably 1, 2, 3, 4, 5 or 6, and wherein, optionally, these groups are linked to a polymer via one or more, preferably one, two or three positions, preferably via the ligands L.
- M is in particular a metal atom selected from transition metals, preferably selected from transition metals of group VIII, or lanthanoides, or actinides, particularly preferably selected from Rh, Os, Ir, Pt, Pd, Au, Sm, Eu, Gd, Tb, Dy, Re, Cu, Zn, W, Mo, Pd, Ag, or Ru, and very particularly preferably selected from Os, Ir, Ru, Rh, Re, Pd, or Pt. M may also be Zn.
- transition metals preferably selected from transition metals of group VIII, or lanthanoides, or actinides, particularly preferably selected from Rh, Os, Ir, Pt, Pd, Au, Sm, Eu, Gd, Tb, Dy, Re, Cu, Zn, W, Mo, Pd, Ag, or Ru, and very particularly preferably selected from Os, Ir, Ru, Rh, Re, Pd, or Pt.
- M may also be Zn.
- the layer of a device or a composition according to the present invention can also comprise at least one metal complex.
- the layer of a devices or a composition according to the present invention comprises 3, particularly preferably 2, and very particularly preferably 1 metal complexes.
- Preferred ligands are 2 phenylpyridine derivatives, 7,8-benzoquinoline derivatives, 2 (2-thienyl)pyridine derivatives, 2 (1-naphthyl)pyridine derivatives or 2 phenylquinoline derivatives. All these compounds may be substituted, for example by fluoro- or trifluoromethyl substituents for blue.
- Auxiliary ligands are preferably acetylacetonate or picric acid.
- Pt porphyrin complexes having an enlarged ring system (US 2009/0061681 A1) and Ir complexes are suitable, for example 2,3,7,8,12,13,17,18-octaethyl-21H, 23H-porphyrin-Pt(II), tetraphenyl-Pt(II)-tetrabenzoporphyrin (US 2009/0061681 A1), cis-bis(2-phenylpyridinato-N,C2′) Pt(II), cis-bis(2-(2′-thienyl)pyridinato-N,C3′)Pt(II), cis-bis(2-(2′-thienyl)quinolinato-N
- Further preferred units from group 1 are, for example, triarylamine, benzidine, tetraaryl-para-phenylenediamine, carbazole, azulene, thiophene, pyrrole and furan derivatives and further O, S or N containing heterocycles with a high HOMO.
- These arylamines and heterocycles preferably result in an HOMO in the polymer of higher than 5.8 eV (against vacuum level), particularly preferably higher than 5.5 eV.
- Ar 1 which may be the same or different, denote, independently if in different repeat units, a single bond or an optionally substituted mononuclear or polynuclear aryl group
- Ar 2 which may be the same or different, denote, independently if in different repeat units, an optionally substituted mononuclear or polynuclear aryl group
- Ar 3 which may be the same or different, denote, independently if in different repeat units, an optionally substituted mononuclear or polynuclear aryl group
- m is 1, 2 or 3
- the said organic functional material is an electron transport or injection polymer comprising groups 2, which is preferably selected from groups comprising the low molecular weight ETMs or EIMs as described above.
- the said organic functional material is a polymer comprising units from group 3 in which structures which increase the hole mobility and the electron mobility (i.e. units from groups 1 and 2) are bonded directly to one another. Some of these units may serve as emitters and shift the emission colour into the green, yellow or red. Their use is thus suitable, for example, for the production of other emission colours or a broad-band emission from originally blue-emitting polymers.
- the said organic functional material is a polymeric triple matrix comprising units of group 5, which can improve the transition from the singlet state to the triplet state and which, employed in support of the structural elements from group 4, improve the phosphorescence properties of these structural elements.
- Suitable for this purpose are, in particular, carbazole and bridged carbazole dimer units, as described in DE 10304819 A1 and DE 10328627 A1.
- ketones, phosphine oxides, sulfoxides, sulfones, silane derivatives and similar compounds as described in DE 10349033 A1.
- Further preferred structure units can be selected from groups comprising the low molecular weight phosphorescent matrices as described above.
- Very preferred structural elements of group 7 are those of Formula 67:
- the groups of Formula 67 are preferably selected from the following Formulae 68 to 72:
- R is preferably F, Cl, Br, I, —CN, —NO 2 , —NCO, —NCS, —OCN, —SCN, —C( ⁇ O)NR 0 R 00 , —C( ⁇ O)X 0 , —C( ⁇ O)R 0 , —NR 0 R 00 , optionally substituted silyl, aryl or heteroaryl with 4 to 40, preferably 6 to 20 C atoms, or straight chain, branched or cyclic alkyl, alkoxy, alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy or alkoxycarbonyloxy with 1 to 20, preferably 1 to 12 C atoms, wherein one or more H atoms are optionally replaced by F or Cl, and wherein R 0 , R 00 and X 0 are as defined above.
- L is H, halogen or optionally fluorinated, linear or branched alkyl or alkoxy with 1 to 12 C atoms, and is preferably H, F, methyl, i-propyl, t-butyl, n-pentoxy, or trifluoromethyl
- L′ is optionally fluorinated, linear or branched alkyl or alkoxy with 1 to 12 C atoms, and is preferably n-octyl or n-octyloxy.
- the polymer used as organic functional material in the invention may be statistical or random copolymers, alternating or regioregular copolymers, block copolymers or combinations thereof.
- the polymer is a conjugated polymer, wherein the functional groups as described above and bellow are integrated into the polymer main chain.
- the polymer is a non-conjugated or partially-conjugated polymer.
- the said polymer is a main-chain non-conjugated polymer, wherein the polymer comprises at least one non-conjugated spacer on main-chain.
- Very particularly preferred non-conjugated or partially-conjugated polymers comprise a non-conjugated backbone unit or a unit interrupting the conjugation of backbone units.
- main-chain non-conjugated polymers give also a high triplet level.
- Preferred non-conjugated backbone units are selected from units comprising indenofluorene derivatives, as shown, for example, in the following Formulae 77 and 78 and as disclosed in DE 102009023156.0.
- the said polymer is a side-chain non-conjugated polymer, which is especially important for phosphorescent OLEDs based on polymer.
- phosphorescent polymer is obtained by means of radical copolymerization of vinyl compounds, and comprises at least one phosphorescent emitter and at least one charge transport unit on side chain, as disclosed in U.S. Pat. No. 7,250,226 B2. Further examples for such phosphorescent polymer are disclosed for example in JP 2007/211243 A2, JP 2007/197574 A2, U.S. Pat. No. 7,250,226B2, JP 2007/059939A.
- alkali metal complexes alkaline-earth metal complexes, rare-earth metals (Sc, Y, Ce, Th, Yb), rare-earth metal complexes, rare-earth metal compounds (preferably YbF 3 , ScF 3 , TbF 3 ) or the like.
- anode is not or only partially transparent further conducting materials can be used.
- Preferred materials for non transparent or partially transparent anodes are selected from, but not limited to, Au, Ir, Mo, Pd, Pt, Cu, Ag, Sn, C, Al, V, Fe, Co, Ni, W, and mixtures thereof.
- the conducting materials can also be mixed with further conducting materials as described above, e.g. In—Cu.
- one of the primary effects of phototherapy is the stimulation of metabolism in the mitochondria. After phototherapy, the cells show an increased metabolism, they communicate better and they survive stressful conditions in a better way.
- the organic radiation emitting fiber may also include an optional radiation scattering layer, comprising scattering particles such as TiO 2 , Al 2 O 3 , or SiO 2 for effective color mixing and brightness uniformity.
- the scattering particles can also be mixed into the encapsulating material 60 , or be formed as a separate layer over the encapsulating material 60 , if desired.
- a typical sequence of layers as found in an OLED and, thus, also find in the radiation emitting layer 30 is, for example:
- Conjugated polymers are discussed, for example, in R. H. Friend, 4 J. Mol. Electronics 37-46 (1988).
- One example of a conjugated polymer is PPV (poly(p-phenylenevinylene).
- PPV poly(p-phenylenevinylene).
- PPV emits light in the spectral range of about 500 to 690 nm and has good resistance to thermal and stress induced cracking.
- the fiber can be deformed plastically without fracture, or elastic, i.e. the fiber deforms reversibly and once the forces responsible for deformation are no longer applied, the object returns to its original shape.
- the fiber is flexible.
- the device comprising the fibers can therefore adopt any shape according to the physiognomy of the subject to be treated and it can follow the movements and changes of its shape instantaneously.
- the fiber deforms plastically. If the fiber is, e.g., incorporated in a bandage or plaster, the plaster can be adopted to the physiognomy of the subject to be treated. However, it may not follow the subject's changes of the surface. Depending on the degree of plasticity and stiffness the plaster or bandage can stabilize parts of the surface to be treated.
- the attachment means comprises an adhesive surface to enable the device to be attached to a patient.
- Devices can generally spoken individually tailored in any form that is required for treatment.
- the fiber devices comprising the functional materials according to the present invention can be used in cosmetics for skin care and skin repair, e.g. as light plaster.
- the wavelengths or range of wavelengths emitted by said devices is in the range between 400 and 800 nm, preferably between 450 and 750 nm, particularly preferably between 500 and 700 nm, and very particularly preferably between 580 and 640 nm.
- PUVA therapy is derived from the therapeutic application of psoralen (7H-furo[3,2-g]chromen-7-one) and derivatives thereof together with UV-A light.
- PUVA can be employed for the treatment of skin diseases characterized by hyperproliferative conditions.
- Psoralen is the parent compound in a family of natural products. It is structurally related to coumarines and can preferably be used for the treatment of psoriasis, eczema, vitiligo, mycosis fungoides, cutaneous T-cell lymphoma, and other autoimmune diseases.
- With PUVA can also bet treated atopic eczema, lichen planus, urticaria pigmentosa, polymorphous light eruption, and alopecia areata.
- vitiligo khellin can be used instead of psoralen.
- the combined treatment with light and khellin is often called KUVA.
- Light exposure can be used as treatment for acne. Used twice weekly, this has been shown to reduce the number of acne lesions by about 64% and is even more effective when applied daily.
- the mechanism appears to be that a porphyrin (Coproporphyrin III) produced within P. acnes generates free radicals when irradiated by 420 nm and shorter wavelengths of light. Particularly when applied over several days, these free radicals ultimately kill the bacteria. Since porphyrins are not otherwise present in skin, and no UV light is employed, it appears to be safe.
- a so called whitehead which is also called closed comedo, is a follicle that is filled with the same material, sebum, but has a microscopic opening to the skin surface. Since the air cannot reach the follicle, the material is not oxidized, and remains white.
- the said fiber devices comprising the functional materials according to the present invention preferably emit light, when used for the treatment of acne, in the range between 350 and 900 nm, preferably between 380 and 850 nm, particularly preferably between 400 and 850 nm, and very particularly preferably between 400 and 800 nm.
- Preferred blue light has emission wavelengths for the treatment of acne are 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429 and 430 nm.
- 414 and 415 nm are particularly suitable in order to kill P. acnes bacteria and to help cure existing blemishes and to prevent further outbreaks.
- Cellulite describes a condition that is claimed to occur in most women, where the skin of the lower limbs, abdomen, and pelvic region becomes dimpled.
- the causes of cellulite are poorly understood and may involve changes in metabolism and physiology such as gender specific dimorphic skin architecture, alteration of connective tissue structure, vascular changes and inflammatory processes.
- a couple of therapies are applied to prevent or to treat cellulite. Heat and the increase of blood flow are two common techniques. Therefore light therapy is considered to be beneficial to individuals suffering from cellulite.
- Said functional material and fiber devices comprising them are suitable for the treatment and/or prophylaxis of cellulite.
- PDT is also suitable for the treatment and/or prophylaxis of cellulite.
- the wavelength for the treatment and/or prophylaxis of cellulite that is to be emitted by the said fiber devices comprising the functional materials is in the range between 400 and 1000 nm, preferably in the range between 400 and 900 nm, particularly preferably between 450 and 900 nm, and very particularly preferably between 500 and 850 nm.
- the more general term skin ageing refers to both the formation of wrinkles and hyperpigmentation.
- the signs of ageing of the human skin resulting from the effects on the skin of intrinsic and extrinsic factors are defined by the appearance of wrinkles and fine lines, by the yellowing of the skin which develops a wizened appearance along with the appearance of pigmentation blemishes, by a change in the thickness of the skin, generally resulting in a thickening of the stratum corneum and of the epidermis and a thinning of the dermis, by disorganization of the elastin and collagen fibers which causes a loss of elasticity, of suppleness and of firmness, and by the appearance of telnagiectasia.
- Phototherapy provides a new way to treat ageing of the skin.
- another subject of the invention is the use of the said functional materials and fiber devices comprising them for the treatment and/or prophylaxis of skin ageing.
- the present invention provides solutions, inter alia, for skin rejuvenation and to reduce or prevent the formation of wrinkles.
- the said fiber devices comprising the functional materials used for the treatment of skin ageing emits light in the range of 600 nm and 650 nm, particularly preferably in the range between 620 nm and 650 nm.
- Further particular preferred light for the treatment and/or prophylaxis of skin ageing has a wavelength between 400 and 900 nm.
- Skin rejuvenation can also be achieved with light of the wavelength of 830 nm or slightly below or above that value. Therefore, fiber devices according to the present invention emitting light in the range between 700 nm and 1000 nm, preferably between 750 nm and 900 nm, particularly preferably between 750 nm and 860 nm, and very particularly preferably between 800 nm and 850 nm are also subject of the present invention. Redness of the skin of a subject can be treated by fiber devices according to the present invention.
- the wavelength for the treatment and/or prophylaxis of redness that is to be emitted by the said devices is in the range between 460 and 660 nm.
- the wavelength is in the range between 500 and 620 nm, and particularly preferably between 540 and 580 nm.
- One particularly preferred wavelength for this purpose is 560 nm.
- Edema formerly known as dropsy or hydropsy
- Edema is an abnormal accumulation of fluid beneath the skin or in one or more cavities of the body.
- the amount of interstitial fluid is determined by the balance of fluid homeostasis, and increased secretion of fluid into the interstitium or impaired removal of this fluid may cause edema.
- Five factors can contribute to the formation of edema: (1) It may be facilitated by increased hydrostatic pressure or by reduced oncotic pressure within blood vessels or (2) by increased blood vessel wall permeability as in inflammation or (4) by obstruction of fluid clearance via the lymphatic or (5) by changes in the water retaining properties of the tissues themselves. Raised hydrostatic pressure often reflects retention of water and sodium by the kidney.
- the functional materials according to the present invention and said fiber devices comprising them can also be used for the treatment and/or prophylaxis and/or diagnosis of infections and inflammatory, neurological, and psychological diseases and/or conditions.
- Preferred wavelengths for the treatment and/or prophylaxis of inflammation are in the range between 350 and 900 nm, particularly preferably between 380 and 900 nm, and very particularly preferably between 400 and 860 nm. Further preferred wavelengths for the treatment and/or prophylaxis of inflammation are 405, 420, and 850 nm.
- the said functional materials and said fiber devices comprising them can be used for the treatment and/or prophylaxis of infections.
- Infections can be caused by bacteria and viruses.
- Light has several positive effects on infections. Light has, e.g., anti-inflammatory effects through the stimulation of the tissue as outlined elsewhere within the present invention.
- Phototherapy with said functional materials and fiber devices comprising them are beneficial for the use to treat wounds.
- Wound healing is often associated with inflammation. Therefore the same wavelengths and ranges of wavelengths as outlined for the treatment and/or prophylaxis of inflammation can be applied.
- Treating wounds by phototherapy also prevents the formation of scares.
- Particularly preferred wavelengths for the treatment and/or prophylaxis of wounds and/or scares are in the range between 600 and 950 nm and very particularly preferably between 650 and 900 nm.
- Further preferred wavelengths for the treatment and/or prophylaxis of wounds and scares are 660, 720, and 880 nm.
- a preferred embodiment of this invention is the use of the said functional materials and said fiber devices comprising them for the treatment and/or prophylaxis of viral infections particularly caused by cytomegalovirus (CMV), encephalo myocarditis virus (EMCV), poliovirus, influenca virus, parainfluenza respiratory influenza virus, respiratory syncytial virus, Japanese encephalitis virus, Dengue virus, hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), hepatitis E virus (HEV), hepatitis F virus (HFV), hepatitis G virus (HGV) Epstein Barr Virus (EBV), human immunodeficiency virus type 1 (HIV-I), human immunodeficiency virus type 2 (HIV-2), varicella zoster virus, herpes simplex virus,
- CMV cytomegalovirus
- EMCV encephalo myocardi
- Said functional materials and said fiber devices comprising them may also be used for the treatment and/or prophylaxis of pain.
- Pain relief by phototherapy is well known.
- the following conditions produce pain that can be treated successfully with phototherapy: carpal tunnel syndrome, chronic wounds, epicondylitis, headache, migraine, plantar fasciitis, tendonditis and bursitis, neck pain, back pain, muscle pain, trigeminal neuralgia, and Whiplash-associated injuries.
- Alopecia areata is a condition affecting humans, in which hair is lost from some or all areas of the body, usually from the scalp. Because it causes bald spots on the scalp, especially in the first stages, it is sometimes called spot baldness. In 1 to 2% of cases, the condition can spread to the entire scalp (alopecia totalis) or to the entire epidermis (alopecia universalis). Conditions resembling alopecia areata, and having a similar cause, occur also in other species.
- said functional materials and light emitting fiber devices comprising them for the disinfection of beverages, preferably water, and particularly preferably drinking water.
- Contaminated water causes many infections worldwide and leads often to severe diseases or death of the individuals.
- the said functional materials and light emitting fiber devices comprising them provide a simple means to disinfect water.
- Water filter systems of commercial providers take advantage of ion exchange technology. The filter, however, often tend to microbial contamination, which, in turn results in water which is contaminated with microbes.
- One solution is to add silver salt which is from a toxicological point of view problematic.
- the said functional materials and light emitting fiber devices comprising them provide a solution to this problem.
- the said functional materials and light emitting fiber devices comprising them can be used for the disinfection of beverages and nutrition for humans and animals.
- the functional materials according to the present invention and said fiber devices comprising them can also be used for the photodynamic therapy (PDT).
- PDT photodynamic therapy
- the functional materials according to the present invention and said fiber devices comprising them can also be used for the treatment and/or prophylaxis of jaundice and crigler naijar.
- Hepatic jaundice causes include acute hepatitis, hepatotoxicity and alcoholic liver disease, whereby cell necrosis reduces the liver's ability to metabolise and excrete bilirubin leading to a buildup in the blood. Less common causes include primary biliary cirrhosis, Gilbert's syndrome (a genetic disorder of bilirubin metabolism which can result in mild jaundice, which is found in about 5% of the population), Crigler-Najjar syndrome, metastatic carcinoma and Niemann-Pick disease, type C. Jaundice seen in the newborn, known as neonatal jaundice, is common, occurring in almost every newborn as hepatic machinery for the conjugation and excretion of bilirubin does not fully mature until approximately two weeks of age.
- Jaundice in particular neonatal jaundice, can lead to severe medical consequences if not or not appropriately treated.
- Increased concentrations of bilirubin can result in a brain-damaging condition known as kernicterus, leading to significant lifelong disability; there are concerns that this condition has been rising in recent years due to inadequate detection and treatment of neonatal hyperbilirubinemia.
- Early treatment often consists of exposing the infant to intensive phototherapy in an more or less isolated incubator. The therapy often represents an emotionally or psychologically difficult situation for both the infant and the parents.
- the said functional materials and said light emitting fiber devices comprising the functional materials can be employed in order to provide flexible and ambulatory devices such as blankets.
- Traditional therapies also easily lead to overheating of the infant, which can also be significantly reduced with the treatment approach according to the present invention.
- the present invention relates to the use of said functional materials and said light emitting fiber devices comprising the functional materials for the treatment of neonatal jaundice.
- the present invention also relates to the use of an organic light emitting fiber for the treatment and/or prophylaxis and/or diagnosis of diseases and/or conditions.
- the present invention also relates to the use of an organic light emitting fiber for the treatment and/or prophylaxis and/or diagnosis of cosmetic conditions.
- FIG. 4 Parallel arrangement of light emitting fibers in a device which emits light with two different wavelengths or ranges of wavelengths.
- FIG. 7 Plaster with attachment side 1 , power supply 2 , reflective material 3 , and light emitting fibers 4 .
- FIG. 8 One way to prepare a fiber comprising the following steps. Step I: deposition of anode 20 on fiber core 10 ; step II: deposition of buffer layer 31 ; step III: deposition of emissive layer 32 ; step IV: deposition of cathode 40 ; step V: free anode
- FIG. 9 Electroluminescence (EL) spectrum of fiber OLED using PB 1 as EML (emissive layer).
- FIG. 11 Schema of a plaster according to present invention with PEN substrate 300 , OLED fibers 400 , cathode 40 , anode 20 , thin conducting wires 310 and 320 , and epoxy resin encapsulation 330 .
- the following polymers are synthesized by employing the Suzuki coupling.
- the reaction can be carried out according to synthetic methods well known to the person skilled in the art. The method is described, for example, in WO 2003/048225.
- the molecular weight (MW) of the PB 1 is distributed between 200000 and 300000 g/mol.
- the molecular weight (MW) of the PR 1 is distributed between 120000 and 720000 g/mol.
- Step I Anode Deposition
- PEDOT (Baytron P Al 4083) is deposited as buffer layer or hole injection layer (HIL) with a thickness of 80 nm onto the fiber by dip-coating and then heated for 10 min. at 180° C.; the thickness can be controlled through the concentration and the pulling speed during the dip-coating. The fiber is then heated for 10 min. at 180° C. to remove residual water.
- HIL hole injection layer
- the emissive layer (EML) 32 then is coated by dip-coating a toluene solution of the emissive polymer with a concentration of 0.1 to 0.8 wt % yielding a layer with a thickness of 65 nm for blue PB 1 and 80 nm for red PR 1 ;
- the fiber is cut into segments of 5 cm in length.
- One end of the cut fiber, where no cathode is deposited, is washed away at first with toluene and then with ethanol to remove the polymer and PEDOT in order to get a free anode which can be contacted.
- the fiber OLEDs Prior to the preparation of plasters, the fiber OLEDs are tested in a glovebox. An EL spectrum is recorded by Ocean Optics USB2000 spectrometer. The EL spectrum of fiber OLEDs using PB 1 as EML is shown in FIG. 9 , and that of fiber OLEDs using PR 1 in FIG. 10 . The fibers are selected for the preparation of a plaster with respect to homogeneity of emission and brightness by optical observation.
- a transparent flexible poly(ethylene naphthalate) (PEN) foil is used as substrate for preparing plasters.
- a plaster according to present invention is schematically shown in FIG. 11 .
- the PEN substrate 300 has an area of ca. 5.5 cm ⁇ 5.5 cm.
- the fiber OLEDs 400 prepared in Example 2 are arranged in parallel in the middle of the substrate, with cathode 40 on one side and anode 20 on the other side.
- thin conducting wires 310 and 320 are connected to all cathode ends and anode ends of the fiber OLEDs, with the help of silver conductive glue.
- the emissive area is defined in the middle area of the substrate, as marked by a dashed line in FIG. 11 .
- UV Resin T-470C2 an advanced UV adhesives for OLED made by Nagase & Co., LTD, is applied to the area as marked as 330 in FIG. 11 being thick enough to cover all fibers on the substrate.
- the device is then exposed to an UV lamp with a dose of about 6 J/cm 2 to cure the resin.
- the cured resin colors slightly yellow. Other transparent resin may be good to get more light out.
- a reflection foil can be put on the plaster to enhance light output of the plaster.
- a 16-week pilot study with 24 female human subjects in the age between 30 and 40 years is conducted according to standard methods well known to the person skilled in the art.
- One of the main selection criteria for the inclusion within the study is the occurrence of crown's feet with almost equal manifestation on both sides of the face, i.e., in proximity to the left and right eye.
- Each subject is treated on the right hand side with a plaster comprising OLED fibers for 25 min, every second day for 16 weeks.
- Comparison of the skin in proximity of the left eye and right eye reveals a significant improvement of the skin on the treated side.
- the crow's feet are shorter and less deeper.
- the skin treated with light emitted by the OLEC device appears smoother as compared to the untreated skin.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Materials Engineering (AREA)
- Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Social Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Developmental Disabilities (AREA)
- Electroluminescent Light Sources (AREA)
- Radiation-Therapy Devices (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Physical Water Treatments (AREA)
Abstract
The present invention relates inter alia to functional materials for the treatment and/or prophylaxis and/or diagnosis of diseases and/or cosmetic conditions. The functional materials can be used for the preparation of light emitting devices comprising fibers as light emitting elements.
Description
- This application is a divisional application of application Ser. No. 13/634,101 filed Sep. 11, 2012 which is incorporated by reference in its entirety. Applicant Ser. No. 13/634,101 is a national stage application (under 35 U.S.C. §371) of PCT/EP2011/000707, filed Feb. 15, 2011, which claims benefit of European application 10002558.4, filed Mar. 11, 2010
- The present invention relates inter alia to compounds, compositions and fiber devices comprising them for the treatment and/or prophylaxis and/or diagnosis of therapeutic diseases and/or cosmetic conditions.
- Phototherapy (also called light therapy) can be employed in a wide range of therapeutic diseases and/or cosmetic (also called aesthetic) conditions. The therapy using light, either from LED or laser, is already being used to treat wounds, injuries, neck pain, osteoarthritis, the side effects of chemotherapy and radiotherapy, for instance.
- Often the borders between therapeutic and cosmetic applications are vague and depend on individual circumstances and the assessment of a physician. Often therapeutic conditions are associated with cosmetic consideration. The treatment or prophylaxis of acne, for example, may have both therapeutic and cosmetic components, depending on the degree of the condition. The same accounts for psoriasis, atopic dermatitis and other diseases and/or conditions. Many diseases and conditions are associated with apparent implications which are often represented by a change in the visibility of a subject's skin, for instance. These cosmetic or aesthetic changes can often lead to psychological modifications resulting, at least in part, in serious diseases.
- Some conditions or diseases may have an emphasis on cosmetic components, even if therapeutic elements may also play a role. Some of these are selected from anti-ageing, anti-wrinkle, the prevention and/or therapy of acne and vitiligo.
- Many diagnostic tools or devices also often require light sources, e.g., in order to determine blood characteristics such as bilirubin, oxygen, or CO. In both cosmetics and medicine the skin is the main target to be radiated, but other targets of the human or animal body can also be accessed by phototherapy. These targets include, but are not limited to, the eye, wounds, nails, and internal parts of the body. Light can also be used in order to facilitate or support disinfection of wounds, surfaces of more or less solid objects, liquids, and beverages, for example. More or less solid surfaces as used herein include any surface with plasticity or elasticity which is not a liquid. Many objects fall in this category and comprise, e.g., nutrition, cuterly, instruments for use in hospitals and surgery and any other object that requires a disinfection. Even wounds of humans and animals can also be subsumed under this definition.
- One of the primary effects of phototherapy is the stimulation of metabolism in the mitochondria. Certain wavelengths of light stimulate cytochrome c oxidase, an enzyme which is responsible for the production of the essential cellular energy in the form of adenosine triphosphate (ATP). ATP is required for cellular energy transfer in order to drive thermodynamically unfavoured biochemical reactions and as cellular energy storage. ATP can also act as signal molecule in order to modulate other biochemical molecules (e.g. reactive oxygen species and nitric oxide) that lead to ageing and cell death (oxidative stress). After phototherapy, the cells show an increased metabolism, they communicate better and they survive stressful conditions in a better way.
- This principle can be applied for many medicinal therapeutic and cosmetic applications, such as wound healing, connective tissue repair, tissue repair, prevention of tissue death, relief of inflammation, pain, acute injuries, chronic diseases, metabolic disorders, neurogenic pain and seasonal effect disorders.
- Another area of the application of light is the treatment of various cancers. In cancer therapy photodynamic therapy (PDT) plays an important role. In PDT light may be used in conjunction with a pharmaceutical. These therapies can be used to treat a variety of skin and internal diseases. In PDT, a light-sensitive therapeutic agent known as a photopharmaceutical is supplied externally or internally to an area of the body which is to be treated. That area is then exposed to light of a suitable frequency and intensity to activate the photopharmaceutical. A variety of photopharmaceutical agents are currently available. For example there are topical agents such as 5-aminolevulinic acid hydrochloride (Crawford Pharmaceuticals), methylaminolevulinic acid (Metfix®, Photocure). There are also injectable drugs used primarily for internal malignancies, including Photofin® (from Axcan) and Foscan® (from Biolitech Ltd). Often, the drug is applied in a non-active form that is metabolised to a light-sensitive photopharmaceutical.
- In photodynamic therapy, the primary technique for supplying light to the photopharmaceutical is to project light of a suitable wavelength from standalone light sources such as lasers or filtered arc lamps. These sources are cumbersome and expensive, and are therefore only suitable for use in hospitals. This leads to inconvenience for the patient, and high cost for the treatment. High light irradiances are needed in order to treat an acceptable number of patients per day (for the treatment to be cost effective) and to avoid unduly inconveniencing the patient.
- WO 98/46130 and U.S. Pat. No. 6,096,066 disclose arrays of LEDs for use in photodynamic therapy. The small LED sources taught therein result in uneven light incident on the patient. Fabrication of arrays is complicated because of the large number of connections required. The devices shown therein are designed for hospital treatment.
- GB 2360461 discloses a flexible garment which uses a conventional photodynamic therapy light source to produce light which is then transmitted through optical fibres. As such light sources are heavy, the device is not ambulatory and is limited to hospital use.
- U.S. Pat. No. 5,698,866 discloses a light source using over-driven inorganic LEDs. The resulting light output is not even. A heat-sinking mechanism is required, and the device is suitable only for hospital treatment.
- WO 93/21842 discloses light sources using inorganic LEDs. Although transportable, the device is not suitable for ambulatory use by a patient at home and clinical treatment is envisaged.
- An essential prerequisite for the wide application of light in the fields mentioned above is the device. The commercial available systems nowadays are mostly based on lasers. However, theses systems are hospital based, i.e. stationary devices. In order to reduce costs and to increase convenience as well as compliance a portable home-use technology is required. In fact, some research has been devoted in this direction.
- Organic light emitting diodes have many advantages over their inorganic counterpart (light emitting diodes—LEDs) in that they are intrinsically flexible, and can be coated on large area by, for example, printing technologies, such as ink jet printing and screen printing. Furthermore they allow more homogenous irradiation as compared to LEDs.
- Rochester et al. disclosed in GB 24082092 a flexible medical light source such as an OLED comprising flexible light emitting diodes on a flexible substrate and resulting diagnostic devices directed to monitor blood characteristics (e.g. levels of CO, oxygen, or bilirubin) and photo-therapeutic devices for the treatment of ailments.
- Vogle Klaus and Kallert Heiko disclosed in EP 018180773 a device for the treatment of skin. The device comprises an potentially flexible organic light emitting diode (OLED) as light source. The device can be integrated in clothes or plaster.
- Attili et al. (Br. J. Dermatol. 161(1), 170-173. 2009) published a clinical open pilot study of ambulatory photodynamic therapy (PDT) using a wearable low-irradiance OLEDs in the treatment of nonmelanoma skin cancer, suggesting that OLED-PDT is less painful than conventional PDT with the added advantage of being lightweight, and therefore has the potential for more convenient PDT at home.
- Samuel et al. disclosed in EP 1444008B15 an ambulatory device for the use in a therapeutic and/or cosmetic treatment, the device comprises an OLEDs and poly(p-phenylene vinylene) (PPV) is used as an example.
- EP 1444008 discloses devices comprising OLEDs for the treatment of photodynamic therapy.
- However, state-of-the-art OLEDs use active metals, such as Ba and Ca, as cathode, and therefore they require excellent encapsulation to ensure an acceptable lifetime related to both storage and operation. For flat large area devices, appropriate encapsulation is even more critical, because defects in even small areas will lead to a total failure of the whole device. In therapeutic and/or cosmetic application lifetime required for the devices is in general much shorter as compared to lifetimes needed for display application. Therefore, it is highly desired to find a device based on OLEDs, which can be easily produced and is flexible and more or less insensitive to local damages.
- Flexible fiber electroluminescent light sources are known in the art, as set forth, for example in U.S. Pat. No. 6,074,071, U.S. Pat. No. 5,485,355 and U.S. Pat. No. 5,876,863. Chemiluminescent fiber light sources are also known. These devices emit light when they are twisted to combine two chemicals contained in the fiber. The chemical reaction between the chemicals produces light while the chemical reaction proceeds for a few hours. However, these prior art chemiluminescent fiber light sources lack sufficient brightness, and are unable to achieve sufficient requirements for the medical or cosmetic use. [
- OLED fibers have been described recently in U.S. Pat. No. 6,538,375 B1, US 2003/0099858, and by Brenndan O'Connor et al. (Adv. Mater. 2007, 19, 3897-3900). Single OLED fibers and their use in lightening is described. However, the OLED fibers disclosed so far were aimed for display and general light applications. The exploitation of OLED fibers in therapeutic and cosmetic applications has not yet disclosed.
- Surprisingly it was found that OLED fibers can be used to overcome the problems of the prior art. OLED fibers can be employed in devices for the treatment and/or prophylaxis and/or diagnosis of diseases and cosmetic conditions. The fibers facilitate the preparation of flexible and preferably plastic or ductile devices for the treatment of a subject. The wavelengths can be tailored easily and a homogenous irradiation of a subject is possible. In addition, by employing light emitting OLED fibers the intensity and wavelength(s) of light required for a specific treatment can be tailored by multiple factors. Intensity can, e.g., adjusted by the number of fibers used (i.e. the density of fibers), the way these fibers are processed or woven, and the voltage applied. The wavelength can also be adjusted easily as outlined elsewhere within the present invention. One fiber can comprise multiple emitter with peaks of emission at different wavelengths. The fiber can also comprise different segments comprising emitter materials with different emission peaks. The use of devices comprising OLED fibers offer new ways to treat many diseases or conditions with a high medical and cosmetic need.
- The present invention relates to the use of a functional material selected from host materials, emissive materials (EM), hole injection materials (HIM), hole transport materials (HTM), hole blocking materials (HBM), electron injection materials (EIM), electron transport materials (ETM), electron blocking materials (EBM), exciton blocking materials (ExBM), metal complexes, and phosphor materials for the preparation of a device for the treatment and/or prophylaxis and/or diagnosis of diseases and/or cosmetic conditions, characterized in that the device comprises at least one organic light emitting fiber.
-
FIG. 1 illustrates fiber with afiber core 10 having an outerfirst electrode 20, alight emitting layer 30, a radiation transmissivesecond electrode 40 positioned over the organiclight emitting layer 30. Eventually the OLEFC may also comprise an optional radiation transmissive moisture and/orair barrier layer 50 and/or an optional radiationtransmissive encapsulating material 60. -
FIG. 2 illustrates fiber divided into segments emitting n different wavelengths λi (i=1 to n) or ranges of wavelengths (a). Preferably n=2 (b). -
FIG. 3 illustrates parallel arrangement of light emitting fibers in a device which emits light with n different wavelengths or ranges of wavelengths. -
FIG. 4 illustrates parallel arrangement of light emitting fibers in a device which emits light with two different wavelengths or ranges of wavelengths. -
FIG. 5 illustrates woven fibers. -
FIG. 6 illustrates woven fibers emitting two different wavelengths or ranges of wavelengths. -
FIG. 7 illustrates plaster withattachment side 1,power supply 2,reflective material 3, and light emitting fibers 4. -
FIG. 8 illustrates one way to prepare a fiber comprising the following steps. Step I: deposition ofanode 20 onfiber core 10; step II: deposition ofbuffer layer 31; step III: deposition of emissive layer 32; step IV: deposition ofcathode 40; step V: free anode -
FIG. 9 illustrates electroluminescence (EL) spectrum of fiber OLED using PB1 as EML (emissive layer). -
FIG. 10 illustrates EL spectrum of fiber OLED using PR1. -
FIG. 11 illustrates a schema of a plaster according to present invention withPEN substrate 300,OLED fibers 400,cathode 40,anode 20,thin conducting wires epoxy resin encapsulation 330. -
FIG. 12 illustrates fiber production line by employing dip coating. 210—fiber core; 130—deposition chamber for the first electrode; 200—deposition chamber for the second electrode; 140—container containing solution of buffer material or HIM; 160—container containing a solution or a formulation of HTM or interlayer material; 180—container containing a solution or a formulation of an emissive composition; 150, 170, and 190 are dryers. -
FIG. 13 illustrates a production method which is all solution based. 250—container containing an ink comprising a conductive material for the second electrode; 220 and 230 are dryers; 240—container comprising an ink comprising a conductive material for the first electrode. - Preference is given to a functional material selected from host materials. Further preference is given to a functional material selected from emissive materials (EM). Further preference is given to a functional material selected from hole injection materials (HIM). Further preference is given to a functional material selected from hole transport materials (HTM). Further preference is given to a functional material selected from hole blocking materials (HBM). Further preference is given to a functional material selected from electron injection materials (EIM) Further preference is given to a functional material selected from electron transport materials (ETM). Further preference is given to a functional material selected from electron blocking materials (EBM). Further preference is given to a functional material selected from exciton blocking materials (ExBM). Further preference is given to a functional material selected from metal complexes. Further preference is given to a functional material selected from phosphor materials.
- In a preferred embodiment the term functional material refers to an organic functional material. The term also refers to organic conductors, semiconductors, organic fluorescent compounds, organic phosphorescent compounds, organo-metallic complexes of transition metals, rare earths, lanthanides and actinides.
- The term emissive materials preferably refers to electroluminescent emitter materials as outlined elsewhere within the present invention.
- The functional material and particularly the organic functional material may be selected from the group of small molecules, polymers, oligomers, or dendrimers, blends or mixtures thereof.
- The term small molecule as used herein is defined as molecule not being a polymer, oligomer, dendrimer, or a blend. In particular, repeating structures are absent in small molecules. The molecular weight of small molecules is typically in the range of polymers with a low number of repeating units, oligomers or less.
- The molecular weight of the small molecule is preferably below 4000 g/mol, particularly preferably below 3000 g/mol, and very particularly preferably below 2000/mol.
- The polymers of the present invention preferably have 10 to 10000, particularly preferably 20 to 5000 and very particularly preferably 50 to 2000 repeat units. Oligomers according to this invention have preferably 2 to 9 repeat units. The branching index of the polymers and oligomers is between 0 (linear polymer without branching) and 1 (completely branched dendrimer). The term dendrimer as used herein is defined according to M. Fischer et al. in Angew. Chem., Int. Ed. 1999, 38, 885).
- The molecular weight (MW) of the polymers of the present invention is preferably in the range of 10000 to 2000000 g/mol, particularly preferably in the range of 100000 to 1500000 g/mol, and very particularly preferably in the range of 200000 to 1000000 g/mol. The determination of MW can be performed according to standard techniques known to the person skilled in the art by employing gel permeation chromatography (GPC) with polystyrene as internal standard, for instance.
- A blend is a mixture comprising at least one polymeric dendrimeric, or oligomeric component.
- Organic functional materials according to the present invention are often characterized by their molecular frontier orbitals, i.e. the highest occupied molecular orbital (HOMO) (sometimes also referred to as valence band) and the lowest unoccupied molecular orbital (LUMO)(sometimes also referred to as conduction band). The HOMO and LUMO levels are routinely measured (by e.g. XPS=X-ray photoelectron spectroscopy, UPS=ultraviolet photoelectron spectroscopy or CV=cyclovoltammetry) or calculated (by quantum chemical methods such as (time dependent) DFT=density functional theory) which are known to the person skilled in the art. One skilled in the art is also aware of the fact that absolute values of these energy levels significantly depend on the method used. The reliable comparison of HOMO and LUMO energy levels of organic functional materials requires the employment of the same measurement method or calculation method The applicants established a consistent combination method to determine the energy levels of organic semiconductors. The HOMO/LUMO levels of a set of semiconductors (more than 20 different semiconductors) are measured by CV with a reliable evaluation method and also calculated by the DFT of Gaussian 03W with the same correction functional, for example B3PW91 and the same basis set, for example 6-31 G(d). The calculated values are then calibrated according to the measured values. Such calibration factor is used for further calculation. The agreement between calculated and measured values is very good. Therefore, the comparison of the energy levels of this invention is set on a sound base. The energy gaps or band gaps are obtained by the difference between HOMO and LUMO energy levels.
- The organic functional materials can be selected from hole injection materials (HIM). A HIM refers to a material or unit capable of facilitating holes (i.e. positive charges) injected from an anode into an organic layer. Typically, a HIM has a HOMO level comparable to or higher than the work function of the anode, i.e.—5.3 eV or higher.
- The organic functional materials can be selected from hole transport materials (HTM). A HTM is characterized in that it is a material or unit capable of transporting holes (i.e. positive charges) injected from a hole injecting material or an anode. A HTM has usually high HOMO, typically higher than −5.4 eV. In many cases, HIM can functions also as HTM, depending on the adjacent layer.
- The organic functional materials can be selected from hole blocking materials (HBM). A HBM refers to a material which, if deposited adjacent to an emissive layer or a hole transporting layer in a multilayer structure, prevents the holes from flowing through. Usually it has a lower HOMO as compared to the HOMO level of the HTM in the adjacent layer. Hole-blocking layers are frequently inserted between the light-emitting layer and the electron-transport layer in OLEDs.
- The organic functional materials can be selected from electron injection materials (EIM). An EIM refers to a material capable of facilitating electrons (i.e. negative charges) injected from cathode into an organic layer. The EIM usually has a LUMO level comparable to or lower than the working function of cathode. Typically, the EIM has a LUMO lower than −2.6 eV.
- The organic functional materials can be selected from electron transport materials (ETM). An ETM refers to a material capable of transporting electrons (i.e. negative charges) injected from an EIM or a cathode. The ETM has usually a low LUMO, typically lower than −2.7 eV. In many cases, an EIM can serve as ETM as well, depending on the adjacent layer.
- The organic functional materials can be selected from electron blocking materials (EBM). An EBM refers to a material which, if deposited adjacent to an emissive or electron transporting layer in a multilayer structure, prevents the electron from flowing through. Usually it has a higher LUMO as compared to the LUMO of the ETM in the adjacent layer.
- The organic functional materials can be selected from exciton blocking materials (ExBM). An ExBM refers to a material which, if deposited adjacent to an emissive layer in a multilayer structure, prevents the excitons from diffusing through. ExBM should have either a higher triplet level or singlet level as compared to the emissive layer or other adjacent layer.
- The organic functional materials can be selected from emitters. The term emitter refers to a material which, upon receiving excitonic energy by any kind of energy transfers from other materials, or by forming an exciton either electrically or optically, undergoes radiative decay to emit light. There are two classes of emitters, fluorescent and phosphorescent emitters. The term fluorescent emitter relates to materials or compounds which undergo a radiative transition from an excited singlet state to its ground. The term phosphorescent emitter, as used herein, relates to luminescent materials or compounds which comprise transition metals. This typically includes materials emitting light caused by spin forbidden transition(s), e.g., transitions from excited triplet states.
- The term dopant as employed herein is also used for the term emitter or emitter material.
- The organic functional materials can be selected from host materials. Host materials are usually used in combination with emitter and have, in general, larger energy gaps between the HOMO and the LUMO as compared to emitter materials. In addition, host materials behave either as electron or hole transport material. Host materials can also have both electron and hole transport properties. In case singlet transitions are predominantly responsible for luminescence in OLEDs, a maximal overlap between the absorption spectrum of the emitter with the photoluminescence spectrum of the host material is desirably. This ensures the energy transfer from the host material to the emitter.
- Host material is also called matrix or matrix material, particularly if a host is meant which is used in combination with a phosphorescent emitter. In the case of a copolymer comprising emitter units, the polymer backbone acts as a host.
- The organic functional materials can be selected from metal complexes. According to quantum mechanics the transition from excited states with high spin multiplicity, e.g. from excited triplet states, to ground state is forbidden.
- However, the existence of an heavy atom, for example iridium, osmium, platinum and europium, results in a strong spin-orbit coupling, i.e. the excited singlet and triplet are mixed so that triplet gains some singlet character; and if singlet-triplet mixing yields a radiative decay rate faster than the non-radiative event, then the luminance can be efficient. This kind of emission can be achieved using metal complex, as firstly reported by Baldo et al.; Nature 395, 151-154 (1998).
- Further to HIMs mentioned elsewhere herein, suitable HIMs are phenylenediamine derivatives (U.S. Pat. No. 3,615,404), arylamine derivatives (U.S. Pat. No. 3,567,450), amino-substituted chalcone derivatives (U.S. Pat. No. 3,526,501), styrylanthracene derivatives (JP Showa 54 (1979) 110837), hydrazone derivatives (U.S. Pat. No. 3,717,462), acylhydrazones, stilbene derivatives (JP Showa 61 (1986) 210363), silazane derivatives (U.S. Pat. No. 4,950,950), polysilane compounds (JP Heisei 2 (1990) 204996), PVK and other electrically conductive macromolecules, aniline-based copolymers (JP Heisei 2 (1990) 282263), electrically conductive, macromolecular thiophene oligomers (JP Heisei 1 (1989) 211399), PEDOT:PSS (spin-coated polymer), plasma-deposited fluorocarbon polymers (U.S. Pat. No. 6,127,004, U.S. Pat. No. 6,208,075, U.S. Pat. No. 6,208,077), porphyrin compounds (JP Showa 63 (1988) 2956965, U.S. Pat. No. 4,720,432), aromatic tertiary amines and styrylamines (U.S. Pat. No. 4,127,412), triphenylamines of the benzidine type, triphenylamines of the styrylamine type, and triphenylamines of the diamine type. Arylamine dendrimers can also be used (JP Heisei 8 (1996) 193191), as can phthalocyanine derivatives, naphthalocyanine derivatives, or butadiene derivatives, are also suitable.
- Preferably, the HIM is selected from monomeric organic compound comprising amine, triarylamine, thiophene, carbazole, phthalocyanine, porphyrine and their derivatives.
- Particular preference is given to the tertiary aromatic amines (US 2008/0102311 A1), for example N,N′-diphenyl-N,N′-di(3-tolyl)benzidine (=4,4′-bis[N-3-methylphenyl]-N-phenylamino)biphenyl (NPD) (U.S. Pat. No. 5,061,569), N,N′-bis(N,N′-diphenyl-4-aminophenyl)-N,N-diphenyl-4,4′-diamino-1,1′-biphenyl (TPD 232) and 4,4′,4″-tris[3-methylphenyl)-phenylamino]-triphenylamine (MTDATA) (JP Heisei 4 (1992) 308688) or phthalocyanine derivatives (for example H2Pc, CuPc, CoPc, NiPc, ZnPc, PdPc, FePc, MnPc, ClAlPc, ClGaPc, ClInPc, ClSnPc, Cl2SiPc, (HO)AlPc, (HO)GaPc, VOPc, TiOPc, MoOPc, GaPc-O-GaPc).
- Particular preference is given to the following triarylamine compounds of the Formulae 1 (TPD 232), 2, 3, and 4, which may also be substituted, and further compounds as disclosed in U.S. Pat. No. 7,399,537 B2, US 2006/0061265 A1, EP 1661888 A1, and JP 08292586 A.
- Further compounds suitable as hole injection material are disclosed in EP 0891121 A1 and EP 1029909 A1. Hole injection layers in general are described in US 2004/0174116.
- in principle any HTM known to one skilled in the art can be employed in formulations according to the present invention. Further to HTM mentioned elsewhere herein, HTM is preferably selected from amines, triarylamines, thiophenes, carbazoles, phthalocyanines, porphyrines, isomers and derivatives thereof. HTM is particularly preferably selected from amines, triarylamines, thiophenes, carbazoles, phthalocyanines, and porphyrines.
- Preferably a layer of a device or a composition according to the present invention comprises 3, particularly preferably 2, and very particularly preferably 1 HTMs.
- Suitable materials for hole-transporting layers are phenylenediamine derivatives (U.S. Pat. No. 3,615,404), arylamine derivatives (U.S. Pat. No. 3,567,450), amino-substituted chalcone derivatives (U.S. Pat. No. 3,526,501), styrylanthracene derivatives (JP A 56-46234), polycyclic aromatic compounds (EP 1009041), polyarylalkane derivatives (U.S. Pat. No. 3,615,402), fluorenone derivatives (JP A 54-110837), hydrazone derivatives (U.S. Pat. No. 3,717,462), stilbene derivatives (JP A 61-210363), silazane derivatives (U.S. Pat. No. 4,950,950), polysilanes (JP A 2-204996), aniline copolymers (JP A 2-282263), thiophene oligomers, polythiophenes, PVK, polypyrroles, polyanilines and further copolymers, porphyrin compounds (JP A 63-2956965), aromatic dimethylidene-type compounds, carbazole compounds, such as, for example, CDBP, CBP, mCP, aromatic tertiary amine and styrylamine compounds (U.S. Pat. No. 4,127,412), and monomeric triarylamines (U.S. Pat. No. 3,180,730). Even more triarylamino groups may also be present in the molecule.
- Preference is given to aromatic tertiary amines containing at least two tertiary amine units (U.S. Pat. No. 4,720,432 and U.S. Pat. No. 5,061,569), such as, for example, 4,4′-bis[N-(1-naphthyl)-N-phenylamino]biphenyl (NPD) (U.S. Pat. No. 5,061,569) or MTDATA (JP A 4-308688), N,N,N′,N′-tetra(4-biphenyl)diaminobiphenylene (TBDB), 1,1-bis(4-di-p-tolylaminophenyl)cyclohexane (TAPC), 1,1-bis(4-di-p-tolylaminophenyl)-3-phenylpropane (TAPPP), 1,4-bis[2-[4-[N,N-di(p-tolyl)amino]phenyl]vinyl]benzene (BDTAPVB), diaminobiphenyl (TTB), TPD, N,N,N′,N′-tetraphenyl-4,4″′-diamino-1,1′:4′,1″:4″,1′″-quaterphenyl, likewise tertiary amines containing carbazole units, such as, for example, 4 (9H-carbazol-9-yl)-N,N-bis[4-(9H-carbazol-9-yl)phenyl]benzeneamine (TCTA). Preference is likewise given to hexaazatriphenylene compounds in accordance with US 2007/0092755 A1.
- Particular preference is given to the following triarylamine compounds of the Formulae 5 to 10, which may also be substituted, and as disclosed in EP 1162193 A1, EP 650955 A1, Synth. Metals 1997, 91(1-3), 209, DE 19646119 A1, WO 2006/122630 A1, EP 1860097 A1, EP 1834945 A1, JP 08053397 A, U.S. Pat. No. 6,251,531 B1, and WO 2009/041635.
- In principle any HBM known to one skilled in the art can be employed according to the present invention. Further to HBM mentioned elsewhere herein, suitable hole-blocking materials are metal complexes (US 2003/0068528), such as, for example, bis(2-methyl-8-quinolinolato)(4-phenylphenolato)-aluminium(III) (BAlQ). Fac-tris(1-phenylpyrazolato-N,C2)iridium(III) (Ir(ppz)3) is likewise used for this purpose (US 2003/0175553 A1). Phenanthroline derivatives, such as, for example, BCP, or phthalimides, such as, for example, TMPP, are likewise employed.
- Further, suitable hole-blocking materials are described in WO 00/70655 A2, WO 01/41512 and WO 01/93642 A1.
- In principle any EIM known to one skilled in the art can be employed according to the present invention. Further to EIM mentioned elsewhere herein, suitable EIM elsewhere herein, EIMs, which comprises at least one organic compound selected from metal complexes of 8-hydroxyquinoline, heterocyclic organic compounds, fluorenones, fluorenylidene methane, perylenetetracarboxylic acid, anthraquinone dimethanes, diphenoquinones, anthrones, anthraquinonediethylene-diamines, isomers and derivates thereof can be used according to the invention.
- Metal complexes of 8 hydroxyquinoline, such as, for example, Alq3 and Gaq3, can be used as EIM for electron-injection layers. A reducing doping with alkali metals or alkaline-earth metals, such as, for example, Li, Cs, Ca or Mg, at the interface to the cathode is advantageous. Preference is given to combinations which include Cs, for example Cs and Na, Cs and K, Cs and Rb or Cs, Na and K.
- Heterocyclic organic compounds, such as, for example, 1,10-phenanthroline derivatives, benzimidazoles, thiopyran dioxides, oxazoles, triazoles, imidazoles or oxadiazoles, are likewise suitable. Examples of suitable five-membered rings containing nitrogen are oxazoles, thiazoles, oxadiazoles, thiadiazoles, triazoles, and compounds which are disclosed in US 2008/0102311 A1.
- Preferred EIMs are selected from compounds with the Formulae 11 to 13, which may be substituted or unsubstituted.
- Organic compounds, such as fluorenones, fluorenylidene methane, perylenetetracarboxylic acid, anthraquinone dimethanes, diphenoquinones, anthrones and anthraquinonediethylenediamines, can also be employed, for example
- In principle any ETM known to one skilled in the art can be employed according to the present invention. Further to ETM mentioned elsewhere herein, suitable ETM is selected from the group consisting of imidazoles, pyridines, pyrimidines, pyridazines, pyrazines, oxadiazoles, chinolines, chinoxalines, anthracenes, benzanthracenes, pyrenes, perylenes, benzimidazoles, triazines, ketones, phosphinoxides, phenazines, phenanthrolines, triarylboranes, isomers and derivatives thereof.
- Further suitable ETMs are selected from imidazoles, pyridines, pyrimidines, pyridazines, pyrazines, oxadiazoles, chinolines, chinoxalines, anthracenes, benzanthracenes, pyrenes, perylenes, benzimidazoles, triazines, ketones, phosphinoxides, phenazines, phenanthrolines, and triarylboranes. The layer of a device or a composition according to the present invention preferably comprises 3, particularly preferably 2, and very particularly preferably 1 ETMs.
- Further suitable ETMs for electron-transporting layers are metal chelates of 8 hydroxyquinoline (for example Liq, Alq3, Gaq3, Mgq2, Znq2, Inq3, Zrq4), Balq, 4 azaphenanthrene-5-ol/Be complexes (U.S. Pat. No. 5,529,853 A; e.g. Formula 16), butadiene derivatives (U.S. Pat. No. 4,356,429), heterocyclic optical brighteners (U.S. Pat. No. 4,539,507), benzazoles, such as, for example, 1,3,5-tris(2-N-phenylbenzimidazolyl)benzene (TPBI) (U.S. Pat. No. 5,766,779, Formula 17), 1,3,5-triazines, pyrenes, anthracenes, tetracenes, fluorenes, spirobifluorenes, dendrimers, tetracenes, for example rubrene derivatives, 1,10-phenanthroline derivatives (JP 2003/115387, JP 2004/311184, JP 2001/267080, WO 2002/043449), silacyl-cyclopentadiene derivatives (EP 1480280, EP 1478032, EP 1469533), pyridine derivatives (JP 2004/200162 Kodak), phenanthrolines, for example BCP and Bphen, also a number of phenanthrolines bonded via biphenyl or other aromatic groups (US 2007/0252517 A1) or phenanthrolines bonded to anthracene (US 2007/0122656 A1, e.g. Formulae 18 and 19), 1,3,4-oxadiazoles, for
example Formula 20, triazoles, for example Formula 21, triarylboranes, for example also with Si (e.g. Formula 48), benzimidazole derivatives and other N heterocyclic compounds (cf. US 2007/0273272 A1), silacyclopentadiene derivatives, borane derivatives, Ga oxinoid complexes. - Preference is given to 2,9,10-substituted anthracenes (with 1- or 2-naphthyl and 4- or 3-biphenyl) or molecules which contain two anthracene units (US 2008/0193796 A1).
- Preference is likewise given to anthracene-benzimidazole derivatives, such as, for example, the compounds of Formulae 22 to 24, and as disclosed in, e.g., U.S. Pat. No. 6,878,469 B2, US 2006/147747 A, and EP 1551206 A1.
- In principle any EBM known to one skilled in the art can be employed according to the present invention. Further to EBM mentioned elsewhere herein, transition-metal complexes, such as, for example, Ir(ppz)3 (US 2003/0175553) can be employed as materials for an electron-blocking layer.
- Preferably, the EBM is further selected from amines, triarylamines, carbazoles, indolocarbazoles and their derivatives.
- It is known to a person skilled in the art that the selection of ExBMs suitable for the use according to the present invention depends on the energy gap of the adjacent layer. Suitable ExBMs are supposed to have a bigger energy gap, either singlet or triplet than the functional material in the adjacent layer which is preferably an emissive layer. Further to ExBMs mentioned elsewhere herein, substituted triarylamines, such as, for example, MTDATA or 4,4′,4″-tris(N,N-diphenylamino)triphenylamine (TDATA), can be used as ExBM for electron-blocking layers. Substituted triarylamines are described, for example, in US 2007/0134514 A1.
- N-substituted carbazole compounds, such as, for example, TCTA, or heterocycles, such as, for example, BCP, are also suitable.
- Metal complexes, such as, for example, Ir(ppz)3 or Alq3, can likewise be used for this purpose.
- In principle any host material known to one skilled in the art can be employed according to the present invention. Depending on the kind of emitter employed host materials can be separated into two categories, hosts for fluorescent emitter and hosts for phosphorescent emitter, whereby the latter is often referred to as matrix or matrix material.
- Preference is given to host materials selected from anthracenes, benzanthracenes, indenofluorenes, fluorenes, spirobifluorenes, phenanthrenes, dehydrophenanthrenes, thiophenes, triazines, imidazole, ketones, carbazoles, triarylamines, and derivatives thereof.
- Particular preference is given to host materials selected from anthracenes, benzanthracenes, indenofluorenes, fluorenes, spirobifluorenes, phenanthrenes, dehydrophenanthrenes, thiophenes, triazines, imidazole, ketones, carbazoles, indolocarbazoles and triarylamines.
- A layer of an OLED or a composition according to the present invention may also comprise more than one host material, preferably it comprises 3 host materials, particularly preferably it comprises 2 host materials, and very particularly preferably one host material. If a layer of an OLED or a composition according to the present invention comprises at least two host materials, the host materials are also referred to as co-host or co-host materials.
- Preferred host materials suitable for fluorescent emitter are selected from anthracenes, benzanthracenes, indenofluorenes, fluorenes, spirobifluorenes, phenanthrenes, dehydrophenanthrenes, thiophenes, triazines, imidazole and derivatives thereof.
- Preferred host materials suitable for fluorescent emitter are selected from anthracenes, benzanthracenes, indenofluorenes, fluorenes, spirobifluorenes, phenanthrenes, dehydrophenanthrenes, thiophenes, triazines, and imidazole.
- Particularly preferred host materials for fluorescent emitter are selected from the classes of the oligoarylenes (for example 2,2′,7,7′-tetraphenylspirobifluorene in accordance with EP 676461 or dinaphthylanthracene), in particular the oligoarylenes containing condensed aromatic groups, such as, for example, phenanthrene, tetracene, coronene, chrysene, fluorene, spirofluorene, perylene, phthaloperylene, naphthaloperylene, decacyclene, rubrene, the oligoarylenevinylenes (for example 4,4′-bis(2,2-diphenylethenyl)-1,1′-biphenyl (DPVBi) or 4,4-bis-2,2-diphenylvinyl-1,1-spirobiphenyl (spiro-DPVBi) in accordance with EP 676461), the polypodal metal complexes (for example in accordance with WO 2004/081017), in particular metal complexes of 8 hydroxyquinoline, for example aluminium(III) tris(8-hydroxyquinoline) (aluminium quinolate, Alq3) or bis(2-methyl-8-quinolinolato)-4-(phenylphenolinolato)aluminium, also with imidazole chelate (US 2007/0092753 A1) and quinoline-metal complexes, aminoquinoline-metal complexes, benzoquinoline-metal complexes, the hole-conducting compounds (for example in accordance with WO 2004/058911), the electron-conducting compounds, in particular ketones, phosphine oxides, sulfoxides, etc. (for example in accordance with WO 2005/084081 and WO 2005/084082), the atropisomers (for example in accordance with WO 2006/048268), the boronic acid derivatives (for example in accordance with WO 2006/117052) or the benzanthracenes (e.g. DE 102007024850). Particularly preferred host materials are selected from the classes of the oligoarylenes, containing naphthalene, anthracene, benzanthracene and/or pyrene, or atropisomers of these compounds, the ketones, the phosphine oxides and the sulfoxides, Very particularly preferred host materials are selected from the classes of the oligoarylenes, containing anthracene, benzanthracene and/or pyrene, or atropisomers of these compounds. For the purposes of this invention, an oligoarylene is intended to be taken to mean a compound in which at least three aryl or arylene groups are bonded to one another.
- Further preferred host materials for fluorescent emitter are selected, in particular, from compounds of the Formula 25
-
Ar4—(Ar5)p—Ar6 Formula 25 - wherein
Ar4, Ar5, Ar6 are on each occurrence, identically or differently, an aryl or heteroaryl group having 5 to 30 aromatic ring atoms, which may be substituted by one or more radicals and
p is 1, 2, or 3,
the sum of the π-electrons in Ar4, Ar5 and Ar6 is at least 30 if p=1 and is at least 36 if p=2 and is at least 42 if p=3. - It is particularly preferred in the host materials of the Formula 25 for the group Ar5 to stand for anthracene, which may be substituted by one or more radicals R1, and for the groups Ar4 and Ar6 to be bonded in the 9 and 10-positions. Very particularly preferably, at least one of the groups Ar4 and/or Ar6 is a condensed aryl group selected from 1- or 2-naphthyl, 2-, 3- or 9-phenanthrenyl or 2-, 3-, 4-, 5-, 6- or 7-benzanthracenyl, each of which may be substituted by one or more radicals R1. Anthracene-based compounds are described in US 2007/0092753 A1 and US 2007/0252517 A1, for example 2-(4-methylphenyl)-9,10-di-(2-naphthyl)anthracene, 9-(2-naphthyl)-10-(1,1′-biphenyl)anthracene and 9,10-bis[4-(2,2-diphenylethenyl)phenyl]anthracene, 9,10-diphenylanthracene, 9,10-bis(phenylethynyl)anthracene and 1,4-bis(9′-ethynylanthracenyl)benzene. Preference is also given to host materials containing two anthracene units (US 2008/0193796 A1), for example 10,10′-bis[1,1′,4′,1″]terphenyl-2-yl-9,9′-bisanthracenyl.
- Further preferred host materials are derivatives of arylamine, styrylamine, fluorescein, perynone, phthaloperynone, naphthaloperynone, diphenylbutadiene, tetraphenylbutadiene, cyclopentadienes, tetraphenylcyclopentadiene, pentaphenylcyclopentadiene, coumarine, oxadiazole, bisbenzoxazoline, oxazone, pyridine, pyrazine, imine, benzothiazole, benzoxazole, benzimidazole (US 2007/0092753 A1), for example 2,2′,2″-(1,3,5-phenylene)tris[1-phenyl-1H-benzimidazole], aldazines, stilbene, styrylarylene derivatives, for example 9,10-bis[4-(2,2-diphenylethenyl)phenyl]anthracene, and distyrylarylene derivatives (U.S. Pat. No. 5,121,029), diphenylethylene, vinylanthracene, diaminocarbazole, pyran, thiopyran, diketopyrrolopyrrole, polymethine, mellocyanine, acridone, quinacridone, cinnamic acid esters and fluorescent dyes.
- Particular preference is given to derivatives of arylamine and styrylamine, for example 4,4′-bis[N-(1-naphthyl)-N-(2-naphthyl)amino]biphenyl (TNB).
- Preferred compounds with oligoarylene as hosts for fluorescent emitter are compounds as disclosed in, e.g., US 2003/0027016 A1, U.S. Pat. No. 7,326,371 B2, US 2006/043858 A, U.S. Pat. No. 7,326,371 B2, US 2003/0027016 A1, WO 2007/114358, WO 2008/145239, JP 3148176 B2, EP 1009044, US 2004/018383, WO 2005/061656 A1, EP 0681019B1, WO 2004/013073A1, U.S. Pat. No. 5,077,142, WO 2007/065678, and US 2007/0205412 A1. Particularly preferred oligoarylene-based compounds are compounds having the Formulae 26 to 32.
- Further host materials for fluorescent emitter can be selected from spirobifluorene and derivates thereof, for example Spiro-DPVBi as disclosed in EP 0676461 and indenofluorene as disclosed in U.S. Pat. No. 6,562,485.
- The preferred host materials for phosphorescent emitter, i.e. matrix materials, are selected from ketones, carbazoles, indolocarbazoles, triarylamines, indenofluorenes, fluorenes, spirobifluorenes, phenathrenes, dehydrophenanthrenes, thiophenes, triazines, imidazoles and their derivatives. Some preferred derivatives are described below in more details.
- If a phosphorescent emitter is employed, e.g. as electroluminescent component in organic light emitting diodes (OLEDs), the host material must fulfil rather different characteristics as compared to host materials used for fluorescent emitter. The host materials used for phosphorescent emitter are required to have a triplet level which is higher in energy as compared to the triplet level of the emitter. The host material can either transport electrons or holes or both of them. In addition, the emitter is supposed to have large spin-orbital coupling constants in order to facilitate singlet-triplet mixing sufficiently. This can be enabled by using metal complexes.
- Preferred matrix materials are N,N-biscarbazolylbiphenyl (CBP), carbazole derivatives (for example in accordance with WO 2005/039246, US 2005/0069729, JP 2004/288381, EP 1205527 or DE 102007002714), azacarbazoles (for example in accordance with EP 1617710, EP 1617711, EP 1731584, JP 2005/347160), ketones (for example in accordance with WO 2004/093207), phosphine oxides, sulfoxides and sulfones (for example in accordance with WO 2005/003253), oligophenylenes, aromatic amines (for example in accordance with US 2005/0069729), bipolar matrix materials (for example in accordance with WO 2007/137725), silanes (for example in accordance with WO 2005/111172), 9,9-diarylfluorene derivatives (e.g. in accordance with DE 102008017591), azaboroles or boronic esters (for example in accordance with WO 2006/117052), triazole derivatives, oxazoles and oxazole derivatives, imidazole derivatives, polyarylalkane derivatives, pyrazoline derivatives, pyrazolone derivatives, distyrylpyrazine derivatives, thiopyran dioxide derivatives, phenylenediamine derivatives, tertiary aromatic amines, styrylamines, indoles, anthrone derivatives, fluorenone derivatives, fluorenylidenemethane derivatives, hydrazone derivatives, silazane derivatives, aromatic dimethylidene compounds, porphyrin compounds, carbodiimide derivatives, diphenylquinone derivatives, phthalocyanine derivatives, metal complexes of 8 hydroxyquinoline derivatives, such as, for example, Alq3, the 8 hydroxyquinoline complexes may also contain triarylaminophenol ligands (US 2007/0134514 A1), various metal complex-polysilane compounds with metal phthalocyanine, benzoxazole or benzothiazole as ligand, hole-conducting polymers, such as, for example, poly(N-vinylcarbazole) (PVK), aniline copolymers, thiophene oligomers, polythiophenes, polythiophene derivatives, polyphenylene derivatives, polyfluorene derivatives.
- Further particularly preferred matrix materials are selected from compounds comprising indolocarbazoles and their derivatives (e.g. Formulae 33 to 39), as disclosed for examples in DE 102009023155.2, EP 0906947B1, EP 0908787B1, EP 906948B1, WO 2008/056746A1, WO 2007/063754A1, WO 2008/146839A1, and WO 2008/149691A1.
- Examples of preferred carbazole derivatives are, 1,3-N,N-dicarbazolebenzene (=9,9′-(1,3-phenylene)bis-9H-carbazole) (mCP), 9,9′-(2,2′-dimethyl[1,1′-biphenyl]-4,4′-diyl)bis-9H-carbazole (CDBP), 1,3-bis(N,N′-dicarbazole)benzene (=1,3-bis(carbazol-9-yl)benzene), PVK (polyvinylcarbazole), 3,5-di(9H-carbazol-9-yl)biphenyl and compounds of the
Formulae 40 to 44. - Preferred Si tetraaryl compounds are, for example, (US 2004/0209115, US 2004/0209116, US 2007/0087219 A1, US 2007/0087219 A1) the compounds of the Formulae 45 to 50.
- A particularly preferred matrix for phosphorescent dopants is the compound of Formula 51 (EP 652273 B1)
- Further particularly preferred matrix materials for phosphorescent dopants are selected from compounds of the general Formula 52 (EP 1923448A1),
-
[M(L)2]n Formula 52 - wherein M, L, and n are defined as in the reference. Preferably M is Zn, and L is quinolinate, and n is 2, 3 or 4. Very particularly preferred are [Znq2]2, [Znq2]3, and [Znq2]4.
- Preference is given to co-hosts selected from metal oxinoid complexes whereby lithium quinolate (Liq) or Alq3 are particularly preferred.
- The emitter compound is required to have a smaller band gap as compared to the host compound. In general, smaller band gaps can be achieved by extending the Tr-electron system of conjugated molecular systems. Emitter compounds tend, therefore, to have more extended conjugated Tr-electron systems than host molecules. Many examples have been published, e.g. styrylamine derivatives as disclosed in JP 2913116B and WO 2001/021729 A1, and indenofluorene derivatives as disclosed in WO 2008/006449 and WO 2007/140847.
- Preferably the layer of a device or a composition according to the present invention comprises 3, particularly preferably 2, and very particularly preferably 1 emitter materials. If more than one emitter material is used the emission spectrum of one emitter material overlaps with the absorption spectrum of the another emitter material in order to facilitate Førster energy transfer.
- Preferably the composition according to the present invention comprises one or more emitter material, in the case of singlet emitter(s), in a concentration range between 0.1 wt % and 20 wt %, preferably between 0.5 wt % and 15 wt %, particularly preferably between 1 wt % and 10 wt %, and very particularly preferably between 1 wt % and 8 wt % with respect to the whole mass of the emissive layer; in the case of phosphorescent emitter(s), in a concentration range between 0.1 wt % and 30 wt %, preferably between 1 wt % and 20 wt %, particularly preferably between 5 wt % and 20 wt %, and very particularly preferably between 10 wt % and 20 wt % with respect to the whole mass of the emissive layer.
- Preferably the device or a composition according to the present invention comprises two emitter materials. Particularly preferably both emitter materials are selected from phosphorescent emitter materials. Particularly preferably both emitter materials are selected from fluorescent emitter materials.
- Blue fluorescent emitters are preferably polyaromatic compounds, such as, for example, 9,10-di(2-naphthylanthracene) and other anthracene derivatives, derivatives of tetracene, xanthene, perylene, such as, for example, 2,5,8,11-tetra-t-butylperylene, phenylene, for example 4,4′-(bis(9-ethyl-3-carbazovinylene)-1,1′-biphenyl, fluorene, arylpyrenes (US 2006/0222886), arylenevinylenes (U.S. Pat. No. 5,121,029, U.S. Pat. No. 5,130,603), derivatives of rubrene, coumarine, rhodamine, quinacridone, such as, for example, N,N′-dimethylquinacridone (DMQA), dicyanomethylenepyrane, such as, for example, 4 (dicyanoethylene)-6-(4-dimethylaminostyryl-2-methyl)-4H-pyrane (DCM), thiopyrans, polymethine, pyrylium and thiapyrylium salts, periflanthene, indenoperylene, bis(azinyl)imine-boron compounds (US 2007/0092753 A1), bis(azinyl)methene compounds and carbostyryl compounds.
- Further preferred blue fluorescent emitters are described in C. H. Chen et al.: “Recent developments in organic electroluminescent materials” Macromol. Symp. 125, (1997), 1-48 and “Recent progress of molecular organic electroluminescent materials and devices” Mat. Sci. and Eng. R, 39 (2002), 143-222.
- Preferred fluorescent dopants according to the present invention are selected from the class of the monostyrylamines, the distyrylamines, the tristyrylamines, the tetrastyrylamines, the styrylphosphines, the styryl ethers and the arylamines.
- A monostyrylamine is taken to mean a compound which contains one substituted or unsubstituted styryl group and at least one, preferably aromatic, amine. A distyrylamine is taken to mean a compound which contains two substituted or unsubstituted styryl groups and at least one, preferably aromatic, amine. A tristyrylamine is taken to mean a compound which contains three substituted or unsubstituted styryl groups and at least one, preferably aromatic, amine. A tetrastyrylamine is taken to mean a compound which contains four substituted or unsubstituted styryl groups and at least one, preferably aromatic, amine. The styryl groups are particularly preferably stilbenes, which may also be further substituted. The corresponding phosphines and ethers are defined analogously to the amines. For the purposes of this invention, an arylamine or an aromatic amine is taken to mean a compound which contains three substituted or unsubstituted aromatic or heteroaromatic ring systems bonded directly to the nitrogen. At least one of these aromatic or heteroaromatic ring systems is preferably a condensed ring system, preferably having at least 14 aromatic ring atoms. Preferred examples thereof are aromatic anthracene-amines, aromatic anthracene-diamines, aromatic pyrene-amines, aromatic pyrene-diamines, aromatic chrysene-amines and aromatic chrysene-diamines. An aromatic anthracene-amine is taken to mean a compound in which one diarylamino group is bonded directly to an anthracene group, preferably in the 9 position. An aromatic anthracene-diamine is taken to mean a compound in which two diarylamino groups are bonded directly to an anthracene group, preferably in the 9,10-position. Aromatic pyrene-amines, pyrene-diamines, chrysene-amines and chrysene-diamines are defined analogously thereto, where the diarylamino groups on the pyrene are preferably bonded in the 1 position or in the 1,6-position.
- Further preferred fluorescent dopants are selected from indenofluorene-amines and indenofluorene-diamines, for example in accordance with WO 2006/122630, benzoindenofluorene-amines and benzoindenofluorene-diamines, for example in accordance with WO 2008/006449, and dibenzoindenofluorene-amines and dibenzoindenofluorene-diamines, for example in accordance with WO 2007/140847.
- Examples of dopants from the class of the styrylamines are substituted or unsubstituted tristilbene-amines or the dopants described in WO 2006/000388, WO 2006/058737, WO 2006/000389, WO 2007/065549 and WO 2007/115610. Distyrylbenzene and distyrylbiphenyl derivatives are described in U.S. Pat. No. 5,121,029. Further styrylamines are found in US 2007/0122656 A1.
- Particularly preferred styrylamine dopants and triarylamine dopants are the compounds of the Formulae 53 to 58 and as disclosed in U.S. Pat. No. 7,250,532 B2, DE 102005058557 A1, CN 1583691 A, JP 08053397 A, U.S. Pat. No. 6,251,531 B1, and US 2006/210830 A.
- Further preferred fluorescent dopants are selected from the group of triarylamines as disclosed in EP 1957606 A1 and US 2008/0113101 A1.
- Further preferred fluorescent dopants are selected from derivatives of naphthalene, anthracene, tetracene, fluorene, periflanthene, indenoperylene, phenanthrene, perylene (US 2007/0252517 A1), pyrene, chrysene, decacyclene, coronene, tetraphenylcyclopentadiene, pentaphenylcyclopentadiene, fluorene, spirofluorene, rubrene, coumarine (U.S. Pat. No. 4,769,292, U.S. Pat. No. 6,020,078, US 2007/0252517 A1), pyran, oxazone, benzoxazole, benzothiazole, benzimidazole, pyrazine, cinnamic acid esters, diketopyrrolopyrrole, acridone and quinacridone (US 2007/0252517 A1).
- Of the anthracene compounds, particular preference is given to 9,10-substituted anthracenes, such as, for example, 9,10-diphenylanthracene and 9,10-bis(phenylethynyl)anthracene. 1,4-Bis(9′-ethynylanthracenyl)benzene is also a preferred dopant.
- Examples of phosphorescent emitters are revealed by the applications WO 00/70655, WO 01/41512, WO 02/02714, WO 02/15645, EP 1191613, EP 1191612, EP 1191614 and WO 2005/033244. In general, all phosphorescent complexes as used in accordance with the prior art for phosphorescent OLEDs and as are known to the person skilled in the art in the area of organic electroluminescence are suitable, and the person skilled in the art will be able to use further phosphorescent complexes without inventive step.
- The phosphorescent emitter may be a metal complex, preferably with the formula M(L)z, wherein M is a metal atom, L is in each occurrence independently of one another an organic ligand that is bonded to or coordinated with M via one, two or more positions, and z is an integer ≧1, preferably 1, 2, 3, 4, 5 or 6, and wherein, optionally, these groups are linked to a polymer via one or more, preferably one, two or three positions, preferably via the ligands L.
- M is in particular a metal atom selected from transition metals, preferably selected from transition metals of group VIII, or lanthanoides, or actinides, particularly preferably selected from Rh, Os, Ir, Pt, Pd, Au, Sm, Eu, Gd, Tb, Dy, Re, Cu, Zn, W, Mo, Pd, Ag, or Ru, and very particularly preferably selected from Os, Ir, Ru, Rh, Re, Pd, or Pt. M may also be Zn.
- The layer of a device or a composition according to the present invention can also comprise at least one metal complex. Preferably the layer of a devices or a composition according to the present invention comprises 3, particularly preferably 2, and very particularly preferably 1 metal complexes.
- Preferred ligands are 2 phenylpyridine derivatives, 7,8-benzoquinoline derivatives, 2 (2-thienyl)pyridine derivatives, 2 (1-naphthyl)pyridine derivatives or 2 phenylquinoline derivatives. All these compounds may be substituted, for example by fluoro- or trifluoromethyl substituents for blue. Auxiliary ligands are preferably acetylacetonate or picric acid.
- In particular, complexes of Pt or Pd with tetradentate ligands of the Formula 59 as disclosed in US 2007/0087219 A1, wherein R1 to R14 and Z1 to Z5 are as defined in the reference, Pt porphyrin complexes having an enlarged ring system (US 2009/0061681 A1) and Ir complexes are suitable, for example 2,3,7,8,12,13,17,18-octaethyl-21H, 23H-porphyrin-Pt(II), tetraphenyl-Pt(II)-tetrabenzoporphyrin (US 2009/0061681 A1), cis-bis(2-phenylpyridinato-N,C2′) Pt(II), cis-bis(2-(2′-thienyl)pyridinato-N,C3′)Pt(II), cis-bis(2-(2′-thienyl)quinolinato-N,C5′)Pt(II), (2-(4,6-difluorophenyl)pyridinato-N,C2′)Pt(II) acetylacetonate, or tris(2-phenylpyridinato-N,C2′)Ir(III) (Ir(ppy)3, green), bis(2-phenylpyridinato-N,C2)Ir(III) acetylacetonate (Ir(ppy)2 acetylacetonate, green, US 2001/0053462 A1, Baldo, Thompson et al. Nature 403, (2000), 750-753), bis(1-phenylisoquinolinato-N,C2′)(2-phenylpyridinato-N,C2′) iridium(III), bis(2-phenylpyridinato-N,C2′)(1-phenylisoquinolinato-N,C2′)iridium(III), bis(2-(2′-benzothienyl)pyridinato-N,C3′)iridium(III) acetylacetonate, bis(2-(4′,6′-difluorophenyl)pyridinato-N,C2′)iridium(III) piccolinate (Firpic, blue), bis(2-(4′,6′-difluorophenyl)pyridinato-N,C2′)Ir(III) tetrakis(1-pyrazolyl)borate, tris(2-(biphenyl-3-yl)-4-tert-butylpyridine)iridium(III), (ppz)2Ir(5phdpym) (US 2009/0061681 A1), (45ooppz)2Ir(5phdpym) (US 2009/0061681 A1), derivatives of 2 phenylpyridine-Ir complexes, such as, for example, iridium(III) bis(2-phenylquinolyl-N,C2′)acetylacetonate (PQIr), tris(2-phenylisoquinolinato-N,C)Ir(II) (red), bis(2-(2′-benzo[4,5-a]thienyl)pyridinato-N,C3)Ir acetylacetonate ([Btp2Ir(acac)], red, Adachi et al. Appl. Phys. Lett. 78 (2001), 1622-1624).
- Also suitable are complexes of trivalent lanthanides, such as, for example, Tb3+ and Eu3+ (J. Kido et al. Appl. Phys. Lett. 65 (1994), 2124, Kido et al. Chem. Lett. 657, 1990, US 2007/0252517 A1), or phosphorescent complexes of Pt(II), Ir(I), Rh(I) with maleonitrile dithiolate (Johnson et al., JACS 105, 1983, 1795), Re(I) tricarbonyl diimine complexes (Wrighton, JACS 96, 1974, 998 inter alia), Os(II) complexes with cyano ligands and bipyridyl or phenanthroline ligands (Ma et al., Synth. Metals 94, 1998, 245) or Alc3 without a host.
- Further phosphorescent emitters with tridentate ligands are described in U.S. Pat. No. 6,824,895 and U.S. Pat. No. 7,029,766. Red-emitting phosphorescent complexes are mentioned in U.S. Pat. No. 6,835,469 and U.S. Pat. No. 6,830,828.
- A particularly preferred phosphorescent dopant is a compound with the
Formula 60 and further compounds as disclosed, e.g., in US 2001/0053462 A1. - A particularly preferred phosphorescent dopant is a compound with the Formula 61 and further compounds as disclosed, e.g., in WO 2007/095118 A1
- Further derivatives are described in U.S. Pat. No. 7,378,162 B2, U.S. Pat. No. 6,835,469 B2, and JP 2003/253145 A.
- Further preference is given to phosphorescent emitter selected from carbene triple emitter, particularly to carbine complexes comprising iridium as metal. Preferred complexes are N-heterocyclic carbine (NHC) iridium complexes as disclosed in WO 2005/091373, WO 2005/113704, and in P. Erk et al.,
SID 2006, 11, 2, 131, e.g. fac-Ir(dpbic)3, Ir(pmbic)3, Ir(pmic)3, Ir(dpnic)3, Ir(cn-pmic)3. - Further to metal complex mentioned elsewhere herein, a suitable metal complex according to the present invention can be selected from transition metals, rare earth elements, lanthanides and actinides is also subject of this invention. Preferably the metal is selected from Ir, Ru, Os, Eu, Au, Pt, Cu, Zn, Mo, W, Rh, Pd, or Ag.
- The functional material according to the present invention may also be selected from small molecules, polymers, oligomers, dendrimers, and blends. The functional polymer is characterized in that different functions may be incorporated into one large molecule or a blend of large molecules. The functions are, inter alia, the ones of a hole injection material, hole transport material, electron blocking material, emissive material, hole blocking material, electron injection material, and electron transport material. The functions which are incorporated into a polymer can be categorized into different groups. By choosing the desired functional groups and the ratio between them, the polymer can be tuned to have the desired function(s).
- The difference between polymers, oligomers and dendrimers is due to the size, size distribution, and branching of the molecular entities as defined above.
- Different structures are, inter alia, those as disclosed and extensively listed in WO 2002/077060 A1 and in DE 10337346 A1. The structural units may originate, for example, from the following groups:
- Group 1: units which increase the hole-injection and/or transport properties of the polymers; It corresponds to the HIMs or HTMs as described above.
- Group 2: units which increase the electron-injection and/or transport properties of the polymers; It corresponds to the EIMs or ETMs as described above.
- Group 3: units which have combinations of individual units from
group 1 andgroup 2; - Group 4: units which modify the emission characteristics to such an extent that electrophosphorescence may be obtained instead of electrofluorescence; typically, it corresponds to the phosphorescent emitter, or more preferably emissive metal complexes as described above.
- Group 5: units which improve the transition from the so called singlet state to higher spin states, e.g. to a triplet state;
- Group 6: units which influence the morphology and/or emission colour of the resultant polymers;
- Group 7: units which are typically used as backbone and which may have electron transport function, hole transport function or both.
- Preferably, the said further organic functional material is a hole transport or injection polymer comprising units of
groups 1, which are preferably selected from units comprising the low molecular weight HTMs or HIMs as described above. - Further preferred units from
group 1 are, for example, triarylamine, benzidine, tetraaryl-para-phenylenediamine, carbazole, azulene, thiophene, pyrrole and furan derivatives and further O, S or N containing heterocycles with a high HOMO. These arylamines and heterocycles preferably result in an HOMO in the polymer of higher than 5.8 eV (against vacuum level), particularly preferably higher than 5.5 eV. - Preferred polymeric HTM or HIM is a polymer comprising at least one of following repeat unit according to Formulae 62.
- wherein
Ar1 which may be the same or different, denote, independently if in different repeat units, a single bond or an optionally substituted mononuclear or polynuclear aryl group,
Ar2 which may be the same or different, denote, independently if in different repeat units, an optionally substituted mononuclear or polynuclear aryl group,
Ar3 which may be the same or different, denote, independently if in different repeat units, an optionally substituted mononuclear or polynuclear aryl group,
m is 1, 2 or 3, - Particularly preferred units of Formula 62 are selected from the group consisting of the Formulae 63 to 65:
- wherein
R which may be the same or different in each occurrence, is selected from H, substituted or unsubstituted aromatic or heteroaromatic group, alkyl, cycloalkyl, alkoxy, aralkyl, aryloxy, arylthio, alkoxycarbonyl, silyl, carboxy group, a halogen atom, cyano group, nitro group or hydroxy group,
r is 0, 1, 2, 3 or 4, and
s is 0, 1, 2, 3, 4 or 5. - Further preferred polymeric HTM or HIM is a polymer comprising at least one of following repeat unit according to Formulae 66.
-
-(T1)c-(Ar4)d-(T2)e-(Ar5)1 Formula 66 - wherein
T1 and T2 are independently of each other selected from thiophene, selenophene, thieno[2,3b]thiophene, thieno[3,2b]thiophene, dithienothiophene, pyrrole, aniline, all of which are optionally substituted with R5,
R5 is in each occurrence independently of each other selected from halogen, —CN, —NC, —NCO, —NCS, —OCN, SCN, C(═O)NR0R00, —C(═O)X, —C(═O)R0, —NH2, —NR0R00, SH, SR0, —SO3H, —SO2R0, —OH, —NO2, —CF3, —SF5, optionally substituted silyl, or carbyl or hydrocarbyl with 1 to 40 C atoms that is optionally substituted and optionally contains one or more hetero atoms,
Ar4 and Ar5 are independently of each other mononuclear or polynuclear aryl or heteroaryl, which is optionally substituted and optionally fused to the 2,3-positions of one or both of the adjacent thiophene or selenophene groups,
c and e are independently of each other 0, 1, 2, 3 or 4, with 1<c+e≦6,
d and f are independently of each other 0, 1, 2, 3 or 4. - Examples for polymeric HTMs are as disclosed in WO 2007131582 A1 and WO 2008/009343A1.
- Preferably, the said organic functional material is an electron transport or injection
polymer comprising groups 2, which is preferably selected from groups comprising the low molecular weight ETMs or EIMs as described above. - Further preferred units from
group 2, which have electron-injection or electron-transport properties, are, for example, pyridine, pyrimidine, pyridazine, pyrazine, oxadiazole, quinoline, quinoxaline and phenazine derivatives, but also triarylboranes and further O, S or N containing heterocycles having a low LUMO. These units in the polymer preferably result in an LUMO of lower than −2.7 eV (against vacuum level), particularly preferably lower than −2.8 eV. - Preferably, the said organic functional material is a polymer comprising units from
group 3 in which structures which increase the hole mobility and the electron mobility (i.e. units fromgroups 1 and 2) are bonded directly to one another. Some of these units may serve as emitters and shift the emission colour into the green, yellow or red. Their use is thus suitable, for example, for the production of other emission colours or a broad-band emission from originally blue-emitting polymers. - Preferably, the said organic functional material is a polymer comprising units of group 4, which is preferably selected from the groups comprising phosphorescent emitter, particularly emissive metal complexes as described above. Particular preference is given here to corresponding structural units which contain elements from groups 8 to 10 (Ru, Os, Rh, Ir, Pd, Pt).
- Preferably, the said organic functional material is a polymeric triple matrix comprising units of group 5, which can improve the transition from the singlet state to the triplet state and which, employed in support of the structural elements from group 4, improve the phosphorescence properties of these structural elements. Suitable for this purpose are, in particular, carbazole and bridged carbazole dimer units, as described in DE 10304819 A1 and DE 10328627 A1. Also suitable for this purpose are ketones, phosphine oxides, sulfoxides, sulfones, silane derivatives and similar compounds, as described in DE 10349033 A1. Further preferred structure units can be selected from groups comprising the low molecular weight phosphorescent matrices as described above.
- Preferably, the said organic functional material is a polymer comprising units of group 6, which influence the morphology and/or emission colour of the polymers, are, besides those mentioned above, those which have at least one further aromatic or another conjugated structure which do not fall under the above-mentioned groups, i.e. which have only little effect on the charge-carrier mobilities, which are not organometallic complexes or which have no influence on the singlet-triplet transition. Structural elements of this type may influence the morphology and/or emission colour of the resultant polymers. Depending on the unit, they can therefore also be employed as emitters. Preference is given here, in the case of fluorescent OLEDs, to aromatic structures having 6 to 40 C atoms or also tolan, stilbene or bisstyrylarylene derivatives, each of which may be substituted by one or more radicals R1. Particular preference is given here to the incorporation of 1,4-phenylene, 1,4-naphthylene, 1,4- or 9,10-anthrylene, 1,6-, 2,7- or 4,9-pyrenylene, 3,9- or 3,10-perylenylene, 4,4′-biphenylylene, 4,4″-terphenylylene, 4,4′
bi - Preferably, the said organic functional material is a polymer comprising units of group 7 which contain aromatic structures having 6 to 40 C atoms which are typically used as polymer backbone. These are, for example, 4,5-dihydropyrene derivatives, 4,5,9,10-tetrahydropyrene derivatives, fluorene derivatives as disclosed for example in U.S. Pat. No. 5,962,631, WO 2006/052457 A2 and WO 2006/118345A1, 9,9′-spirobifluorene derivatives as disclosed for example in WO 2003/020790 A1, 9,10-phenanthrene derivatives as disclosed, for example, in WO 2005/104264 A1, 9,10-dihydrophenanthrene derivatives as disclosed for example in WO 2005/014689 A2, 5,7-dihydrodibenzooxepine derivatives and cis- and trans-indenofluorene derivatives as disclosed for example in WO 2004041901 A1, WO 2004113412 A2 and, binaphthylene derivatives as disclosed for example in WO 2006/063852 A1, and further units as disclosed for example in WO 2005/056633A1. EP 1344788A1 and WO 2007/043495A1, WO 2005/033174 A1, WO 2003/099901A1 and DE 102006003710.3.
- Further preferred structural elements from group 7 are selected from fluorene derivatives, as disclosed for example in U.S. Pat. No. 5,962,631, WO 2006/052457 A2 and WO 2006/118345 A1, spiro-bifluorene derivatives as disclosed for example in WO 2003/020790 A1, benzofluorene, dibenzofluorene, benzothiophene, dibenzofluorene and their derivatives as disclosed for example in WO 20051056633A1, EP 1344788A1 and WO 2007/043495A1
- Very preferred structural elements of group 7 are those of Formula 67:
- wherein
A, B and B′ are independently of each other, and in case of multiple occurrence independently of one another, a divalent group, preferably selected from —CR1R2—, —NR1—, —PR1—, —O—, —S—, —SO—, —SO2—, —CO—, —CS—, —CSe—, —P(═O)R1—, —P(═S)R1— and —SiR1R2—,
R1 and R2 are independently of each other identical or different groups selected from H, halogen, —CN, —NC, —NCO, —NCS, —OCN, —SCN, —C(═O)NR0R00, —C(═O)X, —C(═O)R0, —NH2, —NR0R00, —SH, —SR0, —SO3H, —SO2R0, —OH, —NO2, —CF3, —SF5, optionally substituted silyl, or carbyl or hydrocarbyl with 1 to 40 C atoms that is optionally substituted and optionally comprises one or more hetero atoms, and optionally the groups R1 and R2 form a spiro group with the fluorene moiety to which they are attached,
X is halogen,
R0 and R00 are independently of each other H or an optionally substituted carbyl or hydrocarbyl group optionally comprising one or more hetero atoms,
each g is independently 0 or 1 and each corresponding h in the same subunit is the other of 0 or 1,
m is an integer ≧1
Ar1 and Ar2 are independently of each other mono- or polynuclear aryl or heteroaryl that is optionally substituted and optionally fused to the 7,8-positions or 8,9-positions of the indenofluorene group,
a and b are independently of each other 0 or 1. - If the groups R1 and R2 form a spiro group with the fluorene group to which they are attached, it is preferably spirobifluorene.
- The groups of Formula 67 are preferably selected from the following Formulae 68 to 72:
- wherein R1 is as defined in Formula 67, r is 0, 1, 2, 3 or 4, and R has one of the meanings of R1.
- R is preferably F, Cl, Br, I, —CN, —NO2, —NCO, —NCS, —OCN, —SCN, —C(═O)NR0R00, —C(═O)X0, —C(═O)R0, —NR0R00, optionally substituted silyl, aryl or heteroaryl with 4 to 40, preferably 6 to 20 C atoms, or straight chain, branched or cyclic alkyl, alkoxy, alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy or alkoxycarbonyloxy with 1 to 20, preferably 1 to 12 C atoms, wherein one or more H atoms are optionally replaced by F or Cl, and wherein R0, R00 and X0 are as defined above.
- Particularly preferred groups of Formula 67 are selected from the following Formulae 73 to 76:
- wherein
L is H, halogen or optionally fluorinated, linear or branched alkyl or alkoxy with 1 to 12 C atoms, and is preferably H, F, methyl, i-propyl, t-butyl, n-pentoxy, or trifluoromethyl, and
L′ is optionally fluorinated, linear or branched alkyl or alkoxy with 1 to 12 C atoms, and is preferably n-octyl or n-octyloxy. - Preference is given to polymers suitable for use in the invention which simultaneously comprise one or more units selected from
groups 1 to 7. It may likewise be preferred for more than one structural unit from a group to be present simultaneously. - Preference is given to polymers suitable for use in the invention which, besides structural units of an emitter, also comprise at least one structural unit from the above-mentioned groups. At least two structural units are particularly preferably from different classes of those mentioned above.
- The proportion of the different classes of
groups - Further, a smaller proportion of the emitting units, in particular green- and red-emitting units, may also be preferred, for example for the synthesis of white-emitting copolymers. The way in which white-emitting copolymers can be synthesised is described in detail in DE 10343606 A1.
- The proportion of the different classes of
groups 3 and 4, if present in the polymer, is preferably in each case in the range from 0.01 to 20 mol %, particularly preferably in each case in the range from 1 to 15 mol %, and very particularly preferably in each case in the range from 1 to 10 mol %. - In order to ensure adequate solubility, it is preferred for on average at least 2 non-aromatic C atoms to be present in the substituents per recurring unit. Preference is given here to at least 4 and particularly preferably at least 8 C atoms. In addition, individual C atoms of these may be replaced by O or S. However, it is entirely possible for this to mean that a certain proportion of recurring units does not carry any further non-aromatic substituents. In order to avoid impairing the morphology of the film, it is preferred to have no long-chain substituents having more than 12 C atoms in a linear chain, particularly preferably none having more than 8 C atoms and in particular none having more than 6 C atoms.
- The polymer used as organic functional material in the invention may be statistical or random copolymers, alternating or regioregular copolymers, block copolymers or combinations thereof.
- In a very preferred embodiment, the polymer is a conjugated polymer, wherein the functional groups as described above and bellow are integrated into the polymer main chain.
- In another preferred embodiments, the polymer is a non-conjugated or partially-conjugated polymer.
- In a particularly preferred embodiment, the said polymer is a main-chain non-conjugated polymer, wherein the polymer comprises at least one non-conjugated spacer on main-chain. Very particularly preferred non-conjugated or partially-conjugated polymers comprise a non-conjugated backbone unit or a unit interrupting the conjugation of backbone units. Like side-chain non-conjugated polymers, main-chain non-conjugated polymers give also a high triplet level.
- Preferred non-conjugated backbone units are selected from units comprising indenofluorene derivatives, as shown, for example, in the following Formulae 77 and 78 and as disclosed in DE 102009023156.0.
- wherein X and Y are independently from each other selected from H, F, an alkyl group with 1 to 40 C-atoms, an alkylene group having 2 to 40 C-atoms, an alkinyl group having 2 to 40 C-Atoms, an substituted or unsubstituted aryl group having 6 to 40 C-atoms, and a substituted or unsubstituted heteroaryl group having 5 to 25 atoms.
- Further preferred non-conjugated backbone units are selected from a unit comprising fluorene, phenanthrene, dehydrophenanthrene, indenofluorene derivatives, as shown, for example, in the following Formulae 79 to 92 and as disclosed in DE 102009023154.4.
- wherein R1 to R4 have the same meaning as X and Y, as defined above.
- In another preferred embodiment, the said polymer is a side-chain non-conjugated polymer, which is especially important for phosphorescent OLEDs based on polymer. In general, such phosphorescent polymer is obtained by means of radical copolymerization of vinyl compounds, and comprises at least one phosphorescent emitter and at least one charge transport unit on side chain, as disclosed in U.S. Pat. No. 7,250,226 B2. Further examples for such phosphorescent polymer are disclosed for example in JP 2007/211243 A2, JP 2007/197574 A2, U.S. Pat. No. 7,250,226B2, JP 2007/059939A.
- In a further embodiment, the said polymer can also be a non-conjugated polymer for fluorescent OLEDs. Preferred singlet non-conjugated polymers are, for example, side-chain polymers with antracenenes, benzanthrecenes and their derivates in the side-chain, as disclosed in JP 2005/108556, JP 2005/285661, JP 2003/338375 etc.
- The said polymers can also act as ETM or HTM, preferably the polymer is a non-conjugated polymer.
- Inorganic compounds, such as p type Si and p type SiC, and inorganic oxides, e.g., vanadium oxide (VOx), molybdenum oxide (MoOx) or nickel oxide (NiO)x can also be used as HIM.
- Electron injection layers (EILs) are often constructed from an insulator and semiconductor.
- Preferred alkali metal chalcogenides for EILs are Li2O, LiO, Na2S, Na2Se, NaO, K2O, Cs2O.
- Preferred alkaline-earth metal chalcogenides for EILs are CaO, BaO, SrO, BeO, BaS, CaSe.
- Preferred halides of alkali metals for EILs are LiF, NaF, KF, CsF, LiCl, KCl, NaCl.
- Preferred halides of alkaline-earth metals for EILs are Ca F2, BaF2, SrF2, MgF2, BeF2.
- It is likewise possible to employ alkali metal complexes, alkaline-earth metal complexes, rare-earth metals (Sc, Y, Ce, Th, Yb), rare-earth metal complexes, rare-earth metal compounds (preferably YbF3, ScF3, TbF3) or the like.
- The structure of EILs is described, for example, in U.S. Pat. No. 5,608,287, U.S. Pat. No. 5,776,622, U.S. Pat. No. 5,776,623, U.S. Pat. No. 6,137,223, U.S. Pat. No. 6,140,763, U.S. Pat. No. 6,914,269.
- An electron-transport layer may consist of an intrinsic material or comprise a dopant. Alq3 (EP 278757 B1) and Liq (EP 0569827 A2) are examples of intrinsic layers. 4,7-diphenyl-1,10-phenanthroline (Bphen):Li 1:1 (US 2003/02309890) and rubrene/LiF are examples of doped layers.
- In addition to the materials mentioned above, an organic electroluminescent device according to the present invention may comprise at least one anode, at least one cathode and one or more substrates.
- Preferred materials for the anode are metal oxides selected from, but not limited to, indium tin oxide (ITO), indium zinc oxide (IZO), tin oxide (SnO), ZnO, InO, aluminium-zinc-oxide (AlZnO), and other metal oxides such as Al- and In-zinc oxide doped with zinc oxide, magnesium-indium-oxide, and nickel-tungsten-oxide. Metal nitrides such as gallium nitrides and metal selenides such as zinc-selenide and metal-sulfides such as zinc-sulfide can also be used. Further materials that can be used for anodes are electrically conducting polymers, e.g. polythiophenes, polyanilines and polypyrroles.
- The anode can be transparent, opaque, or reflective. The anode can also adopt an intermediate state, e.g. both being partially reflective and partially transparent.
- If the anode is not or only partially transparent further conducting materials can be used. Preferred materials for non transparent or partially transparent anodes are selected from, but not limited to, Au, Ir, Mo, Pd, Pt, Cu, Ag, Sn, C, Al, V, Fe, Co, Ni, W, and mixtures thereof. The conducting materials can also be mixed with further conducting materials as described above, e.g. In—Cu.
- The anode is preferably transparent and a particularly preferred material for the anode is ITO. In the case of a top-emitting device the anode comprises preferably a reflecting material. Further materials can be used for anodes, which are known to the person skilled in the art.
- A flexible and transparent combination of substrate and anode is described in U.S. Pat. No. 5,844,363 B2 and U.S. Pat. No. 6,602,540 B2, for instance.
- The cathode can be transparent, opaque, or reflective. The cathode is selected from a metal or an alloy with a low work function. Preferably metals, alloys, or conducting compounds or materials with a work function of less than 4.0 eV are used. Particularly preferred cathodes are selected from, but not limited to, Ba, Ca, Sr, Yb, Ga, Cd, Si, Ta, Sb, Zn, Mg, Al, In, Li, Na, Cs, Ag, mixtures of two or more elements such as alloys comprising Mg/Al or Al/Li or Al/Sc/Li or Mg/Ag or metal oxides such as ITO or IZO. Further preferred materials for cathodes, used to form a thin dielectric layer, are selected from a metal which is mixed with LiF, Li2O, BaF2, MgO, or NaF, A typical combination is LiF/Al.
- An Mg/Al cathode with ITO layer on top is described in U.S. Pat. No. 5,703,436, U.S. Pat. No. 5,707,745, U.S. Pat. No. 6,548,956 B2, U.S. Pat. No. 6,576,134 B2. An Mg/Ag alloy is described in U.S. Pat. No. 4,885,221.
- Herein any therapeutic strategy is included, i.e. treatment of a subject with light can be performed with or without a combination with other treatment approaches. Treatment can, for example, be carried out with one or more wavelengths in one or more devices comprising the compounds of the present invention. Furthermore, in addition to said devices comprising the fibers (herein also referred to as fiber devices or light emitting fiber devices) and compounds according to the present invention, further light sources using different technologies can be used for the treatment, such as LEDs, planar OLEDs, and lasers. In addition, the treatment with said compositions and devices comprising them can be combined with any known treatment strategy using drugs and cosmetics.
- If phototherapy is combined with the treatment of chemical compounds such as a drugs and/or cosmetics light can be used to initiate a (photo-) chemical reaction or activation of the chemical compounds, which is called photodynamic therapy (PDT). Phototherapy according to the present invention can also be used in conjunction with chemical compounds without initiating a photochemical reaction or activation. Synergistic effects for the effectiveness and safety of the treatment of a disease can arise from sequential, parallel, and overlapping treatment with both light therapy and drugs and/or cosmetics. The drug(s) or cosmetic compound(s), e.g., can be administered first for a specific time period followed by the application of phototherapy using the compositions according to the present invention or devices comprising them. The time gap between both treatments may also vary, depending on the drug, its photoreactivity, individual circumstances of the subject, and the specific disease or condition. Both treatments may also overlap timely either partly or completely. The exact treatment strategy will depend on the individual circumstances and the severity of the disease or condition.
- The combination therapy can have a synergistic effect and can reduce the side effects of traditional treatment strategies (e.g. the side effects of tetracyclines). This is due to the fact, that smaller doses of the drugs may be required when employing a combined approach as outlined herein.
- Many diagnostic devices comprise light sources for either illumination only or as functional component for the diagnosis itself, e.g. for the determination of blood parameters such as oxygen. Thus the present invention also relates to a composition for diagnostic purposes, characterized in that the composition comprises at least one ionic species and at least one organic electroluminescent compound. The use of light sources comprising the said compositions for diagnostic purposes is also subject of the present invention. Based on the teaching of the present invention, one skilled in the art will have no problems to develop diagnostic devices for which light sources are required comprising the said compositions.
- Treatment is any exposure of a subject to the radiation of the fiber devices comprising the functional material or compositions according to the present invention. The treatment may be performed by direct contact between the subject and the device or without direct contact between them. The treatment may be outside or inside the subject. Treatment outside the subject may be, for instance, treatment of the skin, wounds, eye, gingival, mucosa, tongue, hair, nail bed, and nails. Treatment inside the subject may be, for instance, blood vessels, heart, breast, lung, or any other organ of the subject. Particular devices are required for most applications inside the subject. One such example may be a stent fibers according to the present invention. The said subject may preferably be a human or an animal. The term cosmetic also includes aesthetic applications.
- The wavelength of light that is emitted by the fiber devices can be precisely tailored by the selection of the appropriate functional material. In addition, colour filter and colour converter can be used to get light of the desired wavelength. Depending on the application of the functional material and/or fiber devices comprising the functional material each therapeutic or cosmetic treatment requires a more or less defined wavelength or spectrum of wavelengths to be emitted.
- The fiber devices preferably comprise at least one organic electroluminescent compound which emits light in the range between 200 and 1000 nm, preferably between 300 and 1000 nm, particularly preferably between 300 and 950 nm, and very particularly preferably between 400 and 900 nm.
- As outlined above one of the primary effects of phototherapy is the stimulation of metabolism in the mitochondria. After phototherapy, the cells show an increased metabolism, they communicate better and they survive stressful conditions in a better way.
- The said functional materials and light emitting fiber devices comprising them can be used for cellular stimulation. Preferred wavelengths or ranges of wavelengths for cellular stimulation are in the range between 600 to 900 nm, particularly preferable between 620 and 880 nm, and very particularly preferably between 650 and 870 nm. Examples of particularly preferred wavelengths for cellular stimulation are 683.7, 667.5, 772.3, 750.7, 846, and 812.5 nm.
- Any disease and/or cosmetic condition approachable by phototherapy can be treated with the functional materials and fiber devices, particularly OLEDs, comprising them. These diseases and/or conditions include, e.g., skin diseases, and skin-related conditions including skin-ageing, and cellulite, enlarged pores, oily skin, folliculitis, precancerous solar keratosis, skin lesion, wrinkled and sun-damaged skin, crow's feet, skin ulcers (diabetic, pressure, venous stasis), acne rosacea lesions, cellulite, photomodulation of sebaceous oil glands and the surrounding tissues, reducing wrinkles, acne scars and acne bacteria, inflammation, pain, wounds, psychological and neurological related diseases and conditions, edema, Pagets disease, primary and metastatic tumors, connective tissue disease, manipulation of collagen, fibroblast, and fibroblast derived cell levels in mammalian tissue, illuminating retina, neoplastic, neovascular and hypertrophic diseases, inflammation and allergic reactions, perspiration, sweating and hyperhydrosis from eccrine (sweat) or apocrine glands, jaundice, vitiligo, ocular neovascular diseases, bulimia nervosa, herpes, seasonal affective disorders, mood, sleep disorders, skin cancer, crigler naijar, atopic dermatitis, diabetic skin ulcers, pressure ulcers, bladder infections, relief of muscular pains, pain, stiffness of joints, reduction of bacteria, gingivitis, whitening teeth, treatment of teeth and tissue in mouth, wound healing.
- Cosmetic conditions are preferably selected from acne, skin rejuvenation and skin wrinkles, cellulite, and vitiligo. Many therapeutic treatments also have cosmetic component. Psoriasis, e.g., can be mild, mild-to-moderate, moderate, moderate-to-severe and severe. Any of these categories has a cosmetic component, which may be responsible for severe psychological problems of affected patients.
- The present invention also relates to the use of said functional material and/or light emitting fibers comprising the functional materials characterized in that the fiber comprises a fiber core having an outer first electrode; at least one organic light emitting layer positioned over an outer surface of the first electrode; and a light transmissive second electrode positioned over the organic light emitting layer; wherein the at least one organic light emitting layer comprises at least one organic material that emits light when a voltage is applied across the first and second electrode.
- The organic light emitting fibers used according to the present invention and their preparation are disclosed in U.S. Pat. No. 6,538,375 and US 2003/0099858 which are incorporated herein by reference.
FIG. 1 schematically depicts the setup of organic light emitting fibers (FIG. 1a ) and cross sectional view inFIG. 1b )). They comprise afiber core 10 having afirst electrode 20, at least one organiclight emitting layer 30 positioned over an outer surface of the first electrode, and a light transmissivesecond electrode 40 positioned over the organic light emitting layer. Preferably the first electrode is a cathode and the second electrode is an anode. On the outer surface of the anode may be a metal contact element having a first surface in contact with a first portion of an outer surface of the anode, and a power source electrically connected to the cathode and the metal contact element. - The
fiber core 10 may be transparent, translucent, opaque or reflective. The materials used can be glass, plastic, ceramic or metal foils, where plastic and metal foils are preferably used for flexible substrates. Thefiber core member 10 may comprise a flexible polymeric or metallic material. Suitable polymeric materials forfiber core member 10 are polyolefins such as polyethylene, polypropylene, or polytetrafluorethylene; polysiloxane; epoxy, polyacrylate; polyethyleneterephtalate; and derivatives thereof.Fiber core element 10 may comprise a glass or a metal such as aluminium, copper, or steel. - The glass used can be, for example, soda-lime glass, Ba- or Sr-containing glass, lead glass, aluminium silicate glass, borosilicate glass, Ba borosilicate glass or quartz.
- Plastic plates can consist, for example, of polycarbonate resin, acrylic resin, vinyl chloride resin, polyethylene terephthalate resin, polyimide resin, polyester resin, epoxy resin, phenolic resin, silicone resin, fluorine resin, polyether sulfide resin or polysulfone resin.
- For transparent fibers, use is made, for example, of polyethylene, ethylene-vinyl acetate copolymers, ethylene-vinyl alcohol copolymers, polypropylene, polystyrene, polymethyl methacrylate, PVC, polyvinyl alcohol, polyvinylbutyral, nylon, polyether ether ketone, polysulfone, polyether sulfone, tetrafluoroethylene-perfluoroalkyl vinyl ether copolymers, polyvinyl fluoride, tetrafluoroethylene-ethylene copolymers, tetrafluoroethylene-hexafluoropropylene copolymers, copolymers, polychlorotrifluoroethylene, polyvinylidene fluoride, polyester, polycarbonate, polyurethanes, polyimide or polyether imide.
- Other materials than those mentioned here can also be used as
fiber core 10. Suitable materials are known to the person skilled in the art. - The
flexible core member 10, if present, may comprise a flexible metal wire, such as an aluminum, copper or steel wire, a flexible glass fiber or a flexible plastic fiber. The core member preferably has a diameter (or height or width for non-circular cross sections) of about 1 μm to about 10 mm, particularly preferably 5 μm to 5 mm, and very particularly preferably 10 μm to 1 mm. - If desired, the light emitting fiber may also comprise an optional radiation transmissive moisture and/or
air barrier layer 50 and/or an optional radiationtransmissive encapsulating material 60, as illustrated inFIG. 1 . The inner surface oflayer 50 surrounds the outer surface of theanode 40, and the inner surface ofmaterial 60 surrounds the outer surface of thelayer 50, iflayer 50 is present, or the outer surface of theanode 40. - If desired, the light emitting fiber may also comprise an optional refractive index matching layer or an capping layer. The said refractive index matching layer is used to improve out-coupling of the light from the device. The inner surface of refractive index matching layer surrounds the outer surface of the
anode 40, and the inner surface ofmaterial 50 surrounds the outer surface of refractive index matching layer, iflayer 50 is present. Such refractive index matching layers are helpful for light out-coupling. Suitable materials are dielectric materials with a high refractive index such as CsCl, NPB, C60, MeO-TPD, ZnO, 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline (BCP), Alq3, Au, and SnO2. The thickness of the index matching layer can be in the range between 1 and 300 nm, preferably in the range between 5 and 100 nm, and particularly preferably in the range between 10 and 60 nm. More details on refractive index matching can be found in US 20080231959 A1. - The light emitting fiber has a high brightness and can be made flexible if it has a fiber or tube shape. The fiber or tube shaped OLEDs may have an improved moisture resistance while remaining flexible, in contrast to prior art flat plate OLEDs, by adding an outer moisture/air barrier layer and/or by forming an outer moisture and air impervious metal electrode around the fiber core. The term fiber means a shape having a length which is much greater than the cross sectional diameter (or width or height for non-circular cross sections). In a preferred embodiment of the present invention, the term fiber means a shape that has rather large length to diameter ratio, such as 10:1 or greater. Particularly preferably, the length to diameter ratio is 100:1 or greater.
- The
first electrode 20 may be a cathode and thesecond electrode 40 may be a light transmissive anode. However, the polarity of theelectrodes electrode 20 may be the anode andelectrode 40 may be the cathode. The twoelectrodes radiation emitting layer 30 comprise the OLED device. - The fiber core may comprise a flexible
fiber core member 10 and thefirst electrode 20 over the outer surface of thefiber core member 10. Preferably, thefiber core member 10 has the non-planar outer surface, such as a circular outer surface, and thefirst electrode 20 is formed around the entire outer surface of thefiber core member 10, such that theelectrode 20 also has a non-planar outer surface, such as a circular surface. In an alternative preferred aspect of the present invention, thefiber core member 10 may be omitted, and the fiber core may consist entirely of thefirst electrode 20, such as a metal electrode having an elongated fiber shape. Theelectrode 20 may be hollow or solid. Preferably, the electrode contains a non-planar outer surface, such as a circular surface. - The flexible OLED fiber further comprises a power source electrically connected to the
cathode 20 and theanode 40. The power source may be a voltage source, such as a small battery, a printed battery or a plug that plugs into a socket. The power source is connected to thecathode 20 and theanode 40. The power source may also contain a switch which allows the user to turn the device on and off, and/or a brightness control, such as a potentiometer. - The device may comprise an interactive steering unit. The steering unit may, e.g., allow a switch from continuous illumination to pulsed illumination. It also may allow the precise adaptation of irradiation intensities and/or wavelengths to be emitted. The steering unit may be directly associated to the device. It can also be separated via a permanent or temporary linkage. The device may be disposable and is suitable for uses in the hospital or outside the hospital.
- The steering unit may be used interactively by the user, patient, physician, nurse, or other persons. The steering unit can also be operate according to the specification of expert, e.g., a physician, by programming it.
- The fiber can also comprises a metal contact element in contact with a first portion of the outer surface of the
radiation transmissive anode 40. The purpose of the contact element is to reduce the voltage drop along the length of the OLED fiber, since a radiation transmissive anode material, such as indium tin oxide (ITO), may not have a high enough electrical conductivity to obtain the desired value of the voltage drop. The contact element may comprise any conductive metal, such as aluminum or copper. Themoisture barrier layer 50 may comprise any material that prevents moisture from permeating into theorganic layer 30, such as SiO2, Si3N4 or silicon oxynitride. Theencapsulation material 60 may comprise silicone or epoxy. - While the fiber organic light emitting fiber as depicted in
FIG. 1 has a circular cross section, it may have any other desired cross section. For example, the fiber may contain an oval cross section, a polygonal cross section (e.g. a square cross section) or a combination circular, oval or polygonal cross sections. - The light emitting fiber preferably has a diameter (or height/width for non-circular cross sections) of about 1 μm to about 2 mm, particularly preferably 5 μm to 1 mm, and very particularly preferably 10 μm to 0.5 mm.
- The organic
radiation emitting layer 30 preferably has a thickness of about 20 to about 500 nm, particularly preferably of about 30 to about 200 nm, and very particularly preferably of about 30 to about 90 nm and theelectrodes - Materials for the electrodes and emissive layer(s) are described elsewhere within the present invention. Further materials, the set up of the OLED fibers and the preparation of OLED fibers by, e.g. vapour deposition or liquid deposition methods are described in detail in U.S. Pat. No. 6,538,375 and U 2003/0099858 and are incorporated herein by reference.
- If desired, a luminescent material, such as a phosphor or a fluorescent dye may be added to the
encapsulation material 50. The luminescent material emits visible light having a first wavelength, in response to being irradiated by visible or ultraviolet radiation having a shorter, second wavelength, emitted by the organicradiation emitting layer 30. For example, the luminescent material may emit yellow or white light in response to incident ultraviolet or blue radiation, respectively, fromlayer 30. The mixture of blue and yellow light appears as white light to an observer. Thus, the light emitting fiber appears to emit white light to the observer, even whenlayer 30 does not emit white light. The device may also emit any color of light other than white, if desired. - Examples of phosphor materials that can be utilized include those phosphors based on cerium doped into a Y3Al5O12 (YAG) lattice which crystallizes in the garnet structure. Specific examples include (Y1-x-yGDxCey)3Al5O12 (YAG:Gd,Ce), (Y1-x-Cex)3Al5O12 (YAG:Ce), (Y1-xCex)3(Al1-yGay)5O12 (YAG:Ga,Ce) and (Y1-x-yGdxCey)3(Al5-zGaz)5O12 (YAG:Gd,Ga,Ce) and (Gd1-xCex)Sc2Al3O12 (GSAG). The YAG phosphors can be described generally as (Y1-X-YGdXCeY)3(Al1-ZGaZ)5O12, wherein x+y≦1; 0≦x≦1; 0≦y≦1; and 0≦z≦1. The position of the peak of the emission band varies considerably in the aforementioned phosphors. Depending on the garnet composition, the Ce3+ emission can be tuned from the green (approximately 540 nm; YAG:Ga,Ce) to the red (approximately 600 nm; YAG:Gd:Ce) without appreciable loss in the luminescence efficiency. An appropriate phosphor material or blend of phosphor materials in combination with a blue or UV emission of the organic radiation emitting fiber can produce a white field.
- Green-emitting phosphors that can be used according to the present invention: Ca8Mg(SiO4)4Cl2:Eu2+,Mn2+; GdBO3:Ce3+, Tb3+; CeMgAl11O19:Tb3+; Y2SiO5:Ce3+,Tb3+; and BaMg2Al16O:Eu2+,Mn2+.
- Red-emitting phosphors that can be used according to the present invention: Y2O3:Bi3+; Sr2P2O7:Eu2+,Mn2+; SrMgP2O7:Eu2+, Mn2+; (Y,Gd)(V,B)O4:Eu3+; and 3.5 MgO.0.5MgF2.GeO2: Mn4+.
- Blue-emitting phosphors that can be used according to the present invention: BaMg2Al16O27:Eu2+ and Sr5(PO4)10Cl2:Eu2+.
- Still other ions may be incorporated into the inorganic phosphor to transfer energy from the light emitted from the organic material to other activator ions in the phosphor host lattice as a way to increase the energy utilization. For example, when Sb3+ and Mn2+ ions exist in the same phosphor lattice, Sb3+ efficiently absorbs light in the blue region, which is not absorbed very efficiently by Mn2+, and transfers the energy to Mn2+ ion. Thus, a larger total amount of light emitted by the organic EL material is absorbed by both ions, resulting in higher quantum efficiency of the total device.
- In addition, more than one phosphor material may be combined together and then utilized with an organic radiation emitting device to achieve different colors, color temperatures, and color rendition indices. Other phosphors which can be used are described in U.S. Ser. No. 09/469,702, which is hereby incorporated by reference. An example of a suitable red emitting inorganic phosphor is SrB4O7:Sm2+, where the Sm2+ following the colon represents an activator. This phosphor absorbs most visible wavelengths shorter than 600 nm and emits light as a deep red line with a wavelength greater than 650 nm. An example of a suitable green emitting inorganic phosphor is SrGa2S4:Eu2+. This phosphor absorbs below 500 nm and has a maximum emission at 535 nm. An example of a suitable blue emitting inorganic phosphor is BaMg2Al16O27:Eu2+. BaMg2Al16O27:Eu2+ absorbs most wavelengths below 430 nm and has a maximum emission at 450 nm. Examples of organic dyes which can be utilized as the luminescent material include coumarin 460 (blue), coumarin 6 (green), and nile red.
- The organic radiation emitting fiber may also include an optional radiation scattering layer, comprising scattering particles such as TiO2, Al2O3, or SiO2 for effective color mixing and brightness uniformity. The scattering particles can also be mixed into the encapsulating
material 60, or be formed as a separate layer over the encapsulatingmaterial 60, if desired. - A variety of organic
radiation emitting layers 30 can be used in conjunction with exemplary embodiments of the invention. The organic radiation emitting layer may comprise at least one polymer layer or at least one organic molecule containing layer. - The
radiation emitting layer 30 comprise at least one functional layer. The functional layer can be selected from any type of functional layer typically found in OLEDs. The materials found in these functional layer can be selected from any functional material known to one skilled in the art. - Preferably the functional materials described elsewhere within the present invention are used in the functional layer. The functional materials used in functional layers can therefore be small molecules, polymers, oligomers, dendrimers, and blends. Typical functional layers found in OLEDs are emissive layer (EML), hole injection layer (HIL), hole transport layer (HTL), hole blocking layer (HBL), electron transport layer (ETL), electron injection layer (EIL), electron blocking layer (EBL), and exciton blocking layer (ExBL).
- A typical sequence of layers as found in an OLED and, thus, also find in the
radiation emitting layer 30 is, for example: -
- optionally a hole injection layer (HIL),
- optionally a hole transport layer (HTL) and/or an electron blocking layer (EBL),
- an emissive layer,
- optionally an electron transport layer (ETL) and/or a hole blocking layer (HBL),
- optionally an electron injection layer (EIL),
- The sequence of the given layer structure is exemplary. Other sequences are possible. Mainly depending on the deposition technique used, different layer structures can be obtained. In the case of thermal vacuum evaporation, multi-layer OLEDs are preferred, such as anode/HIL/HTL/EML/ETL/EIL/cathode, allowing to separate and optimise the different functions in the corresponding layers. In the case of solution-based coating techniques, such as inkjet printing, screen printing and spin-coating, simple device structures with a few layers are preferred, e.g., anode/HIL/EML/cathode. By employing a suitable immobilisation technique, for example cross-linking, a multilayer structure can also be obtained by a solution-based coating technique. A polymer is a typical soluble materials suitable for a solution-based coating technique. State-of-the-art PLEDs often comprise an interlayer.
- The term interlayer (IL) as used herein is defined as layer between the hole injection layer (or buffer layer) and the emissive layer in polymer light emitting diodes (PLEDs), being an electron blocking layer, as disclosed for example in WO 2004/084260 A2. The typical device structure of PLEDs with interlayer is therefore anode/HIL/IL/EML/cathode.
- Preferably the organic
radiation emitting layer 30 comprises a single layer. The organicradiation emitting layer 30 may comprise, for example, a conjugated polymer which is luminescent, a hole-transporting polymer doped with electron transport molecules and a luminescent material, or an inert polymer doped with hole transporting molecules and a luminescent material. The organicradiation emitting layer 30 may also comprise an amorphous film of luminescent small organic molecules which can be doped with other luminescent molecules. - The organic
radiation emitting layer 30 comprises two or more sublayers which carry out the functions of hole injection, hole transport, electron injection, electron transport, and luminescence. Only the luminescent layer is required for a functioning device. The organicradiation emitting layer 30 can comprise 1 to 6 sublayers including, for example, a hole injection sublayer, a hole transport sublayer, a luminescent sublayer, and an electron injection sublayer. - In another very preferred embodiment, the
radiation emitting layer 30 is a soluble based system comprising a multilayer structure as follows: HIL/IL/EML as disclosed for example in WO 2004/084260 A2, wherein theradiation emitting layer 30 comprises soluble organic compounds, which can be a mixture of small molecules, a mixture of small molecules and polymer(s), and a blend of polymers, particularly preferably a conjugated polymer or a mixture comprising at least one phosphorescent emitter, which can be selected from the phosphorescent emitters as described above, either being a small molecule or a polymer. - Conjugated polymers are discussed, for example, in R. H. Friend, 4 J. Mol. Electronics 37-46 (1988). One example of a conjugated polymer is PPV (poly(p-phenylenevinylene). PPV emits light in the spectral range of about 500 to 690 nm and has good resistance to thermal and stress induced cracking.
- Other examples of suitable conjugated polymers are those comprising backbone units selected from for example, 4,5-dihydropyrene derivatives, 4,5,9,10-tetrahydropyrene derivatives, fluorene derivatives as disclosed for example in U.S. Pat. No. 5,962,631, WO 2006/052457 A2 and WO 2006/118345A1, 9,9′-spirobifluorene derivatives as disclosed for example in WO 2003/020790 A1, 9,10-phenanthrene derivatives as disclosed, for example, in WO 2005/104264 A1, 9,10-dihydrophenanthrene derivatives as disclosed for example in WO 2005/014689 A2, 5,7-dihydrodibenzooxepine derivatives and cis- and trans-indenofluorene derivatives as disclosed for example in WO 2004041901 A1, WO 2004113412 A2 and, binaphthylene derivatives as disclosed for example in WO 2006/063852 A1, and further backbone units as disclosed for example in WO 2005/056633A1, EP 1344788A1 and WO 2007/043495A1, WO 2005/033174 A1, WO 2003/099901A1 and DE 102006003710.3.
- Further suitable conjugated polymer based on fluorene derivatives, as disclosed for example in U.S. Pat. No. 5,962,631, WO 2006/052457 A2 and WO 2006/118345 A1, spiro-bifluorene derivatives as disclosed for example in WO 2003/020790 A1, benzofluorene, dibenzofluorene, benzothiophene, dibenzofluorene and their derivatives as disclosed for example in WO 2005/056633A1, EP 1344788A1 and WO 2007/043495A1
- In a particularly preferred embodiment, the
radiation emitting layer 30 comprises a phosphorescent composition. The preferred phosphorescent composition is a mixture of host material and emissive metal complex, as disclosed for example in EP2005005021 and WO 2005040302_A1, and further preferably, the host material is selected from non-conjugated polymers, as disclosed from example in DE 102009023156.0. and DE 102009023154.4. - The above described oligomers, polymers, or mixtures of small molecules and/or polymers are readily soluble in common organic solvents. They are processable into thin films or coatings by conventional techniques such as spin coating, spray coating, dip coating, inkjet printing, and roller coating. Upon curing, such films demonstrate resistance to common organic solvents and high heat resistance.
- The fiber OLED according to the present invention can be preferably mass produced using dip-coating. One general production line is schematically shown in
FIG. 12 , taking, for example, a fiber OLED having a structure of anode/HIM/interlayer/EML/cathode, wherein the electrodes are deposited by physical vapor deposition and the organic function layers, HIM, interlayer and EML are coated by dip-coating. The physical vapor deposition methods could be selected from such as thermal vacuum evaporation, sputtering, Cathodic Arc Deposition, Pulsed laser deposition and e-beam etc. Another particularly preferred production method is all solution based, as schematically shown inFIG. 13 . The components used in bothFIGS. 12 and 13 are explained as follows: 210 is a fiber core; 130 is a deposition chamber for the first electrode; 200 is a deposition chamber for the second electrode; 240 is a container comprising an ink comprising a conductive material for the first electrode; 140 is a container containing solution of buffer material or HIM; 160 is a container containing a solution or a formulation of HTM or interlayer material; 180 is a container containing a solution or a formulation of an emissive composition; 250 is a container containing an ink comprising a conductive material for the second electrode; 150, 170, 190, 220 and 230 are dryers. - The treatment and/or prophylaxis and/or diagnosis of therapeutic conditions and/or cosmetic conditions by phototherapy requires, at least in some cases, the employment of different wavelengths. In order to prepare a device emitting more than one wavelength or more than one ranges of wavelengths different strategies are possible and all of them are covered by the present invention. Different wavelengths can be achieved by the use of more than one
radiation emitting layer 30 in one fiber with different functional materials emitting light of different wavelengths or ranges of wavelengths. Preferably the light emitting fiber according to the present invention comprises 3, particularly preferably 2, and very particularly preferably 1radiation emitting layer 30. - As outlined elsewhere within the present invention the
radiation emitting layer 30 shows the typical structure of layers or sublayers typically found in OLEDs. Thus, theradiation emitting layer 30 can comprise one or more layer. Theradiation emitting layer 30 can also comprises different emissive materials in either the same emissive layer or in different emissive layers. Preferably theradiation emitting layer 30 comprises 3, particularly preferably 2, and very particularly preferably 1 emissive layers. Preferably theradiation emitting layer 30 comprises 3, particularly preferably 2, and very particularly preferably 1 emissive materials. The emissive layer can preferably comprise 3, particularly preferably 2, and very particularly preferably 1 emissive materials. The different emissive materials are selected from the emissive materials as described above, but any other emissive material suitable can be employed. If two emissive materials are used in one emissive layer the absorption spectrum of one of the two emissive materials preferably overlaps with the emission spectrum of the other emissive material. - Different wavelengths can also be accomplished by dividing the light emitting fiber into small segments having n distinct
radiation emitting layer 30 as depicted inFIG. 2a ) and b) emitting n different wavelengths or ranges of wavelengths. If multiple segments are used in one fiber then n is preferably 4, particularly preferably 3, and very particularly preferably 2 (seeFIG. 2b ). However, even if n is 1, multiple segments can be used in one fiber. - Devices emitting different wavelengths or ranges of wavelengths can also be obtained by employing different light emitting fibers as depicted in
FIG. 3 andFIG. 4 , whereby n is defined as above. Particular preference is given to a device comprising two distinct light emitting fibers (seeFIG. 4 ). - The parallel arrangement of light emitting fibers in an device is only one possibility. Any processing known for fibers can be employed. The fibers can, e.g. be woven as depicted in
FIG. 5 . Hereby different light emitting fibers can be processed in order to get a canvas emitting different wavelengths or ranges of wavelengths. The fibers emitting the same wavelength(s) can be arranged in parallel to each other so that fibers emitting different wavelength(s) are perpendicular to each other (FIG. 6 ). The fibers emitting different wavelength(s) can also be arranged in an alternating fashion. -
FIG. 7 shows as exemplary embodiment of the present invention a light emitting device which is a plaster. It comprises a side for attaching 1 the plaster to the subject to be treated. It can also comprise apower supply 2 which can be, e.g., a battery and particularly a printed battery. In 2 also a steering unit may be incorporated. The plaster can also comprise areflective material 3 which is not transparent or only partly transparent. Thereflective material 3 improves the efficiency of the device. The device may, dependant on the light emitting fibers 4 emit different wavelengths λ1 to λn, wherein n is preferably 3, particularly preferably 2, and very particularly preferably 1. - The device comprising the light emitting fibers can be stiff or flexible, wherein flexibility includes both plasticity and elasticity. By choosing the appropriate materials the degree of flexibility of the light emitting fibers can be tailored to any desired value. Stiffness can be achieved by either stiffness of the device, stiffness of the fibers or stiffness of both device and fibers. The overall device can be, at least in part, flexible even if the light emitting fibers are not. This can be accomplished, e.g., if the fibers are arranged on the device so that they run in parallel. The parallel fibers can be fixed on a flexible substrate, such as a plaster and flexibility occurs perpendicular to the fibers. The fibers can be stiff or flexible and flexible fibers can either be ductile, i.e. it can be deformed plastically without fracture, or elastic, i.e. the fiber deforms reversibly and once the forces responsible for deformation are no longer applied, the object returns to its original shape. Preferably the fiber is flexible. The device comprising the fibers can therefore adopt any shape according to the physiognomy of the subject to be treated and it can follow the movements and changes of its shape instantaneously. In another preferred embodiment the fiber deforms plastically. If the fiber is, e.g., incorporated in a bandage or plaster, the plaster can be adopted to the physiognomy of the subject to be treated. However, it may not follow the subject's changes of the surface. Depending on the degree of plasticity and stiffness the plaster or bandage can stabilize parts of the surface to be treated.
- The said functional materials can be used as outlined above, e.g., in order to treat humans. The said functional materials can also be used as outlined above, e.g., in order to treat animals. The functional materials are used in light emitting fibers and the light emitting fibers are used in devices employed for the said treatments. The device comprises an attachment means for attaching the device to a human or animal subject.
- Further subjects and objects suitable to be treated by the irradiation with said functional materials and light emitting fibers comprising them are, e.g., plants, microbes, bacteria, fungi, and any kind of liquids and solids. Microbes include, but are not limited to, prokaryotes such as bacteria and archaea and eukaryotes such as protists, animals, fungi and plants. Preferred liquids are soft drinks, beverages and particularly preferably water and drinking water. Further preferred objects to be treated are foodstuff and nutrition.
- As already outlined within the present invention the device can have any shape, be rigid or flexible. The device requires energy supply in any form. The energy supply may be directly associated to the device or separated by, e.g., a cable. A battery, particularly a printable battery, may be attached to the device in order to provide a device which is comfortable for the subject to be treated forming a totally self-contained portable unit. Irradiation may, thus, occur at any time and at any place without disturbing the subject to be treated in its habits or daily life. Home use of devices according to the present invention is particularly preferable. The device may be self adhesive and detachable. It may conform a planar or non-planar portion of the body or be an implantable probe.
- As already outlined within the present invention the device may comprise an interactive steering unit. The steering unit may allow a switch from continuous illumination to pulsed illumination. It also may allow the precise adaptation of irradiation intensities and/or wavelengths to be emitted. The steering unit may be directly associated to the device. It can also be separated via a permanent or temporary linkage. The device may be disposable and is suitable for uses in the hospital or outside the hospital.
- In any case the device according to the present invention is suitable as light weight device for portable use. However, stationary devices can also be prepared. The device is sufficiently portable to enable ambulatory treatment i.e. treatment in which the subject can move around freely. It can be subsequently removed in the human subjects own time, so that treatment could take place almost everywhere. This results in a better convenience and lower costs (from avoiding either an out-patient or inpatient stay in hospital).
- In the case of PDT the treatment is often associated with pain. Ambulatory devices according to the present invention can be used with lower light levels since exposure can occur for a longer period of time. This overcomes a problem of pain induced in some patients by the high irradiances from conventional sources used in hospitals. In addition lower irradiance is more effective in PDT due to reduction of the extent of photobleaching of the photopharmaceutical.
- The devices may be provided with a photochemical and/or a photopharmaceutical preparation present. This may be in the form of a gel, ointment or cream. Alternatively, or as well, the device may be provided with a thin film impregnated with the photopharmaceutical. Typically, the photopharmaceutical preparation is provided as a layer in contact with the light source. Provided that the photopharmaceutical preparation is transparent or sufficiently translucent for the frequency of stimulating light, the resulting device can be readily applied without a separate step of applying the photopharmaceutical to a patient. Creams which would scatter the light may nevertheless be used if they are absorbed before the light source is switched on. A photopharmaceutical layer may be covered by a peelable release medium, such as a silicone-backed sheet. The photopharmaceutical preparation may comprise an inactive compound which is metabolised in vivo to an active compound. Delivery of the photopharmaceutical can be assisted by iontophoresis.
- The output of light from the device may be pulsed and an electronic control circuit or microprocessor may be provided to control this pulsing and/or other aspects of device function such as duration of exposure(s) of the area to be treated and the intensity of emitted light. Pulsed devices may be provided with a preparation of a photochemical and/or a photopharmaceutical substance which is photobleachable or which is metabolised in vivo to a photobleachable chemical species.
- The output of the device may take the form of a train of pulses, preferably in which the duration of the pulses is substantially the same as the interval between successive pulses. The period of the pulse train may, for example, be in the range of 20 ms to 2000 s, depending on the photobleaching characteristics of said substance.
- Preferably, the attachment means comprises an adhesive surface to enable the device to be attached to a patient.
- Further preferred features correspond to the first aspect above.
- Preferably, the ambulatory device is provided with a photochemical and/or a photopharmaceutical preparation present. Preferred features of the preparation and its delivery are as above. In particular, the photochemical and/or photopharmaceutical may be photobleachable or may be metabolised in vivo to a photobleachable chemical species.
- The means for activating and deactivating the source may control other aspects of device function such as duration of exposure(s) of the area to be treated and the intensity of emitted light.
- The control means may preferably be operable to cover the source to emit a pulse train having any one or more of the preferred features of the pulse train produced by a device.
- Suitable devices according to the present invention are selected from sleeves, bandages, pads, plaster, implantable probes, nasogastric tubes, chest drains, stents, clothe like devices, blankets, sleeping bags, canvas and any kind of clothes, devices covering at least one tooth in the mouth, and patches.
- The device may be used as a stent, for example a tube of 1.25 to 2.25 cm radius of
say 10 to 12 cm length for use inside the oesophagus. - The device may be a blanket or sleeping bag in order to treat, e.g., jaundice of infants. Currently infants suffering from jaundice are separated from their parents and illuminated in incubators blindfold. This represents an unpleasant situation for both the infant and the parents. In addition, the infant is not able to adjust his body temperature as easily as adults can do and overheating in the incubator is a critical issue. Flexible blankets and sleeping bag provide a way to treat the infant without these problems. The infant covered by the blanket or sleeping bag can be irradiated while laying in his parents' arms and overheating of the infant's body is not as critical as compared to traditional therapies. This is due to the fact that the devices according to the present invention require less power and produce, in turn, less heat.
- In psoriatic patients plaques are often found in body folds. Conventional phototherapy represents a problem which is due to the fact that light emitted by a light source does not reach the plaque in the body folds. OLEDs can be designed to fit into body folds in order to treat psoriasis and other diseases and/or conditions found in body folds. Ductile characteristics of the light emitting fibers and devices comprising them as outlined above can be beneficial for a device intended for the treatment in body folds.
- Devices can generally spoken individually tailored in any form that is required for treatment.
- The device itself may comprise a therapeutic agent which is released in a controlled way during the treatment.
- The functional materials can be used to prepare devices comprising light emitting fibers for the treatment and/or prophylaxis and/or diagnosis of diseases and/or cosmetic conditions. Preferably, the light emitting fiber comprises or consists of an organic light emitting diode (OLED).
- Preferably the functional materials according to the present invention can be used for the treatment and/or prophylaxis and/or diagnosis of skin diseases and/or cosmetic skin conditions
- Skin as used herein is defined as the largest organ of the integumentary system including hair, scales, feathers and nails. The term skin also includes the tongue, mucosa and gingival.
- In principle any therapeutic and cosmetic condition that is approachable by phototherapy is covered by the present invention. The distinction between the terms therapeutic and cosmetic depends, as outlined above, on individual circumstances, the severity of the condition and the assessment of the physician. As outlined in this invention many therapeutic conditions are associated with cosmetic effects, independent of the severity of the disease.
- The skin diseases and skin related conditions include, but are not limited to acneiform eruptions, autoinflammatory skin diseases or conditions, chronic blistering, conditions of the mucous membranes, conditions of the skin appendages, conditions of the subcutaneous fat, connective tissue diseases, abnormalities of dermal fibrous and elastic tissue, dermal and subcutaneous growths, dermatitis, atopic dermatitis, contact dermatitis, eczema, pustular dermatitis, seborrheic dermatitis and eczema, disturbances of pigmentation, drug eruptions, endocrine-related diseases and conditions, epidermal nevi diseases and conditions, neoplasms, cysts, erythemas, genodermatoses, infection-related diseases and conditions, bacterium-related diseases and conditions, mycobacterium-related diseases and conditions, mycosis-related diseases and conditions, parasitic infestations, stings, and bites, virus-related diseases and conditions, lichenoid eruptions, lymphoid-related diseases and conditions, melanocytic nevi and neoplasms, monocyte- and macrophage-related diseases and conditions, mucinoses, neurocutaneous, noninfectious immunodeficiency-related diseases and conditions, nutrition-related diseases and conditions, papulosquamous hyperkeratotic related diseases and conditions, pruritic related diseases and conditions, psoriasis (mild, mild to severe, and severe), reactive neutrophilic diseases and conditions, recalcitrant palmoplantar eruptions, diseases and conditions resulting from errors in metabolism, diseases and conditions resulting from physical factors, urticaria and angioedema, vascular-related diseases and conditions, and periodontitis or other diseases and conditions of the gingival.
- Skin related diseases and conditions also include skin tumors, pre-malignant tumors, malignant tumors, cell carcinomas, secondary metastasis, radiodermatitis and keratosis.
- The healing of wounds can also be assigned to skin diseases and skin related conditions. Wound healing can, hereby, occur at the outer surface of the subject to be treated, at its internal parts, at the skin, eye, nail or nail bed, any surface in the subject's mouth, and at the mucosa, gingival, epithelial surface of the vascular system or other part of the subjects body.
- The fiber devices comprising the functional materials according to the present invention can be used in cosmetics for skin care and skin repair, e.g. as light plaster. The wavelengths or range of wavelengths emitted by said devices is in the range between 400 and 800 nm, preferably between 450 and 750 nm, particularly preferably between 500 and 700 nm, and very particularly preferably between 580 and 640 nm.
- Preferably the functional materials according to the present invention can be used for the treatment and/or prophylaxis and/or diagnosis of skin diseases and/or cosmetic skin conditions selected from acne, psoriasis, eczema, dermatitis, atopic dermatitis, edema, vitiligo, Bowens disease, tumors, pre-malignant tumors, malignant tumors, basal cell carcinomas, squamous cell carcinomas, secondary metastases, cutaneous T-cell lymphomas, solar keratosis, arsenical keratosis, radiodermatitis, and cellulite.
- Further preferred skin diseases and skin-related conditions are selected from psoriasis, polymorphous light eruption, solar urticaria, actinic reticuloid atopic eczema, vitiligo, pruritus, lichen planus, early cutaneous T-cell lymphoma, dermographism, and pityriasis lichenoides. Preferably theses diseases and conditions are treated with light having a wavelength or a range of wavelengths between 200 and 500 nm, particularly preferably between 250 and 400 nm, and very particularly preferably between 270 and 350 nm.
- The functional materials according to the present invention and fiber devices comprising them can be used for PUVA therapy. PUVA therapy is derived from the therapeutic application of psoralen (7H-furo[3,2-g]chromen-7-one) and derivatives thereof together with UV-A light. PUVA can be employed for the treatment of skin diseases characterized by hyperproliferative conditions. Psoralen is the parent compound in a family of natural products. It is structurally related to coumarines and can preferably be used for the treatment of psoriasis, eczema, vitiligo, mycosis fungoides, cutaneous T-cell lymphoma, and other autoimmune diseases. With PUVA can also bet treated atopic eczema, lichen planus, urticaria pigmentosa, polymorphous light eruption, and alopecia areata.
- Psoralen can be administered orally or topically to the skin. Preferred compounds are psoralen, 8-methoxypsoralen (8-MOP), 5-methoxypsoralen (5-MOP), and 4,5′,8-trimethylpsoralen (TMP). After oral administration of 8-MOP, patients become gradually reactive to UV-A and therefore to photochemotherapeutic treatment. The patients are maximally reactive 2 to 3 hours after ingestion of the drug, and during this period the irradiation is carried out.
- In the case of vitiligo khellin can be used instead of psoralen. The combined treatment with light and khellin is often called KUVA.
- The functional materials according to the present invention and fiber devices comprising them can also be used for photopheresis. Photophoreresis is a process by which peripheral blood is exposed in an extracorporeal flow system to photoactivate 5-MOP and represents a treatment for disorders caused by aberrant T lymphocytes. It is a therapy for advanced cutaneous T-cell lymphoma, pemphigus vulgaris and progressive systemic sclerosis (scleroderma). It can be used to treat autoimmune disorders. Further diseases that can be treated include multiple sclerosis, organ transplant rejection, rheumatoid arthritis, and AIDS.
- The present invention particularly refers to said functional materials and devices comprising them for the treatment of acneiform eruptions. The term acneiform eruption refers to a group of dermatoses including acne vulgaris, rosacea, folliculitis, and perioral dermatitis. Acneiform eruptions are, generally spoken, caused by changes in the pilosebaceous unit and are selected from acne aestivalis (Mallorca acne), acne conglobata, acne cosmetica, acne fulminans (acute febrile ulcerative acne), acne keloidalis (acne keloidalis nuchae, dermatitis papillaris capillitii, folliculitis keloidalis, folliculitis keloidis nuchae, nuchal keloid acne), acne mecánica, acne medicamentosa, acne miliaris necrotica (acne varioliformis), acne vulgaris, acne with facial edema (solid facial edema), acneiform eruptions, blepharophyma, erythrotelangiectatic rosacea (erthemaotelangiectatic rosacea), excoriated acne (acne excoriee des jeunes filles, Picker's acne), glandular rosacea, gnathophyma, gram-negative rosacea, granulomatous facial dermatitis, granulomatous perioral dermatitis, halogen acne, hidradenitis suppurativa (acne inversa, Verneuil's disease), idiopathic facial aseptic granuloma, infantile acne, lupoid rosacea (granulomatous rosacea, micropapular tuberculid, rosacea-like tuberculid of Lewandowsky), lupus miliaris disseminatus faciei, metophyma, neonatal acne (acne infantum, acne neonatorum), occupational acne, ophthalmic rosacea (ocular rosacea, ophthalmorosacea), otophyma, persistent edema of rosacea (chronic upper facial erythematous edema, Morbihan's disease, Rosaceous lymphedema), pomade acne, papulopustular rosacea, perifolliculitis capitis abscedens et suffodiens (dissecting cellulitis of the scalp, dissecting folliculitis, perifolliculitis capitis abscedens et suffodiens of Hoffman), perioral dermatitis, periorbital dermatitis (periocular dermatitis), pyoderma faciale (rosacea fulminans), rhinophyma, rosacea (acne rosacea), rosacea conglobata, rosacea fulminans, SAPHO syndrome, steroid rosacea, tropical acne.
- Acne vulgaris (commonly called acne) is a common skin condition, caused by changes in pilosebaceous units, skin structures consisting of a hair follicle and its associated sebaceous gland, via androgen stimulation. It is characterized by noninflammatory follicular papules or comedones and by inflammatory papules, pustules, and nodules in its more severe forms. Acne vulgaris affects the areas of skin with the densest population of sebaceous follicles; these areas include the face, the upper part of the chest, and the back. Severe acne is inflammatory, but acne can also manifest in noninflammatory forms. Acne lesions are commonly referred to as pimples, blemishes, spots, zits, or simply acne.
- Acne occurs most commonly during adolescence, affecting more than 89% of teenagers, and frequently continues into adulthood. In adolescence, acne is usually caused by an increase in male sex hormones, which people of both genders accrue during puberty. For most people, acne diminishes over time and tends to disappear—or at the very least decrease—after one reaches one's early twenties. There is, however, no way to predict how long it will take to disappear entirely, and some individuals will carry this condition well into their thirties, forties and beyond.
- The face and upper neck are the most commonly affected, but the chest, back and shoulders may have acne as well. The upper arms can also have acne, but lesions found there are often keratosis pilaris. Typical acne lesions are comedones, inflammatory papules, pustules and nodules. Some of the large nodules are also called cysts and the term nodulocystic has been used to describe severe cases of inflammatory acne.
- Aside from scarring, its main effects are psychological, such as reduced self-esteem and, in some cases, depression or suicide. Acne usually appears during adolescence, when people already tend to be most socially insecure. Early and aggressive treatment is therefore advocated by some to lessen the overall impact to individuals.
- Light exposure can be used as treatment for acne. Used twice weekly, this has been shown to reduce the number of acne lesions by about 64% and is even more effective when applied daily. The mechanism appears to be that a porphyrin (Coproporphyrin III) produced within P. acnes generates free radicals when irradiated by 420 nm and shorter wavelengths of light. Particularly when applied over several days, these free radicals ultimately kill the bacteria. Since porphyrins are not otherwise present in skin, and no UV light is employed, it appears to be safe.
- The treatment apparently works even better if used with a mixture of the violet/blue light and red visible light (e.g. 660 nm) resulting in a 76% reduction of lesions after three months of daily treatment for 80% of the patients; and overall clearance was similar or better than benzoyl peroxide. Unlike most of the other treatments few if any negative side effects are typically experienced, and the development of bacterial resistance to the treatment seems very unlikely. After treatment, clearance can be longer lived than is typical with topical or oral antibiotic treatments; several months is not uncommon. In addition, basic science and clinical work by dermatologists has produced evidence that intense blue/violet light (405 to 425 nm) can decrease the number of inflammatory acne lesion by 60 to 70% in four weeks of therapy, particularly when the P. acnes is pre-treated with delta-aminolevulinic acid (ALA), which increases the production of porphyrins.
- The present invention therefore also relates to a combination of the functional materials and devices comprising them and further active drugs for the treatment of diseases and/or cosmetic conditions. In particular, the present invention relates to the combined use of said functional materials and drugs used for the treatment of acne. The drugs can be selected from any drugs typically employed in order to treat acne, such as antibiotics (topical and/or oral), hormonal treatments, topical retinoids, topical bactericidals, sulfur. Suitable topical bactericidals are, for example, benzoyl peroxide, triclosan, and chlorhexidine gluconate. Suitable topical antibiotics are, for example, erythromycin, clindamycin, and tetracycline. Suitable oral antibiotics are, for example, erythromycin, tetracycline antibiotics (e.g. oxytetracycline, doxycycline, minocycline, or lymecycline), trimethoprim, and minocycline.
- Suitable hormones are, e.g., selected from estrogen, progestogen, a combination of estrogen and progestogen, cyproterone, oestrogen, a combination of cyproterone and oestrogen, drospirenone, spironolactone, and cortisone. Suitable oral retinoids are, for example, vitamin A derivatives such as isotretinoin (e.g. Accutane, Amnesteem, Sotret, Claravis, Clarus). Suitable topical retinoids are, for example, tretinoin (e.g. Retin-A), adapalene (e.g. Differin), tazarotene (e.g. Tazorac), isotretinoin, and retinol. Further suitable drugs are, e.g. selected from anti-inflammatory drugs.
- The compositions according to the present invention and devices comprising them can also be used in combination with dermabrasion to treat or prevent acne. Dermabrasion is a cosmetic medicinal procedure in which the surface of the skin is removed by abrasion (sanding).
- Hereby any therapeutic strategy is included. The drug, e.g., can be administered first for a specific time period followed by the application of phototherapy using the compositions according to the present invention. The time gap between both treatments may also vary, depending on the drug, its photoreactivity, individual circumstances of the subject, and the specific disease or condition. Both treatments may also overlap timely either partly or completely. The exact treatment strategy will depend on the individual circumstances and the severity of the disease or condition.
- The combination therapy can have a synergistic effect and can reduce the side effects of traditional treatment strategies (e.g. the side effects of tetracyclines). This is due to the fact, that smaller doses of the drugs may be required when following the combined approach as outlined herein.
- Comedones, also called blackhead, can also be treated by phototherapy employing the said functional materials and devices comprising them. A comedon is a yellow or blackish bump or plug on the skin. Actually, it is a type of acne vulgaris. Comedones are caused by excess oils that have accumulated in the sebaceous gland's duct. The substance found in these bumps mostly consists of keratin and modified sebum, which darkens as it oxidizes. Clogged hair follicles, where blackheads often occur, reflect light irregularly to produce a comedon. For this reason, the blockage might not necessarily look black when extracted from the pore, but may have a more yellow-brown colour as a result of its melanin content.
- In contrast, a so called whitehead, which is also called closed comedo, is a follicle that is filled with the same material, sebum, but has a microscopic opening to the skin surface. Since the air cannot reach the follicle, the material is not oxidized, and remains white.
- The said fiber devices comprising the functional materials according to the present invention preferably emit light, when used for the treatment of acne, in the range between 350 and 900 nm, preferably between 380 and 850 nm, particularly preferably between 400 and 850 nm, and very particularly preferably between 400 and 800 nm.
- Further particularly preferred light for the treatment of acne is blue light. Preferred blue light has emission wavelengths for the treatment of acne are 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429 and 430 nm. For example 414 and 415 nm are particularly suitable in order to kill P. acnes bacteria and to help cure existing blemishes and to prevent further outbreaks. Studies on the application of phototherapy to treat acne revealed that a combination of different wavelengths or ranges of wavelengths are particularly suitable to treat acne efficiently. Particularly preferred is therefore a combination of red light and blue light to treat acne. The said red light is preferably selected from the range between 590 to 750 nm, particularly preferably between 600 and 720 nm, and very particularly preferably between 620 and 700 nm. Two further preferred wavelengths for the treatment of acne are 633 and 660 nm. The blue light can be selected from the wavelengths as described above.
- In the case of comedo the said fiber devices preferably emit light with a wavelength of 500 nm or light in the range between 500 and 700 nm are particularly preferred.
- Cellulite describes a condition that is claimed to occur in most women, where the skin of the lower limbs, abdomen, and pelvic region becomes dimpled. The causes of cellulite are poorly understood and may involve changes in metabolism and physiology such as gender specific dimorphic skin architecture, alteration of connective tissue structure, vascular changes and inflammatory processes. A couple of therapies are applied to prevent or to treat cellulite. Heat and the increase of blood flow are two common techniques. Therefore light therapy is considered to be beneficial to individuals suffering from cellulite. Said functional material and fiber devices comprising them are suitable for the treatment and/or prophylaxis of cellulite. PDT is also suitable for the treatment and/or prophylaxis of cellulite.
- The wavelength for the treatment and/or prophylaxis of cellulite that is to be emitted by the said fiber devices comprising the functional materials is in the range between 400 and 1000 nm, preferably in the range between 400 and 900 nm, particularly preferably between 450 and 900 nm, and very particularly preferably between 500 and 850 nm.
- The more general term skin ageing refers to both the formation of wrinkles and hyperpigmentation. The signs of ageing of the human skin resulting from the effects on the skin of intrinsic and extrinsic factors are defined by the appearance of wrinkles and fine lines, by the yellowing of the skin which develops a wizened appearance along with the appearance of pigmentation blemishes, by a change in the thickness of the skin, generally resulting in a thickening of the stratum corneum and of the epidermis and a thinning of the dermis, by disorganization of the elastin and collagen fibers which causes a loss of elasticity, of suppleness and of firmness, and by the appearance of telnagiectasia.
- Some of these signs are more particularly associated with intrinsic or physiological ageing, that is so to say with “normal” ageing associated with age, whereas others are more specific to extrinsic ageing, that is so to say ageing caused by the environment in general; such ageing is more particularly photo-ageing due to exposure to the sun. Other factors causing ageing of the skin are atmospheric pollution, wounds, infections, traumatisms, anoxia, cigarette smoke, hormonal status, neuropeptides, electromagnetic fields, gravity, lifestyle (e.g. excessive consumption of alcohol), repetitive facial expressions, sleeping positions, and psychological stressors.
- The changes in the skin which occur due to intrinsic ageing are the consequence of a genetically programmed sequence involving endogenous factors. This intrinsic ageing in particular causes slowing down of the regeneration of skin cells, which is reflected essentially in the appearance of clinical damage such as a reduction of the subcutaneous adipose tissue and the appearance of fine lines or small wrinkles, and in histopathological changes such as an increase in the number and thickness of the elastic fibers, a loss of vertical fibers from the elastic tissue membrane and the presence of large irregular fibroblasts in the cells of this elastic tissue.
- In contrast, extrinsic ageing results in clinical damage such as thick wrinkles and the formation of flabby and weather-beaten skin, and in histopathological changes such as an excessive accumulation of elastic substance in the upper dermis and degeneration of the collagen fibers.
- There are different biological and molecular mechanisms which are responsible for the ageing of the skin and the process is currently not fully understood. However, it was recognized that both intrinsic and extrinsic factors of ageing of the skin share common mechanisms [P. U. Giacomoni et al.,
Biogerontology 2004, 2, 219-229]. These factors trigger a process leading to the accumulation of damages in the skin resulting in skin ageing since the expression of cell adhesion molecules provokes recruitment and diapedesis of circulating immune cells, which digest the extracellular matrix (ECM) by secreting collagenases, myeloperoxidases and reactive oxygen species. - The activation of these lytic processes provokes random damage of these resident cells, which in turn secrete prostaglandins and leukotrienes. These signaling molecules induce the degranulation of resident mast cells which release the autacoid histamine and the cytokine TNFalpha thus activating endothelial cells lining adjacent capillaries which release P-selectin and the synthesis of cell adhesion molecules such as E-selectin and ICAM-1. This closes a self-maintained micro-inflammatory cycle, which results in the accumulation of ECM damage, i.e. skin ageing.
- There is a strong cosmetic and therapeutic need for novel strategies, materials, and devices for the treatment or prophylaxis of skin ageing. Various cosmetic and therapeutic compositions (including for skin care) intended inter alia to prevent or treat ageing of the skin are known. Retinoic acid and derivatives thereof have been described as anti-ageing agents in skin care, cosmetic, or dermatological compositions, in particular in U.S. Pat. No. 4,603,146. Hydroxy acids such as lactic acid, glycolic or alternatively citric acid are also known for this same application, these acids having been described in numerous patents and publications (e.g. EP-A-413528) and introduced into numerous skin care, cosmetic, or dermatological compositions on the market. Aromatic orthohydroxy acids such as salicylic acid have also been proposed (e.g. WO 93/10756 and WO 93/10755).
- All of these compounds act against ageing of the skin by desquamation, that is to say removal of the dead cells at the surface of the stratum corneum. This desquamation is also referred as to a keratolytic property. However, these compounds also have side effects, consisting of stinging and redness, which the user finds unpleasant. Thus, there remains a need for anti-ageing strategies which are at least as effective as the known compounds, but do not exhibit their drawbacks. Unlike the established strategies to treat or prevent skin ageing, intervening the micro-inflammation cascade at a very early stage is a novel concept and treating and preventing intrinsic and extrinsic skin ageing according to the present inventions represents a strategy without the drawbacks known from other strategies.
- Phototherapy provides a new way to treat ageing of the skin. Thus, another subject of the invention is the use of the said functional materials and fiber devices comprising them for the treatment and/or prophylaxis of skin ageing. This means, that the present invention provides solutions, inter alia, for skin rejuvenation and to reduce or prevent the formation of wrinkles.
- The wavelength for the treatment of skin ageing that is to be emitted by the said fiber devices is in the range between 400 and 950 nm. Preferably the wavelength is in the range between 550 and 900 nm, and particularly preferably between 550 and 860 nm.
- The fiber devices comprising the functional materials may also emit light of different wavelengths or wavelength ranges which also applies for other embodiments of the present invention.
- In another preferred embodiment of the present invention the said fiber devices comprising the functional materials used for the treatment of skin ageing emits light in the range of 600 nm and 650 nm, particularly preferably in the range between 620 nm and 650 nm.
- The said fiber devices used for the treatment and/or prevention of skin ageing preferably comprises at least one organic electroluminescent compound which emits light in the range between 350 and 950 nm, preferably between 380 and 900 nm, and particularly preferably between 400 and 900 nm.
- Further particularly preferred light for the treatment and/or prophylaxis of skin ageing is blue light. Preferred blue light has emission wavelengths for the treatment and/or prophylaxis of skin ageing are 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, and 430 nm. For example 415 nm is particularly suitable.
- Further particular preferred light for the treatment and/or prophylaxis of skin ageing has a wavelength between 400 and 900 nm.
- Skin rejuvenation can also be achieved with light of the wavelength of 830 nm or slightly below or above that value. Therefore, fiber devices according to the present invention emitting light in the range between 700 nm and 1000 nm, preferably between 750 nm and 900 nm, particularly preferably between 750 nm and 860 nm, and very particularly preferably between 800 nm and 850 nm are also subject of the present invention. Redness of the skin of a subject can be treated by fiber devices according to the present invention. The wavelength for the treatment and/or prophylaxis of redness that is to be emitted by the said devices is in the range between 460 and 660 nm. Preferably the wavelength is in the range between 500 and 620 nm, and particularly preferably between 540 and 580 nm. One particularly preferred wavelength for this purpose is 560 nm.
- Dermatitis of a subject can be treated by said fiber devices. The wavelength for the treatment and/or prophylaxis of dermatitis that is to be emitted by the fiber devices is in the range between 470 and 670 nm. Preferably the wavelength is in the range between 490 and 650 nm, and particularly preferably between 530 and 610 nm, Two particularly preferred wavelengths for this purpose are 550 nm and 590 nm.
- Atopic eczema of a subject can be treated by fiber devices according to the present invention. The wavelength for the treatment and/or prophylaxis of atopic eczema that is to be emitted by the said fiber devices is in the range between 470 and 670 nm. Preferably the wavelength is in the range between 490 and 650 nm, and particularly preferably between 530 and 610 nm, One particularly preferred wavelength for this purpose is 320 nm.
- Psoriasis can be treated by said devices according to the present invention. The wavelength for the treatment and/or prophylaxis of psoriasis that is to be emitted by the said devices is in the range between 240 and 600 nm. Preferably the wavelength is in the range between 290 and 500 nm, and particularly preferably between 300 and 480 nm. Examples of particularly preferred wavelengths for the treatment of psoriasis are 310, 311, 320, 400, 410, and 420 nm.
- Vitiligo can be treated by fiber devices according to the present invention. The wavelength for the treatment and/or prophylaxis of vitiligo that is to be emitted by the said fiber devices is in the range between 240 and 500 nm. Preferably the wavelength is in the range between 290 and 400 nm, and particularly preferably between 300 and 330 nm. One particularly preferred wavelength for this purpose is 311 nm.
- Targeted phototherapy has enabled therapeutic dosing of ultraviolet light to specific dermatoses while minimizing exposure of healthy skin. Specifically, the 308 nm wavelength of light within the ultraviolet B range has been shown as particularly effective for many dermatoses, including vitiligo; psoriasis; and leukoderma such as that associated with scars, striae alba and post-CO2 laser resurfacing.
- The fiber devices according to the present invention can also be used for the treatment of edema. Edema, formerly known as dropsy or hydropsy, is an abnormal accumulation of fluid beneath the skin or in one or more cavities of the body. Generally, the amount of interstitial fluid is determined by the balance of fluid homeostasis, and increased secretion of fluid into the interstitium or impaired removal of this fluid may cause edema. Five factors can contribute to the formation of edema: (1) It may be facilitated by increased hydrostatic pressure or by reduced oncotic pressure within blood vessels or (2) by increased blood vessel wall permeability as in inflammation or (4) by obstruction of fluid clearance via the lymphatic or (5) by changes in the water retaining properties of the tissues themselves. Raised hydrostatic pressure often reflects retention of water and sodium by the kidney.
- The fiber devices according to the present invention used for the treatment of edema preferably comprises at least one organic electroluminescent compound (which is a functional material) which emits light in the range between 760 and 940 nm, preferably between 780 and 920 nm, particularly preferably between 800 and 900 nm, and very particularly preferably between 820 and 880 nm.
- One further particularly preferred emission wavelength for the treatment of edema is 850 nm.
- The functional materials according to the present invention and said fiber devices comprising them can also be used for the treatment and/or prophylaxis and/or diagnosis of infections and inflammatory, neurological, and psychological diseases and/or conditions.
- Many inflammatory diseases, disorder, and conditions can be treated with phototherapy. Thus, the use of said functional material for the preparation of a device for the treatment and/or prophylaxis and/or diagnosis of inflammatory disorders wherein the device comprises a least one organic light emitting device is also subject of the present invention.
- Inflammatory diseases and conditions cover a wide range of indications. Many diseases or condition which are seemingly unrelated to inflammation have inflammatory components that can be treated with the functional materials according to the present invention. The skin diseases and conditions mentioned in the present invention all have inflammatory components, such as acne, psoriasis, atopic dermatitis, eczema. A non limiting selection of further inflammatory diseases and conditions that can be treated with functional materials according to the present invention are arthritis, inflammatory bowel disease, gingival inflammation, inflammation of the mucosa, inflammation of the nail bed, arteriosclerosis, and inflammation of the vascular system.
- Preferred wavelengths for the treatment and/or prophylaxis of inflammation are in the range between 350 and 900 nm, particularly preferably between 380 and 900 nm, and very particularly preferably between 400 and 860 nm. Further preferred wavelengths for the treatment and/or prophylaxis of inflammation are 405, 420, and 850 nm.
- The said functional materials and said fiber devices comprising them can be used for the treatment and/or prophylaxis of infections. Infections can be caused by bacteria and viruses. Light has several positive effects on infections. Light has, e.g., anti-inflammatory effects through the stimulation of the tissue as outlined elsewhere within the present invention.
- Phototherapy with said functional materials and fiber devices comprising them are beneficial for the use to treat wounds. Wound healing is often associated with inflammation. Therefore the same wavelengths and ranges of wavelengths as outlined for the treatment and/or prophylaxis of inflammation can be applied. Treating wounds by phototherapy also prevents the formation of scares. Particularly preferred wavelengths for the treatment and/or prophylaxis of wounds and/or scares are in the range between 600 and 950 nm and very particularly preferably between 650 and 900 nm. Further preferred wavelengths for the treatment and/or prophylaxis of wounds and scares are 660, 720, and 880 nm.
- Other infections that can efficiently be treated with said functional materials and said fiber devices comprising them are caused by bacteria.
- Further infections that can efficiently be treated with said functional materials and said fiber devices comprising them are caused by viruses. A preferred embodiment of this invention is the use of the said functional materials and said fiber devices comprising them for the treatment and/or prophylaxis of viral infections particularly caused by cytomegalovirus (CMV), encephalo myocarditis virus (EMCV), poliovirus, influenca virus, parainfluenza respiratory influenza virus, respiratory syncytial virus, Japanese encephalitis virus, Dengue virus, hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), hepatitis E virus (HEV), hepatitis F virus (HFV), hepatitis G virus (HGV) Epstein Barr Virus (EBV), human immunodeficiency virus type 1 (HIV-I), human immunodeficiency virus type 2 (HIV-2), varicella zoster virus, herpes simplex virus, in particular herpes simplex virus type 1 (HSV-I), herpes simplex virus type 2 (HSV-2), or human herpes virus 1, 2, 3, 4, 7, or 8, Kaposi's sarcoma-associated herpesvirus (KSHV), rotavirus, papilloma virus, and human papilloma virus (HPV), in particular HPV of the types: 1, 2, 3, 4, 5, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19-29, 31, 32, 34, 36-38, 46-50, 56, or 58.
- In particular viral skin diseases and/or tumor disorders can be treated with said functional materials and said fiber devices comprising them such as genital warts, benign tumors of the skin and/or mucosa caused by papilloma viruses, in particular verrucae plantares, verrucae vulgares, verrucae planae juveniles, epidermodysplasia verruciformis, Condylomata acuminate, Condylomata plana, bowenoid papulosis, papilloma on the larynx and oral mucosa, focal epithelial hyperplasia, herpes labialis, varicella and shingles.
- In a particularly preferred embodiments of the present invention said functional materials and said fiber devices comprising them can be used for the treatment and/or prophylaxis of warts. Pulsed light therapy might be one way to treat warts with said functional materials and said fiber devices comprising them.
- Said functional materials and said fiber devices comprising them for the treatment and/or prophylaxis of neurological or psychological diseases and/or conditions is also subject of the present invention.
- A preferred neurological disease according to the present invention is Morbus Parkinson (MB). When light reaches a certain level of intensity, it inhibits melatonin which in turn limits the production of dopamine. By limiting the melatonin is supposed to lead to a have better production and use of dopamine in the brain. Recent case studies of light therapy on MB patients involving bright light therapy have had positive results with marked improvement in bradykinesia and rigidity in most patients while being exposed for only ninety minutes.
- Further preferred neurological and psychological diseases and/or conditions according to the present invention are mood and sleep related. Light is well known to be beneficial on the mood in many circumstances. Phototherapy can also be employed to treat depression, seasonal affective disorder (SAD), non seasonal depression, circadian rhythm sleep disorder (chronic circadian rhythm sleep disorder (CRSD), situational CRSD).
- The US National Library of Medicine notes that some people experience a serious mood change when the seasons change. They may sleep too much, have little energy, and crave sweets and starchy foods. They may also feel depressed. Though symptoms can be severe, they usually clear up. The condition in the summer is often referred to as Reverse Seasonal Affective Disorder, and can also include heightened anxiety. It has been estimated that 1.5 to 9% of adults in the US experience SAD.
- There are different treatments for classic (winter-based) seasonal affective disorder, including light therapy with bright lights, antidepressant medication, cognitive-behavioral therapy, ionized-air administration, and carefully timed supplementation of the hormone melatonin.
- The wavelength for the treatment and/or prophylaxis of these neurological and psychological diseases and/or conditions that is to be emitted by the said functional materials and said fiber devices comprising them is in the range between 350 and 600 nm. Preferably the wavelength is in the range between 400 and 550 nm, and particularly preferably between 440 and 500 nm. Two particularly preferred wavelengths for this purpose are 460 and 480 nm.
- Said functional materials and said fiber devices comprising them may also be used for the treatment and/or prophylaxis of pain. Pain relief by phototherapy is well known. The following conditions produce pain that can be treated successfully with phototherapy: carpal tunnel syndrome, chronic wounds, epicondylitis, headache, migraine, plantar fasciitis, tendonditis and bursitis, neck pain, back pain, muscle pain, trigeminal neuralgia, and Whiplash-associated injuries.
- Preferably, muscle pain is treated with said functional materials and said fiber devices comprising them emitting red or infrared light.
- Alopecia areata is a condition affecting humans, in which hair is lost from some or all areas of the body, usually from the scalp. Because it causes bald spots on the scalp, especially in the first stages, it is sometimes called spot baldness. In 1 to 2% of cases, the condition can spread to the entire scalp (alopecia totalis) or to the entire epidermis (alopecia universalis). Conditions resembling alopecia areata, and having a similar cause, occur also in other species.
- Alopecia areata (autoimmune hair loss) can be treated with said functional materials and said fiber devices comprising them. The wavelength for the treatment and/or prophylaxis of alopecia areata that is to be emitted by the said functional materials and said fiber devices comprising them is in the range between 240 and 500 nm. Preferably the wavelength is in the range between 290 and 400 nm, and particularly preferably between 300 and 330 nm. One particularly preferred wavelength for this purpose is 311 nm.
- The functional materials according to the present invention and said fiber devices comprising them can also be used for the disinfection of beverages and nutrition.
- The use of light as disinfectant is well known. The said functional materials and light emitting fiber devices comprising them can be used for disinfection. Hereby any kind of disinfection is meant and includes without limitation the disinfection of wounds, nutrition, and solid and liquids objects, such cosmetic, medical devices, devices used for surgery and beverages.
- Preference is given to the use of said functional materials and light emitting fiber devices comprising them for the disinfection of beverages, preferably water, and particularly preferably drinking water. Contaminated water causes many infections worldwide and leads often to severe diseases or death of the individuals. The said functional materials and light emitting fiber devices comprising them provide a simple means to disinfect water. Water filter systems of commercial providers take advantage of ion exchange technology. The filter, however, often tend to microbial contamination, which, in turn results in water which is contaminated with microbes. One solution is to add silver salt which is from a toxicological point of view problematic. The said functional materials and light emitting fiber devices comprising them provide a solution to this problem. They can be incorporated into the water filter system in order to provide a safe, efficient, and low cost way to provide water with a low degree of microbial contamination. The light source can irradiate both the water before or after filtering or the filter cartridge itself. Preferably the light source comprising functional materials irradiates both the filter cartridge and the already filtered water.
- The procedure of disinfection of water as outlined above can basically be applied to any other liquid, in particularly for soft drinks and beverages analogously.
- Therefore, the said functional materials and light emitting fiber devices comprising them can be used for the disinfection of beverages and nutrition for humans and animals.
- Wavelengths for disinfection according to the present invention are in the range between 200 nm and 600 nm, preferably between 250 nm and 500 nm, and very particularly preferably between 280 nm and 450 nm.
- The functional materials according to the present invention and said fiber devices comprising them can also be used for the photodynamic therapy (PDT).
- Wavelengths required for PDT according to the present invention are in the range between 300 and 700 nm, preferably between 400 and 700 nm, and very particularly preferably between 500 and 700 nm. Four further preferred wavelengths are 595, 600, 630, and 660 nm.
- Any therapy known as PDT can be carried out using the said functional materials and light emitting fiber devices comprising them. The property of dyes with a polycyclic hydrocarbon type chemical structure to accumulate in greater amounts in tumor tissues than in normal tissues is well known. The dyes include acridines, xanthenes, psoralens, and porphyrins. The latter dyes, in particular, hematoporphyrin (Hp) and some of its chemical derivatives (e.g. Hp D, wherein Hp D is a mixture of Hp derivatives), have superior tumor-localizing properties, which are the basis of phototherapeutic treatment of tumors with red light irradiation at predetermined times after systemic administration of the drug.
- Drug used for PDT are preferably selected from aminolevulinic acid/methyl aminolevulinate, efaproxiral porphyrin derivatives (porfimer sodium, talaporfin, temoporfin, verteporfin).
- The functional materials according to the present invention and said fiber devices comprising them can also be used for the treatment and/or prophylaxis of jaundice and crigler naijar.
- Jaundice, which is also known as icterus, is a yellowish discoloration of the skin, the conjunctival membranes over the sclerae (whites of the eyes), and other mucous membranes. The discoloration is caused by hyperbilirubinemia (increased levels of bilirubin in the blood). This hyperbilirubinemia subsequently causes increased levels of bilirubin in the extracellular fluids. Jaundice is classified in three groups, pre-hepatic (hemolytic) jaundice, hepatic (hepatocellular) jaundice, and post-hepatic (obstructive) jaundice.
- Pre-hepatic jaundice is caused by anything which causes an increased rate of hemolysis, i.e. breakdown of red blood cells. In tropical countries, malaria can cause jaundice in this manner. Certain genetic diseases, such as sickle cell anemia, spherocytosis and glucose 6-phosphate dehydrogenase deficiency can lead to increased red cell lysis and therefore hemolytic jaundice. Commonly, diseases of the kidney, such as hemolytic uremic syndrome, can also lead to coloration. Defects in bilirubin metabolism also present as jaundice. Jaundice usually comes with high fevers. Rat fever (leptospirosis) can also cause jaundice.
- Hepatic jaundice causes include acute hepatitis, hepatotoxicity and alcoholic liver disease, whereby cell necrosis reduces the liver's ability to metabolise and excrete bilirubin leading to a buildup in the blood. Less common causes include primary biliary cirrhosis, Gilbert's syndrome (a genetic disorder of bilirubin metabolism which can result in mild jaundice, which is found in about 5% of the population), Crigler-Najjar syndrome, metastatic carcinoma and Niemann-Pick disease, type C. Jaundice seen in the newborn, known as neonatal jaundice, is common, occurring in almost every newborn as hepatic machinery for the conjugation and excretion of bilirubin does not fully mature until approximately two weeks of age.
- Post-hepatic jaundice, also called obstructive jaundice, is caused by an interruption to the drainage of bile in the biliary system. The most common causes are gallstones in the common bile duct, and pancreatic cancer in the head of the pancreas. Also, a group of parasites known as “liver flukes” can live in the common bile duct, causing obstructive jaundice. Other causes include strictures of the common bile duct, biliary atresia, ductal carcinoma, pancreatitis and pancreatic pseudocysts. A rare cause of obstructive jaundice is Mirizzi's syndrome.
- Jaundice, in particular neonatal jaundice, can lead to severe medical consequences if not or not appropriately treated. Increased concentrations of bilirubin can result in a brain-damaging condition known as kernicterus, leading to significant lifelong disability; there are concerns that this condition has been rising in recent years due to inadequate detection and treatment of neonatal hyperbilirubinemia. Early treatment often consists of exposing the infant to intensive phototherapy in an more or less isolated incubator. The therapy often represents an emotionally or psychologically difficult situation for both the infant and the parents. The said functional materials and said light emitting fiber devices comprising the functional materials can be employed in order to provide flexible and ambulatory devices such as blankets. Thus, the infant can be treated while laying in its parents' arms. Traditional therapies also easily lead to overheating of the infant, which can also be significantly reduced with the treatment approach according to the present invention.
- Preferably the present invention relates to the use of said functional materials and said light emitting fiber devices comprising the functional materials for the treatment of neonatal jaundice.
- The wavelength for the treatment and/or prophylaxis of jaundice is in the range between 300 and 700 nm. Preferably the wavelength is in the range between 350 and 600 nm, and particularly preferably between 370 and 580 nm. Further preferred wavelengths are in the range between 400 and 550 nm. Particularly preferred wavelengths are in the range between 410 and 470 nm, Two particularly preferred wavelengths for this purpose are 450 and 466 nm.
- The light emitting fiber devices according to the present invention comprise at least one said functional material. Often the devices used for therapeutic and/or cosmetic applications comprise compositions of said functional materials. The present invention also relates to the use of a composition comprising at least one functional material selected from host materials, emissive materials (EM), hole injection materials (HIM), hole transport materials (HTM), hole blocking materials (HBM), electron injection materials (EIM), electron transport materials (ETM), electron blocking materials (EBM), exciton blocking materials (ExBM), metal complexes, and phosphor materials and at least one further compound for the preparation of a device for the treatment and/or prophylaxis and/or diagnosis of diseases and/or cosmetic conditions, characterized in that the device comprises at least one organic light emitting fiber.
- Preferably the composition comprises 1, particularly preferably 2, and very particularly preferably 3 functional materials. Any functional materials as outlined within the present invention can be used.
- The composition may also comprise further materials such as solvents, additives, wetting agents, and surfactants.
- The present invention also relates to a device for the treatment and/or prophylaxis and/or diagnosis of diseases, characterized in that the device comprises at least one organic light emitting fiber. The present invention also relates to a device for the treatment and/or prophylaxis and/or diagnosis of cosmetic conditions, characterized in that the device comprises at least one organic light emitting fiber. The fiber is preferably an OLED fiber.
- Preferably the device comprises more than one fiber. The diseases and cosmetic conditions are selected from the ones as defined elsewhere within the present invention. The device setup is also described within the present invention.
- The present invention also relates to a device for the treatment and/or prophylaxis and/or diagnosis of diseases and/or cosmetic conditions, characterized in that the device comprises at least one organic light emitting fiber and wherein the light emitting fiber comprises a functional material selected from host materials, emissive materials (EM), hole injection materials (HIM), hole transport materials (HTM), hole blocking materials (HBM), electron injection materials (EIM), electron transport materials (ETM), electron blocking materials (EBM), exciton blocking materials (ExBM), metal complexes, and phosphor materials.
- The functional materials are the same as described elsewhere within the present invention.
- Particular preference is given to the said device for the treatment and/or prophylaxis and/or diagnosis of skin diseases and/or cosmetic skin conditions selected from acne, psoriasis, eczema, dermatitis, atopic dermatitis, edema, vitiligo, Bowens disease, tumors, pre-malignant tumors, malignant tumors, basal cell carcinomas, squamous cell carcinomas, secondary metastases, cutaneous T-cell lymphomas, solar keratosis, arsenical keratosis, radiodermatitis, cellulite, skin desensibilisation, infections, inflammation, neurological and psychological diseases and/or conditions, photodynamic therapy (PDT), jaundice and crigler naijar.
- The present invention also relates to the use of an organic light emitting fiber for the treatment and/or prophylaxis and/or diagnosis of diseases and/or conditions.
- Both the organic light emitting fiber and the diseases and/or conditions are the same as described elsewhere within the present invention.
- The present invention also relates to the use of an organic light emitting fiber for the treatment and/or prophylaxis and/or diagnosis of cosmetic conditions.
- Both the organic light emitting fiber and the cosmetic conditions are the same as described elsewhere within the present invention.
- It will be appreciated that variations to the foregoing embodiments of the invention can be made while still falling within the scope of the invention. Each feature disclosed in this specification, unless stated otherwise, may be replaced by alternative features serving the same, equivalent or similar purpose. Thus, unless stated otherwise, each feature disclosed is one example only of a generic series of equivalent or similar features.
- All of the features disclosed in this specification may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. In particular, the preferred features of the invention are applicable to all aspects of the invention and may be used in any combination. Likewise, features described in non-essential combinations may be used separately (not in combination).
- It will be appreciated that many of the features described above, particularly of the preferred embodiments, are inventive in their own right and not just as part of an embodiment of the present invention. Independent protection may be sought for these features in addition to or alternative to any invention presently claimed.
- The teaching as disclosed here can be abstracted and combined with other examples disclosed.
- Other features of the invention will become apparent in the course of the following description of exemplary embodiments and drawings, which are given for illustration of the invention and are not intended to be limiting thereof.
-
FIG. 1 : Fiber with afiber core 10 having an outerfirst electrode 20, alight emitting layer 30, a radiation transmissivesecond electrode 40 positioned over the organiclight emitting layer 30. Eventually the OLEFC may also comprise an optional radiation transmissive moisture and/orair barrier layer 50 and/or an optional radiationtransmissive encapsulating material 60. -
FIG. 2 : Fiber divided into segments emitting n different wavelengths λi (i=1 to n) or ranges of wavelengths (a). Preferably n=2 (b). -
FIG. 3 : Parallel arrangement of light emitting fibers in a device which emits light with n different wavelengths or ranges of wavelengths. -
FIG. 4 : Parallel arrangement of light emitting fibers in a device which emits light with two different wavelengths or ranges of wavelengths. -
FIG. 5 : Woven fibers. -
FIG. 6 : Woven fibers emitting two different wavelengths or ranges of wavelengths. -
FIG. 7 : Plaster withattachment side 1,power supply 2,reflective material 3, and light emitting fibers 4. -
FIG. 8 ; One way to prepare a fiber comprising the following steps. Step I: deposition ofanode 20 onfiber core 10; step II: deposition ofbuffer layer 31; step III: deposition of emissive layer 32; step IV: deposition ofcathode 40; step V: free anode -
FIG. 9 : Electroluminescence (EL) spectrum of fiber OLED using PB1 as EML (emissive layer). -
FIG. 10 : EL spectrum of fiber OLED using PR1. -
FIG. 11 : Schema of a plaster according to present invention withPEN substrate 300,OLED fibers 400,cathode 40,anode 20,thin conducting wires epoxy resin encapsulation 330. -
FIG. 12 : Fiber production line by employing dip coating. 210—fiber core; 130—deposition chamber for the first electrode; 200—deposition chamber for the second electrode; 140—container containing solution of buffer material or HIM; 160—container containing a solution or a formulation of HTM or interlayer material; 180—container containing a solution or a formulation of an emissive composition; 150, 170, and 190 are dryers. -
FIG. 13 : Production method which is all solution based. 250—container containing an ink comprising a conductive material for the second electrode; 220 and 230 are dryers; 240—container comprising an ink comprising a conductive material for the first electrode. - The following polymers are synthesized by employing the Suzuki coupling. The reaction can be carried out according to synthetic methods well known to the person skilled in the art. The method is described, for example, in WO 2003/048225.
- Polymer PB1, a blue emitting polymer, is a copolymer comprising the following monomers with mol % as indicated:
- The molecular weight (MW) of the PB1 is distributed between 200000 and 300000 g/mol.
- Polymer PR1, a red emitting polymer, is a copolymer comprising the following monomers with mol % as indicated by the indices of the repeating units:
- The molecular weight (MW) of the PR1 is distributed between 120000 and 720000 g/mol.
- Both PB1 and PR1 are well soluble in toluene.
- The
fiber core 10 used in the present invention is a hard polymer-clad silica optical fiber (by CeramOptec Industries, Inc.), which has a silica core of 400 μm in diameter and 25 μm polyimide as jacket. Prior to the deposition of electrode, the fibers are cleaned successively by rubbing with a detergent, rinsing in deionized water, and cleaning by sonication in trichloroethylene, acetone and then isopropyl alcohol. - The fabrication steps I to V are schematically depicted in
FIG. 8 . - The
anode 20 is deposited conformally through a shadow mask using vacuum thermal evaporation at 10−7 Torr. The fibers are axially rotated at a speed of 60 rpm during the evaporation. Then 50 nm Al is evaporated at first on the cleanedfiber core 10, and then 5 nm Ni is deposited on Al as anode. Ni is then oxided by exposure to oxygen plasma followed by UV ozone at 20 mW/cm2 for 5 min. - PEDOT (Baytron P Al 4083) is deposited as buffer layer or hole injection layer (HIL) with a thickness of 80 nm onto the fiber by dip-coating and then heated for 10 min. at 180° C.; the thickness can be controlled through the concentration and the pulling speed during the dip-coating. The fiber is then heated for 10 min. at 180° C. to remove residual water.
- The emissive layer (EML) 32 then is coated by dip-coating a toluene solution of the emissive polymer with a concentration of 0.1 to 0.8 wt % yielding a layer with a thickness of 65 nm for blue PB1 and 80 nm for red PR1;
- The thickness of the film on the fiber is determined as follows. A flat glass substrate is coated by dip-coating in the same solution; the thickness of the film on glass substrate is then measured by Surface Profiler (Dektak3 ST). The concentration of the solution and pulling speeding are adjusted until the desired thickness is obtained. The same condition, concentration and pulling speed will be applied to coat the corresponding film on the fiber.
- The device is heated at 180° C. for 10 minutes to remove residual solvent;
- In analogy to the procedure in step I the
cathode 40 is deposited conformally through a shadow mask using vacuum thermal evaporation at 10−7 Torr. The fibers are axially rotated at a speed of 60 rpm during the evaporation. Ba/Ag cathode is conformally deposited through a shadow mask by thermal vacuum evaporation onto the emissive layer with a thickness of 3 nm/15 nm; both anode and cathode along the fiber is 4 cm in one segment. And they displace with each other so that having an overlappingarea 3 cm, corresponding to the emissive area. - The fiber is cut into segments of 5 cm in length. One end of the cut fiber, where no cathode is deposited, is washed away at first with toluene and then with ethanol to remove the polymer and PEDOT in order to get a free anode which can be contacted.
- Prior to the preparation of plasters, the fiber OLEDs are tested in a glovebox. An EL spectrum is recorded by Ocean Optics USB2000 spectrometer. The EL spectrum of fiber OLEDs using PB1 as EML is shown in
FIG. 9 , and that of fiber OLEDs using PR1 inFIG. 10 . The fibers are selected for the preparation of a plaster with respect to homogeneity of emission and brightness by optical observation. - A transparent flexible poly(ethylene naphthalate) (PEN) foil is used as substrate for preparing plasters.
- A plaster according to present invention is schematically shown in
FIG. 11 . ThePEN substrate 300 has an area of ca. 5.5 cm×5.5 cm. Thefiber OLEDs 400 prepared in Example 2 are arranged in parallel in the middle of the substrate, withcathode 40 on one side andanode 20 on the other side. - Here either PB1 fiber OLEDs or PR1 fiber OLEDs, or both fiber OLEDs, which are positioned alternatively on the PEN substrate, are used.
- Then
thin conducting wires FIG. 11 . - The device is then fixed and encapsulated by using UV-cured epoxy resin. UV Resin T-470C2, an advanced UV adhesives for OLED made by Nagase & Co., LTD, is applied to the area as marked as 330 in
FIG. 11 being thick enough to cover all fibers on the substrate. The device is then exposed to an UV lamp with a dose of about 6 J/cm2 to cure the resin. The cured resin colors slightly yellow. Other transparent resin may be good to get more light out. A reflection foil can be put on the plaster to enhance light output of the plaster. - The plaster device of Example 3 comprising PR1 as light emitting component can be used for the treatment and/or prophylaxis of wrinkles. The plasters have a printed battery as power supply. The battery supplies energy for a irradiation time of about 50 min.
- A 16-week pilot study with 24 female human subjects in the age between 30 and 40 years is conducted according to standard methods well known to the person skilled in the art. One of the main selection criteria for the inclusion within the study is the occurrence of crown's feet with almost equal manifestation on both sides of the face, i.e., in proximity to the left and right eye. Each subject is treated on the right hand side with a plaster comprising OLED fibers for 25 min, every second day for 16 weeks. Comparison of the skin in proximity of the left eye and right eye reveals a significant improvement of the skin on the treated side. The crow's feet are shorter and less deeper. The skin treated with light emitted by the OLEC device appears smoother as compared to the untreated skin.
- Plasters comprising OLED fibers emitting two different wavelengths or ranges of wavelengths is prepared according to the procedures as outlined herein (see Example 2 and 3, and
FIG. 11 ). Further, in the plasters the two sort of fiber OLEDs, i.e. PB1 and PR1, can be connected separately to a steering unit which allows the programming of treatment intervals and the turn on and turn off times of both wavelengths separately. The plaster comprising the two different kinds of fiber OLEDs can, thus, emit either blue or red light or both blue and red light, at least in part, at the same time. The plaster comprising the OLED fibers has a squared shape with an emissive area of about 9 cm2, but any other customized shape is possible. - A 10-week pilot study with 30 subjects is conducted according to standard methods well known to the person skilled in the art. The subjects have Fitzpatrick skin types II to IV with mild to severe symmetric facial acne vulgaris. The right half of the forehead is treated with the plaster comprising the fiber OLEDs. Overall 10 treatments are carried out where the area to be treated is irradiated with blue and red light at the same time.
- Treatment time per treatment is 20 min. One week later the same skin is treated again as outlined above. Comparing the left hand side and the right hand side of the foreheads of the treated subjects after 10 weeks of treatment reveals a significant improvement of the treated skin as compared to the untreated skin. Redness of the skin is significantly reduced. Furthermore, mean lesion count reduction is also significant.
Claims (12)
1-18. (canceled)
19. A device for the treatment and/or prophylaxis and/or diagnosis of diseases and/or cosmetic conditions, wherein the device comprises at least one organic light emitting fiber.
20. The device according to claim 19 , wherein the light emitting fiber comprises a functional material selected from host materials, emissive materials (EM), hole injection materials (HIM), hole transport materials (HTM), hole blocking materials (HBM), electron injection materials (EIM), electron transport materials (ETM), electron blocking materials (EBM), exciton blocking materials (ExBM), metal complexes, and phosphor materials.
21. The device according to claim 19 , wherein the device is used for the treatment and/or prophylaxis and/or diagnosis of skin diseases and/or cosmetic skin conditions selected from acne, psoriasis, eczema, dermatitis, atopic dermatitis, edema, vitiligo, Bowens disease, tumors, pre-malignant tumors, malignant tumors, basal cell carcinomas, squamous cell carcinomas, secondary metastases, cutaneous T-cell lymphomas, solar keratosis, arsenical keratosis, radiodermatitis, cellulite, skin desensibilisation, infections, inflammation, neurological and psychological diseases and/or conditions, photodynamic therapy (PDT), jaundice and crigler naijar.
22. The device as claimed in claim 19 , wherein the device emits more than one range of wavelengths.
23. The device as claimed in claim 22 , wherein the fiber is divided into segments having n distinct radiation emitting layers and wherein n is an integer.
24. The device as claimed in claim 23 , wherein n is 4.
25. The device as claimed in claim 23 , wherein n is 3.
26. The device as claimed in claim 23 , wherein n is 2.
27. The device as claimed in claim 19 , wherein the fibers are woven.
28. The device as claimed in claim 19 , wherein the device comprises at least two different fibers that emit different ranges of wavelengths.
29. The device as claimed in claim 28 , wherein the device comprises exactly two distinct light emitting fibers.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/389,655 US20170100607A1 (en) | 2010-03-11 | 2016-12-23 | Fibers in therapy and cosmetics |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10002558 | 2010-03-11 | ||
EP10002558.4 | 2010-03-11 | ||
PCT/EP2011/000707 WO2011110277A1 (en) | 2010-03-11 | 2011-02-15 | Fibers in therapy and cosmetics |
US201213634101A | 2012-09-11 | 2012-09-11 | |
US15/389,655 US20170100607A1 (en) | 2010-03-11 | 2016-12-23 | Fibers in therapy and cosmetics |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/634,101 Division US9539438B2 (en) | 2010-03-11 | 2011-02-15 | Fibers in therapy and cosmetics |
PCT/EP2011/000707 Division WO2011110277A1 (en) | 2010-03-11 | 2011-02-15 | Fibers in therapy and cosmetics |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170100607A1 true US20170100607A1 (en) | 2017-04-13 |
Family
ID=44021764
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/634,101 Expired - Fee Related US9539438B2 (en) | 2010-03-11 | 2011-02-15 | Fibers in therapy and cosmetics |
US15/389,655 Abandoned US20170100607A1 (en) | 2010-03-11 | 2016-12-23 | Fibers in therapy and cosmetics |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/634,101 Expired - Fee Related US9539438B2 (en) | 2010-03-11 | 2011-02-15 | Fibers in therapy and cosmetics |
Country Status (5)
Country | Link |
---|---|
US (2) | US9539438B2 (en) |
EP (1) | EP2544765A1 (en) |
JP (2) | JP6246468B2 (en) |
KR (1) | KR20130020883A (en) |
WO (1) | WO2011110277A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10309614B1 (en) | 2017-12-05 | 2019-06-04 | Vital Vivo, Inc. | Light directing element |
WO2019108431A1 (en) * | 2017-12-01 | 2019-06-06 | Vital Vio, Inc. | Devices using flexible light emitting layer for creating disinfecting illuminated surface, and related method |
US10413626B1 (en) | 2018-03-29 | 2019-09-17 | Vital Vio, Inc. | Multiple light emitter for inactivating microorganisms |
US10753575B2 (en) | 2015-07-30 | 2020-08-25 | Vital Vio, Inc. | Single diode disinfection |
US10918747B2 (en) | 2015-07-30 | 2021-02-16 | Vital Vio, Inc. | Disinfecting lighting device |
US11369704B2 (en) | 2019-08-15 | 2022-06-28 | Vyv, Inc. | Devices configured to disinfect interiors |
US11541135B2 (en) | 2019-06-28 | 2023-01-03 | Vyv, Inc. | Multiple band visible light disinfection |
US11581487B2 (en) | 2017-04-26 | 2023-02-14 | Oti Lumionics Inc. | Patterned conductive coating for surface of an opto-electronic device |
US11639897B2 (en) | 2019-03-29 | 2023-05-02 | Vyv, Inc. | Contamination load sensing device |
US11730012B2 (en) | 2019-03-07 | 2023-08-15 | Oti Lumionics Inc. | Materials for forming a nucleation-inhibiting coating and devices incorporating same |
US11751415B2 (en) | 2018-02-02 | 2023-09-05 | Oti Lumionics Inc. | Materials for forming a nucleation-inhibiting coating and devices incorporating same |
US11878084B2 (en) | 2019-09-20 | 2024-01-23 | Vyv, Inc. | Disinfecting light emitting subcomponent |
US11985841B2 (en) | 2020-12-07 | 2024-05-14 | Oti Lumionics Inc. | Patterning a conductive deposited layer using a nucleation inhibiting coating and an underlying metallic coating |
US12069938B2 (en) | 2019-05-08 | 2024-08-20 | Oti Lumionics Inc. | Materials for forming a nucleation-inhibiting coating and devices incorporating same |
US12101987B2 (en) | 2019-04-18 | 2024-09-24 | Oti Lumionics Inc. | Materials for forming a nucleation-inhibiting coating and devices incorporating same |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10167564A (en) * | 1996-12-05 | 1998-06-23 | Toray Ind Inc | Carbon fiber package and carbon fiber packaged body |
EP2545600A2 (en) * | 2010-03-11 | 2013-01-16 | Merck Patent GmbH | Radiative fibers |
US20120109042A1 (en) * | 2010-10-28 | 2012-05-03 | John Koo | Methods of Treating Diseased Tissue |
WO2012149992A1 (en) | 2011-05-04 | 2012-11-08 | Merck Patent Gmbh | Device for preserving fresh goods |
DE102011104745A1 (en) | 2011-06-17 | 2012-12-20 | Merck Patent Gmbh | Materials for organic electroluminescent devices |
KR20140123555A (en) * | 2012-01-30 | 2014-10-22 | 메르크 파텐트 게엠베하 | Nanocrystals on fibers |
CN102623516B (en) * | 2012-04-01 | 2015-10-28 | 东华大学 | Solar cell that a kind of single line structural flexibility can weave and preparation method thereof |
EP2856528B1 (en) * | 2012-05-24 | 2019-07-03 | Merck Patent GmbH | Metal complexes comprising condensed heteroaromatic rings |
KR101894713B1 (en) * | 2012-10-12 | 2018-09-04 | 메르크 파텐트 게엠베하 | Emitter and hosts with aromatic units |
JP6363090B2 (en) | 2012-11-30 | 2018-07-25 | メルク パテント ゲーエムベーハー | Electronic element |
US20140276354A1 (en) * | 2013-03-14 | 2014-09-18 | Klox Technologies Inc. | Biophotonic materials and uses thereof |
EP3446743B1 (en) | 2013-03-15 | 2020-10-14 | Carewear Corp. | Ultrasonic transducer device |
CN105848713A (en) * | 2013-11-14 | 2016-08-10 | 学校法人圣玛丽安娜医科大学 | Carbon monoxide poisoning resolving device, jacket for carbon monoxide poisoning treatment having said device, and catheter for carbon monoxide poisoning treatment |
WO2016010765A1 (en) * | 2014-07-18 | 2016-01-21 | Dabney Paul | Medical and veterinary applications of light to therapeutic compounds |
JP6673214B2 (en) * | 2014-11-13 | 2020-03-25 | コニカミノルタ株式会社 | Organic electroluminescence therapy device |
EP4201358A1 (en) * | 2014-11-14 | 2023-06-28 | Boston Scientific Scimed, Inc. | Surgical laser systems and laser devices |
US10840450B2 (en) | 2014-12-04 | 2020-11-17 | Guangzhou Chinaray Optoelectronic Materials Ltd. | Polymer, and mixture or formulation, and organic electronic device containing same, and monomer thereof |
CN107406384B (en) | 2014-12-04 | 2021-07-23 | 广州华睿光电材料有限公司 | Deuterated organic compounds, mixtures, compositions and organic electronic devices comprising said compounds |
WO2016091217A1 (en) | 2014-12-11 | 2016-06-16 | 广州华睿光电材料有限公司 | Organic metal complex, and polymer, mixture, composition and organic electronic device containing same and use thereof |
WO2016091219A1 (en) | 2014-12-11 | 2016-06-16 | 广州华睿光电材料有限公司 | Organic compound, mixture comprising same, composite, and organic electronic component |
CN107108862B (en) | 2015-01-13 | 2019-08-02 | 广州华睿光电材料有限公司 | Conjugated polymer, the mixture comprising it, composition, organic electronic device and its application of the crosslinked group containing acetenyl |
RU2732087C2 (en) | 2015-02-27 | 2020-09-11 | Колгейт-Палмолив Компани | Oral cavity treatment system |
EP3351292B1 (en) | 2015-05-18 | 2019-08-21 | The General Hospital Corporation | System for phototherapy for preventing or treating carbon monoxide poisoning |
US12109429B2 (en) * | 2015-07-28 | 2024-10-08 | Know Bio, Llc | Phototherapeutic light for treatment of pathogens |
CN108291103B (en) | 2015-11-12 | 2021-12-07 | 广州华睿光电材料有限公司 | Printing composition, electronic device comprising same and preparation method of functional material film |
US10968243B2 (en) | 2015-12-04 | 2021-04-06 | Guangzhou Chinaray Optoelectronic Materials Ltd. | Organometallic complex and application thereof in electronic devices |
KR101689150B1 (en) * | 2016-01-25 | 2016-12-23 | 주식회사 포비드림 | Portable linear emergency guidance device |
EP3448292A4 (en) | 2016-04-25 | 2020-04-08 | Immunolight, Llc. | Insertion devices and systems for production of emitted light internal to a medium and methods for their use |
AU2017271535B2 (en) | 2016-05-26 | 2022-09-08 | Carewear Corp | Photoeradication of microorganisms with pulsed purple or blue light |
WO2018095382A1 (en) | 2016-11-23 | 2018-05-31 | 广州华睿光电材料有限公司 | Aromatic amine derivative, preparation method therefor, and uses thereof |
CN109790194B (en) | 2016-11-23 | 2021-07-23 | 广州华睿光电材料有限公司 | Metal organic complex, high polymer, composition and organic electronic device |
WO2018095392A1 (en) | 2016-11-23 | 2018-05-31 | 广州华睿光电材料有限公司 | Organic mixture, composition, and organic electronic component |
EP3547384B1 (en) | 2016-11-23 | 2022-10-05 | Guangzhou Chinaray Optoelectronic Materials Ltd. | High polymer, mixture containing same, composition, organic electronic component, and monomer for polymerization |
US11518723B2 (en) | 2016-11-23 | 2022-12-06 | Guangzhou Chinaray Optoelectronic Materials Ltd. | Fused ring compound, high polymer, mixture, composition and organic electronic component |
WO2018095397A1 (en) | 2016-11-23 | 2018-05-31 | 广州华睿光电材料有限公司 | Organic compound containing boron and uses thereof, organic mixture, and organic electronic device |
WO2018095381A1 (en) | 2016-11-23 | 2018-05-31 | 广州华睿光电材料有限公司 | Printing ink composition, preparation method therefor, and uses thereof |
WO2018095388A1 (en) | 2016-11-23 | 2018-05-31 | 广州华睿光电材料有限公司 | Organic compound |
CN109843837B (en) | 2016-11-23 | 2022-03-18 | 广州华睿光电材料有限公司 | Nitrogen-containing fused heterocyclic compound and application thereof |
EP3553152B1 (en) | 2016-12-08 | 2021-02-17 | Guangzhou Chinaray Optoelectronic Materials Ltd. | Mixture, composition and organic electronic device |
US11672174B2 (en) | 2016-12-08 | 2023-06-06 | Guangzhou Chinaray Optoelectronic Materials Ltd. | Pyrene-triazine derivative and applications thereof in organic electronic component |
US20200109235A1 (en) * | 2016-12-13 | 2020-04-09 | Guangzhou Chinaray Optoelectronic Materials Ltd. | Conjugated polymer and use thereof in organic electronic device |
CN109790118A (en) | 2016-12-13 | 2019-05-21 | 广州华睿光电材料有限公司 | Conjugated polymer and its application in organic electronic device |
US11404644B2 (en) | 2016-12-22 | 2022-08-02 | Guangzhou Chinaray Optoelectronic Materials Ltd. | Organic functional compounds, mixtures, formulations, organic functional thin films and preparation methods therefor and organic electronic devices |
US11289654B2 (en) | 2016-12-22 | 2022-03-29 | Guangzhou Chinaray Optoelectronic Materials Ltd. | Polymers containing furanyl crosslinkable groups and uses thereof |
US11292875B2 (en) | 2016-12-22 | 2022-04-05 | Guangzhou Chinaray Optoelectronic Materials Ltd. | Cross-linkable polymer based on Diels-Alder reaction and use thereof in organic electronic device |
US10639496B2 (en) * | 2016-12-28 | 2020-05-05 | Hua Shang | Blood vessel optical fiber guide wire |
US10293148B2 (en) | 2017-01-06 | 2019-05-21 | Paul Dabney | System, retainer and method of preventing and treating nosocomial infections including methicillin-resistant Staphylococcus aureus infections |
US11404651B2 (en) | 2017-12-14 | 2022-08-02 | Guangzhou Chinaray Optoelectronic Materials Ltd. | Transition metal complex material and application thereof in electronic devices |
US11674080B2 (en) | 2017-12-14 | 2023-06-13 | Guangzhou Chinaray Optoelectronic Materials Ltd. | Transition metal complex, polymer, mixture, formulation and use thereof |
WO2019114764A1 (en) | 2017-12-14 | 2019-06-20 | 广州华睿光电材料有限公司 | Organometallic complex, and polymer, mixture and composition comprising same, and use thereof in electronic device |
WO2019120263A1 (en) | 2017-12-21 | 2019-06-27 | 广州华睿光电材料有限公司 | Organic mixture and application thereof in organic electronic devices |
US11020605B2 (en) | 2018-05-29 | 2021-06-01 | Carewear Corp. | Method and system for irradiating tissue with pulsed blue and red light to reduce muscle fatigue, enhance wound healing and tissue repair, and reduce pain |
USD888957S1 (en) * | 2018-11-15 | 2020-06-30 | Forward Science Technologies, LLC | Skin cancer screening device |
USD928958S1 (en) * | 2018-11-15 | 2021-08-24 | Forward Science Technologies, LLC | Skin cancer screening device |
US11324944B1 (en) * | 2019-07-23 | 2022-05-10 | Verily Life Sciences Llc | Flexible cable assembly for medical implantation |
EP4086263A4 (en) | 2019-12-30 | 2024-04-24 | Guangzhou Chinaray Optoelectronic Materials Ltd. | Organic electroluminescence device and aromatic compound containing fused-ring |
US12011611B2 (en) | 2020-03-19 | 2024-06-18 | Know Bio, Llc | Illumination devices for inducing biological effects |
US11986666B2 (en) | 2020-03-19 | 2024-05-21 | Know Bio, Llc | Illumination devices for inducing biological effects |
US12115384B2 (en) | 2021-03-15 | 2024-10-15 | Know Bio, Llc | Devices and methods for illuminating tissue to induce biological effects |
CN115611919A (en) | 2021-07-12 | 2023-01-17 | 广州华睿光电材料有限公司 | Organic compound containing heterocycle, mixture, composition and organic electronic device |
CN115991726A (en) | 2021-10-18 | 2023-04-21 | 广州华睿光电材料有限公司 | Metal complexes, mixtures, compositions and organic electronic devices |
CN116082248A (en) | 2021-11-01 | 2023-05-09 | 广州华睿光电材料有限公司 | Aromatic amine organic compound and application thereof |
CN116082266A (en) | 2021-11-03 | 2023-05-09 | 广州华睿光电材料有限公司 | Organic compounds, mixtures, compositions, light extraction layer materials and organic electronic devices |
CN117447495A (en) | 2023-03-23 | 2024-01-26 | 深圳市华星光电半导体显示技术有限公司 | Organic boron nitrogen compound, organic electronic device and electronic equipment |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4234907A (en) * | 1979-01-29 | 1980-11-18 | Maurice Daniel | Light emitting fabric |
US6538375B1 (en) * | 2000-08-17 | 2003-03-25 | General Electric Company | Oled fiber light source |
US20030099858A1 (en) * | 2001-11-27 | 2003-05-29 | General Electric Company One Research Circle | Environmentally-stable organic electroluminescent fibers |
US20060012294A1 (en) * | 1998-12-22 | 2006-01-19 | Christensen Alton O Sr | Electroluminescent devices and displays with integrally fabricated address and logic devices fabricated by printing or weaving |
US20060149342A1 (en) * | 2004-12-30 | 2006-07-06 | Industrial Technology Research Institute | Light therapeutic device |
US7144249B2 (en) * | 2000-11-15 | 2006-12-05 | Biolase Technology, Inc. | Device for dental care and whitening |
US20070251526A1 (en) * | 2006-04-28 | 2007-11-01 | Marc Alan Zocher | Treatment of airflow |
US7304201B2 (en) * | 2002-06-12 | 2007-12-04 | University Of Florida Research Foundation, Inc. | Phototherapy bandage |
US20100010593A1 (en) * | 2006-08-07 | 2010-01-14 | Koninklijke Philips Electronics N.V. | System of plaster and radiation device |
US20100114263A1 (en) * | 2008-11-04 | 2010-05-06 | Pressler Tiffany J | Phototherapy garment |
Family Cites Families (225)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL124075C (en) | 1959-04-09 | |||
US3526501A (en) | 1967-02-03 | 1970-09-01 | Eastman Kodak Co | 4-diarylamino-substituted chalcone containing photoconductive compositions for use in electrophotography |
US3567450A (en) | 1968-02-20 | 1971-03-02 | Eastman Kodak Co | Photoconductive elements containing substituted triarylamine photoconductors |
US3615404A (en) | 1968-04-25 | 1971-10-26 | Scott Paper Co | 1 3-phenylenediamine containing photoconductive materials |
US3717462A (en) | 1969-07-28 | 1973-02-20 | Canon Kk | Heat treatment of an electrophotographic photosensitive member |
BE756943A (en) | 1969-10-01 | 1971-03-16 | Eastman Kodak Co | NEW PHOTOCONDUCTIVE COMPOSITIONS AND PRODUCTS CONTAINING THEM, USED IN PARTICULAR IN ELECTROPHOTOGRAPHY |
US4127412A (en) | 1975-12-09 | 1978-11-28 | Eastman Kodak Company | Photoconductive compositions and elements |
JPS54110837A (en) | 1978-02-17 | 1979-08-30 | Ricoh Co Ltd | Electrophotographic photoreceptor |
JPS5646234A (en) | 1979-09-21 | 1981-04-27 | Ricoh Co Ltd | Electrophotographic receptor |
US4356429A (en) | 1980-07-17 | 1982-10-26 | Eastman Kodak Company | Organic electroluminescent cell |
US4603146A (en) | 1984-05-16 | 1986-07-29 | Kligman Albert M | Methods for retarding the effects of aging of the skin |
US4470988A (en) | 1983-02-10 | 1984-09-11 | Ciba-Geigy Corporation | Benzazocinone and benzazoninone derivatives, and their pharmaceutical use |
US4539507A (en) | 1983-03-25 | 1985-09-03 | Eastman Kodak Company | Organic electroluminescent devices having improved power conversion efficiencies |
JPS61210363A (en) | 1985-03-15 | 1986-09-18 | Canon Inc | Electrophotographic sensitive body |
US4885221A (en) | 1986-12-06 | 1989-12-05 | Kabushiki Kaisha Toshiba | Electrophotography apparatus and electrophtographic process for developing positive image from positive or negative film |
US5091171B2 (en) | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
US4885211A (en) | 1987-02-11 | 1989-12-05 | Eastman Kodak Company | Electroluminescent device with improved cathode |
US4720432A (en) | 1987-02-11 | 1988-01-19 | Eastman Kodak Company | Electroluminescent device with organic luminescent medium |
US4769292A (en) | 1987-03-02 | 1988-09-06 | Eastman Kodak Company | Electroluminescent device with modified thin film luminescent zone |
JPS63295696A (en) | 1987-05-27 | 1988-12-02 | Mitsubishi Electric Corp | Phosphor for cathode ray tube |
US5121029A (en) | 1987-12-11 | 1992-06-09 | Idemitsu Kosan Co., Ltd. | Electroluminescence device having an organic electroluminescent element |
JPH02282263A (en) | 1988-12-09 | 1990-11-19 | Nippon Oil Co Ltd | Hole transferring material |
JP2727620B2 (en) | 1989-02-01 | 1998-03-11 | 日本電気株式会社 | Organic thin film EL device |
US5130603A (en) | 1989-03-20 | 1992-07-14 | Idemitsu Kosan Co., Ltd. | Organic electroluminescence device |
US5077142A (en) | 1989-04-20 | 1991-12-31 | Ricoh Company, Ltd. | Electroluminescent devices |
US4950950A (en) | 1989-05-18 | 1990-08-21 | Eastman Kodak Company | Electroluminescent device with silazane-containing luminescent zone |
US5061569A (en) | 1990-07-26 | 1991-10-29 | Eastman Kodak Company | Electroluminescent device with organic electroluminescent medium |
JP2913116B2 (en) | 1990-11-20 | 1999-06-28 | 株式会社リコー | EL device |
JP3016896B2 (en) | 1991-04-08 | 2000-03-06 | パイオニア株式会社 | Organic electroluminescence device |
ATE238763T1 (en) | 1991-11-25 | 2003-05-15 | Richardson Vicks Inc | USE OF SALICYLIC ACID TO CONTROL SKIN WRINKLES AND/OR SKIN ATROPHY |
AU3073692A (en) | 1991-11-25 | 1993-06-28 | Richardson-Vicks Inc. | Compositions for regulating skin wrinkles and/or skin atrophy |
AU3786093A (en) | 1992-04-30 | 1993-11-29 | American Cyanamid Company | High-power light-emitting diodes for photodynamic therapy |
EP0569827A2 (en) | 1992-05-11 | 1993-11-18 | Idemitsu Kosan Company Limited | Organic electroluminescence device |
IL104052A (en) | 1992-12-10 | 1996-07-23 | Elam Electroluminescent Ind Lt | Electroluminescent light sources |
US5529853A (en) | 1993-03-17 | 1996-06-25 | Sanyo Electric Co., Ltd. | Organic electroluminescent element |
DE69432686T2 (en) | 1993-09-29 | 2004-03-18 | Idemitsu Kosan Co. Ltd. | Acrylenediamine derivatives and organic electroluminescent element containing them |
DE69412567T2 (en) | 1993-11-01 | 1999-02-04 | Hodogaya Chemical Co., Ltd., Tokio/Tokyo | Amine compound and electroluminescent device containing it |
JPH07133483A (en) | 1993-11-09 | 1995-05-23 | Shinko Electric Ind Co Ltd | Organic luminescent material for el element and el element |
DE59510315D1 (en) | 1994-04-07 | 2002-09-19 | Covion Organic Semiconductors | Spiro compounds and their use as electroluminescent materials |
DE69511755T2 (en) | 1994-04-26 | 2000-01-13 | Tdk Corp | Phenylanthracene derivative and organic EL element |
JP2686418B2 (en) | 1994-08-12 | 1997-12-08 | 東洋インキ製造株式会社 | Diarylamine derivative, production method and use thereof |
US5698866A (en) | 1994-09-19 | 1997-12-16 | Pdt Systems, Inc. | Uniform illuminator for phototherapy |
US5707745A (en) | 1994-12-13 | 1998-01-13 | The Trustees Of Princeton University | Multicolor organic light emitting devices |
US5703436A (en) | 1994-12-13 | 1997-12-30 | The Trustees Of Princeton University | Transparent contacts for organic devices |
US6548956B2 (en) | 1994-12-13 | 2003-04-15 | The Trustees Of Princeton University | Transparent contacts for organic devices |
US5608287A (en) | 1995-02-23 | 1997-03-04 | Eastman Kodak Company | Conductive electron injector for light-emitting diodes |
JPH08292586A (en) | 1995-04-21 | 1996-11-05 | Hodogaya Chem Co Ltd | Electrophotographic photoreceptor |
WO1996037001A1 (en) | 1995-05-19 | 1996-11-21 | Uniax Corporation | Electrochemical light-emitting devices |
US5708130A (en) | 1995-07-28 | 1998-01-13 | The Dow Chemical Company | 2,7-aryl-9-substituted fluorenes and 9-substituted fluorene oligomers and polymers |
EP0765106B1 (en) | 1995-09-25 | 2002-11-27 | Toyo Ink Manufacturing Co., Ltd. | Light-emitting material for organic electroluminescence device, and organic electroluminescence device for which the light-emitting material is adapted |
US5753381A (en) | 1995-12-22 | 1998-05-19 | Add Vision Inc | Electroluminescent filament |
US5776623A (en) | 1996-07-29 | 1998-07-07 | Eastman Kodak Company | Transparent electron-injecting electrode for use in an electroluminescent device |
US5776622A (en) | 1996-07-29 | 1998-07-07 | Eastman Kodak Company | Bilayer eletron-injeting electrode for use in an electroluminescent device |
US5844363A (en) | 1997-01-23 | 1998-12-01 | The Trustees Of Princeton Univ. | Vacuum deposited, non-polymeric flexible organic light emitting devices |
KR100462723B1 (en) | 1996-08-12 | 2004-12-20 | 더 트러스티즈 오브 프린스턴 유니버시티 | Flexible orgarnic light emitting device and method of preparing thereof |
US5766779A (en) | 1996-08-20 | 1998-06-16 | Eastman Kodak Company | Electron transporting materials for organic electroluminescent devices |
DE19646119A1 (en) | 1996-11-08 | 1998-05-14 | Hoechst Ag | Electroluminescent device |
JP3654909B2 (en) | 1996-12-28 | 2005-06-02 | Tdk株式会社 | Organic EL device |
US5827186A (en) | 1997-04-11 | 1998-10-27 | Light Sciences Limited Partnership | Method and PDT probe for minimizing CT and MRI image artifacts |
JP3148176B2 (en) | 1998-04-15 | 2001-03-19 | 日本電気株式会社 | Organic electroluminescence device |
US6251127B1 (en) * | 1997-08-25 | 2001-06-26 | Advanced Photodynamic Technologies, Inc. | Dye treatment solution and photodynamic therapy and method of using same |
US5843607A (en) | 1997-10-02 | 1998-12-01 | Xerox Corporation | Indolocarbazole photoconductors |
US5952115A (en) | 1997-10-02 | 1999-09-14 | Xerox Corporation | Electroluminescent devices |
US5942340A (en) | 1997-10-02 | 1999-08-24 | Xerox Corporation | Indolocarbazole electroluminescent devices |
IL122388A (en) * | 1997-12-01 | 2004-05-12 | Atlantium Lasers Ltd | Method and device for disinfecting liquids or gases |
US6140763A (en) | 1998-07-28 | 2000-10-31 | Eastman Kodak Company | Interfacial electron-injecting layer formed from a doped cathode for organic light-emitting structure |
US6137223A (en) | 1998-07-28 | 2000-10-24 | Eastman Kodak Company | Electron-injecting layer formed from a dopant layer for organic light-emitting structure |
EP1029909A4 (en) | 1998-09-09 | 2007-01-10 | Idemitsu Kosan Co | Organic electroluminescence device and phenylenediamine derivative |
US6096066A (en) | 1998-09-11 | 2000-08-01 | Light Sciences Limited Partnership | Conformal patch for administering light therapy to subcutaneous tumors |
US6830828B2 (en) | 1998-09-14 | 2004-12-14 | The Trustees Of Princeton University | Organometallic complexes as phosphorescent emitters in organic LEDs |
GB9822963D0 (en) | 1998-10-20 | 1998-12-16 | Agner Erik | Improvements in or relating to chromatography |
US6208077B1 (en) | 1998-11-05 | 2001-03-27 | Eastman Kodak Company | Organic electroluminescent device with a non-conductive fluorocarbon polymer layer |
US6208075B1 (en) | 1998-11-05 | 2001-03-27 | Eastman Kodak Company | Conductive fluorocarbon polymer and method of making same |
US6361886B2 (en) | 1998-12-09 | 2002-03-26 | Eastman Kodak Company | Electroluminescent device with improved hole transport layer |
US6465115B2 (en) | 1998-12-09 | 2002-10-15 | Eastman Kodak Company | Electroluminescent device with anthracene derivatives hole transport layer |
US6020078A (en) | 1998-12-18 | 2000-02-01 | Eastman Kodak Company | Green organic electroluminescent devices |
US6229259B1 (en) * | 1998-12-22 | 2001-05-08 | Alton O. Christensen, Sr. | Woven polymer fiber video displays with improved efficiency and economy of manufacture |
US6127004A (en) | 1999-01-29 | 2000-10-03 | Eastman Kodak Company | Forming an amorphous fluorocarbon layer in electroluminescent devices |
KR100913568B1 (en) | 1999-05-13 | 2009-08-26 | 더 트러스티즈 오브 프린스턴 유니버시티 | Very high efficiency organic light emitting devices based on electrophosphorescence |
US6074071A (en) | 1999-06-29 | 2000-06-13 | Elam Electroluminescent Industries Ltd. | Aquarium lighting system |
KR100790663B1 (en) | 1999-09-21 | 2008-01-03 | 이데미쓰 고산 가부시키가이샤 | Organic electroluminescence and organic luminous medium |
CN1840607B (en) | 1999-12-01 | 2010-06-09 | 普林斯顿大学理事会 | Complexes of form l2mx as phosphorescent dopants for organic LEDs |
JP4876311B2 (en) | 2000-01-14 | 2012-02-15 | 東レ株式会社 | Light emitting element |
GB2360459B (en) | 2000-03-23 | 2002-08-07 | Photo Therapeutics Ltd | Therapeutic light source and method |
US6660410B2 (en) | 2000-03-27 | 2003-12-09 | Idemitsu Kosan Co., Ltd. | Organic electroluminescence element |
JP4024009B2 (en) | 2000-04-21 | 2007-12-19 | Tdk株式会社 | Organic EL device |
JP4048521B2 (en) | 2000-05-02 | 2008-02-20 | 富士フイルム株式会社 | Light emitting element |
US6645645B1 (en) | 2000-05-30 | 2003-11-11 | The Trustees Of Princeton University | Phosphorescent organic light emitting devices |
US20020121638A1 (en) | 2000-06-30 | 2002-09-05 | Vladimir Grushin | Electroluminescent iridium compounds with fluorinated phenylpyridines, phenylpyrimidines, and phenylquinolines and devices made with such compounds |
CN100505375C (en) | 2000-08-11 | 2009-06-24 | 普林斯顿大学理事会 | Organometallic compounds and emission-shifting organic electrophosphorescence |
JP4154140B2 (en) | 2000-09-26 | 2008-09-24 | キヤノン株式会社 | Metal coordination compounds |
JP4154138B2 (en) | 2000-09-26 | 2008-09-24 | キヤノン株式会社 | Light emitting element, display device and metal coordination compound |
US7318966B2 (en) | 2000-11-24 | 2008-01-15 | Toray Industries, Inc. | Luminescent element material and luminescent element comprising the same |
US20020074937A1 (en) * | 2000-12-18 | 2002-06-20 | Felix Guberman | Flexible material for electrooptic displays |
US6479172B2 (en) | 2001-01-26 | 2002-11-12 | Xerox Corporation | Electroluminescent (EL) devices |
US20040082813A1 (en) | 2001-03-16 | 2004-04-29 | Toshihiro Iwakuma | Method for producting aromatic amino compound |
JP4259875B2 (en) | 2001-03-24 | 2009-04-30 | メルク パテント ゲーエムベーハー | Conjugated polymers containing spirobifluorene units and fluorene units and uses thereof |
US7071615B2 (en) | 2001-08-20 | 2006-07-04 | Universal Display Corporation | Transparent electrodes |
KR100917347B1 (en) | 2001-08-29 | 2009-09-16 | 더 트러스티즈 오브 프린스턴 유니버시티 | Organic light emitting devices having carrier blocking layers comprising metal complexs |
JP4629643B2 (en) | 2001-08-31 | 2011-02-09 | 日本放送協会 | Organic light emitting device and display device |
US7250226B2 (en) | 2001-08-31 | 2007-07-31 | Nippon Hoso Kyokai | Phosphorescent compound, a phosphorescent composition and an organic light-emitting device |
DE10143353A1 (en) | 2001-09-04 | 2003-03-20 | Covion Organic Semiconductors | Conjugated polymers containing spirobifluorene units and their use |
JP2003115387A (en) | 2001-10-04 | 2003-04-18 | Junji Kido | Organic light emitting element and its manufacturing method |
US6835469B2 (en) | 2001-10-17 | 2004-12-28 | The University Of Southern California | Phosphorescent compounds and devices comprising the same |
GB0127581D0 (en) | 2001-11-17 | 2002-01-09 | Univ St Andrews | Therapeutic Light-emitting device |
DE10159946A1 (en) | 2001-12-06 | 2003-06-18 | Covion Organic Semiconductors | Process for the production of aryl-aryl coupled compounds |
US6863997B2 (en) | 2001-12-28 | 2005-03-08 | The Trustees Of Princeton University | White light emitting OLEDs from combined monomer and aggregate emission |
KR100691543B1 (en) | 2002-01-18 | 2007-03-09 | 주식회사 엘지화학 | New material for transporting electron and organic electroluminescent display using the same |
JP2003253145A (en) | 2002-02-28 | 2003-09-10 | Jsr Corp | Light-emitting composition |
JP4256182B2 (en) | 2002-03-14 | 2009-04-22 | Tdk株式会社 | Organic EL device |
SG128438A1 (en) | 2002-03-15 | 2007-01-30 | Sumitomo Chemical Co | Polymer compound and polymer light emitting deviceusing the same |
AU2003241788A1 (en) | 2002-05-28 | 2003-12-12 | Sumitomo Chemical Company, Limited | Polymer and polymeric luminescent element comprising the same |
US7169482B2 (en) | 2002-07-26 | 2007-01-30 | Lg.Philips Lcd Co., Ltd. | Display device with anthracene and triazine derivatives |
JP4025137B2 (en) | 2002-08-02 | 2007-12-19 | 出光興産株式会社 | Anthracene derivative and organic electroluminescence device using the same |
KR100946476B1 (en) | 2002-08-23 | 2010-03-10 | 이데미쓰 고산 가부시키가이샤 | Organic electroluminescence device and anthracene derivative |
JPWO2004034751A1 (en) | 2002-10-09 | 2006-02-09 | 出光興産株式会社 | Organic electroluminescence device |
JP4142404B2 (en) | 2002-11-06 | 2008-09-03 | 出光興産株式会社 | Aromatic amine derivative and organic electroluminescence device using the same |
GB0226010D0 (en) | 2002-11-08 | 2002-12-18 | Cambridge Display Tech Ltd | Polymers for use in organic electroluminescent devices |
JP2004200162A (en) | 2002-12-05 | 2004-07-15 | Toray Ind Inc | Light emitting element |
US6866678B2 (en) | 2002-12-10 | 2005-03-15 | Interbational Technology Center | Phototherapeutic treatment methods and apparatus |
US20060063027A1 (en) | 2002-12-23 | 2006-03-23 | Covion Organic Semiconductors Gmbh | Organic electroluminescent element |
DE10304819A1 (en) | 2003-02-06 | 2004-08-19 | Covion Organic Semiconductors Gmbh | Carbazole-containing conjugated polymers and blends, their preparation and use |
DE10310887A1 (en) | 2003-03-11 | 2004-09-30 | Covion Organic Semiconductors Gmbh | Matallkomplexe |
EP1602648B1 (en) | 2003-03-13 | 2013-04-17 | Idemitsu Kosan Co., Ltd. | Nitrogen-containing heterocycle derivative and organic electroluminescent element using the same |
JP4411851B2 (en) | 2003-03-19 | 2010-02-10 | コニカミノルタホールディングス株式会社 | Organic electroluminescence device |
GB0306409D0 (en) | 2003-03-20 | 2003-04-23 | Cambridge Display Tech Ltd | Electroluminescent device |
US20060261329A1 (en) * | 2004-03-24 | 2006-11-23 | Michele Muccini | Organic electroluminescence devices |
JP2004311184A (en) | 2003-04-04 | 2004-11-04 | Junji Kido | Electron transportation material formed of multinucleate phenanthroline derivative, charge control material, and organic luminescent element using them |
KR20040089567A (en) | 2003-04-14 | 2004-10-21 | 가부시키가이샤 도요다 지도숏키 | Organic electroluminescent element that suppresses generation of ultraviolet light and lighting system that has organic electroluminescent element |
EP1618170A2 (en) | 2003-04-15 | 2006-01-25 | Covion Organic Semiconductors GmbH | Mixtures of matrix materials and organic semiconductors capable of emission, use of the same and electronic components containing said mixtures |
US20040209116A1 (en) | 2003-04-21 | 2004-10-21 | Xiaofan Ren | Organic light emitting devices with wide gap host materials |
US20040209115A1 (en) | 2003-04-21 | 2004-10-21 | Thompson Mark E. | Organic light emitting devices with wide gap host materials |
US7740955B2 (en) | 2003-04-23 | 2010-06-22 | Konica Minolta Holdings, Inc. | Organic electroluminescent device and display |
EP1478032A2 (en) | 2003-05-16 | 2004-11-17 | Kabushiki Kaisha Toyota Jidoshokki | Light emitting diode method for forming the same |
JP2004349138A (en) | 2003-05-23 | 2004-12-09 | Toyota Industries Corp | Organic electroluminescent element and its manufacturing method |
EP1486551B1 (en) | 2003-06-13 | 2016-03-16 | Semiconductor Energy Laboratory Co., Ltd. | Light emitting element and light emitting device |
EP1491568A1 (en) | 2003-06-23 | 2004-12-29 | Covion Organic Semiconductors GmbH | Semiconductive Polymers |
DE10328627A1 (en) | 2003-06-26 | 2005-02-17 | Covion Organic Semiconductors Gmbh | New materials for electroluminescence |
EP1644459B1 (en) | 2003-07-07 | 2017-08-23 | Merck Patent GmbH | Mixtures of organic emissive semiconductors and matrix materials, and electronic components comprising said mixtures |
DE10337346A1 (en) | 2003-08-12 | 2005-03-31 | Covion Organic Semiconductors Gmbh | Conjugated polymers containing dihydrophenanthrene units and their use |
DE10343606A1 (en) | 2003-09-20 | 2005-04-14 | Covion Organic Semiconductors Gmbh | White-emitting copolymers, their preparation and use |
JP2005108556A (en) | 2003-09-29 | 2005-04-21 | Tdk Corp | Organic el element and organic el display |
DE10345572A1 (en) | 2003-09-29 | 2005-05-19 | Covion Organic Semiconductors Gmbh | metal complexes |
US7795801B2 (en) | 2003-09-30 | 2010-09-14 | Konica Minolta Holdings, Inc. | Organic electroluminescent element, illuminator, display and compound |
GB2424895B (en) | 2003-10-01 | 2008-07-09 | Sumitomo Chemical Co | Polymer light-emitting material and polymer light-emitting device |
JP2007517079A (en) | 2003-10-22 | 2007-06-28 | メルク パテント ゲーエムベーハー | Novel materials for electroluminescence and their use |
DE10349033A1 (en) | 2003-10-22 | 2005-05-25 | Covion Organic Semiconductors Gmbh | Organic semiconductor, for use in organic LEDs and solar cells and laser diodes, contains a polymer and structural units which emit light from the triplet state and a triplet emitter |
GB2408209A (en) * | 2003-11-18 | 2005-05-25 | Qinetiq Ltd | Flexible medical light source |
US7029766B2 (en) | 2003-12-05 | 2006-04-18 | Eastman Kodak Company | Organic element for electroluminescent devices |
US6824895B1 (en) | 2003-12-05 | 2004-11-30 | Eastman Kodak Company | Electroluminescent device containing organometallic compound with tridentate ligand |
TW201235442A (en) | 2003-12-12 | 2012-09-01 | Sumitomo Chemical Co | Polymer and light-emitting element using said polymer |
CN101980395B (en) | 2003-12-19 | 2014-05-07 | 出光兴产株式会社 | Organic electroluminescent device |
DE102004008304A1 (en) | 2004-02-20 | 2005-09-08 | Covion Organic Semiconductors Gmbh | Organic electronic devices |
US20080237580A1 (en) | 2004-03-22 | 2008-10-02 | Suguru Okuyama | Organic Semiconductor Element and Organic El Display Device Using the Same |
US7326371B2 (en) | 2004-03-25 | 2008-02-05 | Eastman Kodak Company | Electroluminescent device with anthracene derivative host |
JP4466160B2 (en) | 2004-03-30 | 2010-05-26 | Tdk株式会社 | Organic EL element and organic EL display |
US7790890B2 (en) | 2004-03-31 | 2010-09-07 | Konica Minolta Holdings, Inc. | Organic electroluminescence element material, organic electroluminescence element, display device and illumination device |
KR100787425B1 (en) | 2004-11-29 | 2007-12-26 | 삼성에스디아이 주식회사 | Phenylcarbazole-based compound and Organic electroluminescence display employing the same |
DE102004020298A1 (en) | 2004-04-26 | 2005-11-10 | Covion Organic Semiconductors Gmbh | Electroluminescent polymers and their use |
DE102004023277A1 (en) | 2004-05-11 | 2005-12-01 | Covion Organic Semiconductors Gmbh | New material mixtures for electroluminescence |
WO2005113704A2 (en) | 2004-05-18 | 2005-12-01 | The University Of Southern California | Luminescent compounds with carbene ligands |
CN100368363C (en) | 2004-06-04 | 2008-02-13 | 友达光电股份有限公司 | Anthracene compound and organic electroluminescent apparatus containing it |
JP4862248B2 (en) | 2004-06-04 | 2012-01-25 | コニカミノルタホールディングス株式会社 | Organic electroluminescence element, lighting device and display device |
DE102004031000A1 (en) | 2004-06-26 | 2006-01-12 | Covion Organic Semiconductors Gmbh | Organic electroluminescent devices |
TW200613515A (en) | 2004-06-26 | 2006-05-01 | Merck Patent Gmbh | Compounds for organic electronic devices |
US20060017059A1 (en) * | 2004-07-21 | 2006-01-26 | Eastman Kodak Company | Packaged OLED light source |
US20060094859A1 (en) | 2004-11-03 | 2006-05-04 | Marrocco Matthew L Iii | Class of bridged biphenylene polymers |
EP1655359A1 (en) | 2004-11-06 | 2006-05-10 | Covion Organic Semiconductors GmbH | Organic electroluminescent device |
TW200639140A (en) | 2004-12-01 | 2006-11-16 | Merck Patent Gmbh | Compounds for organic electronic devices |
TW200639193A (en) | 2004-12-18 | 2006-11-16 | Merck Patent Gmbh | Electroluminescent polymers and their use |
KR101169901B1 (en) | 2005-01-05 | 2012-07-31 | 이데미쓰 고산 가부시키가이샤 | Aromatic amine derivative and organic electroluminescent device using same |
KR100803125B1 (en) | 2005-03-08 | 2008-02-14 | 엘지전자 주식회사 | Red phosphorescent compounds and organic electroluminescence devices using the same |
JP4263700B2 (en) | 2005-03-15 | 2009-05-13 | 出光興産株式会社 | Aromatic amine derivative and organic electroluminescence device using the same |
WO2006100896A1 (en) | 2005-03-18 | 2006-09-28 | Idemitsu Kosan Co., Ltd. | Aromatic amine derivative and organic electroluminescence device utilizing the same |
US20060217787A1 (en) | 2005-03-23 | 2006-09-28 | Eastman Kodak Company | Light therapy device |
JP2008140786A (en) | 2005-03-28 | 2008-06-19 | Pioneer Electronic Corp | Methods of manufacturing gate insulating film, organic transistor, and organic electroluminescent display device, and display |
US20060222886A1 (en) | 2005-04-04 | 2006-10-05 | Raymond Kwong | Arylpyrene compounds |
CN101184789B (en) | 2005-04-28 | 2012-05-30 | 住友化学株式会社 | High-molecular compound and high-molecular luminescent device using the same |
CN103204996B (en) | 2005-05-03 | 2015-12-09 | 默克专利有限公司 | Organic electroluminescence device |
DE102005023437A1 (en) | 2005-05-20 | 2006-11-30 | Merck Patent Gmbh | Connections for organic electronic devices |
EP1731953A1 (en) | 2005-06-07 | 2006-12-13 | Sony Ericsson Mobile Communications AB | Improved Visibility Display Device using an Index-Matching Scheme |
WO2007002989A1 (en) | 2005-07-01 | 2007-01-11 | Schefenacker Vision Systems Australia Pty Ltd | Charge conducting medium |
CN101321801A (en) | 2005-10-07 | 2008-12-10 | 住友化学株式会社 | Copolymer and polymer light emitting devices made by using the same |
US7588839B2 (en) | 2005-10-19 | 2009-09-15 | Eastman Kodak Company | Electroluminescent device |
US20070092755A1 (en) | 2005-10-26 | 2007-04-26 | Eastman Kodak Company | Organic element for low voltage electroluminescent devices |
US20070092753A1 (en) | 2005-10-26 | 2007-04-26 | Eastman Kodak Company | Organic element for low voltage electroluminescent devices |
US7553558B2 (en) | 2005-11-30 | 2009-06-30 | Eastman Kodak Company | Electroluminescent device containing an anthracene derivative |
CN102633820B (en) | 2005-12-01 | 2015-01-21 | 新日铁住金化学株式会社 | Compound for organic electroluminescent element and organic electroluminescent element |
DE102005058543A1 (en) | 2005-12-08 | 2007-06-14 | Merck Patent Gmbh | Organic electroluminescent devices |
DE102005058557A1 (en) | 2005-12-08 | 2007-06-14 | Merck Patent Gmbh | Organic electroluminescent device |
US7709105B2 (en) | 2005-12-14 | 2010-05-04 | Global Oled Technology Llc | Electroluminescent host material |
JP4879591B2 (en) | 2006-01-26 | 2012-02-22 | 昭和電工株式会社 | Polymer light-emitting material, organic electroluminescence element, and display device |
EP1818077A1 (en) | 2006-02-03 | 2007-08-15 | WaveLight AG | Phototherapy device for treating the skin |
KR20080094718A (en) | 2006-02-06 | 2008-10-23 | 코닌클리케 필립스 일렉트로닉스 엔.브이. | Body cover, glasses and/or at least partial head cover, method for radiating at least part of a human body and use of a body cover |
KR102103062B1 (en) | 2006-02-10 | 2020-04-22 | 유니버셜 디스플레이 코포레이션 | METAL COMPLEXES OF CYCLOMETALLATED IMIDAZO[1,2-f]PHENANTHRIDINE AND DIIMIDAZO[1,2-A:1',2'-C]QUINAZOLINE LIGANDS AND ISOELECTRONIC AND BENZANNULATED ANALOGS THEREOF |
KR100872692B1 (en) | 2006-03-06 | 2008-12-10 | 주식회사 엘지화학 | New anthracene derivatives and organic electronic device using the same |
DE102006015183A1 (en) | 2006-04-01 | 2007-10-04 | Merck Patent Gmbh | New benzocycloheptene compound useful in organic electronic devices e.g. organic electroluminescent device, polymer electroluminescent device and organic field-effect-transistors |
JP4995475B2 (en) | 2006-04-03 | 2012-08-08 | 出光興産株式会社 | Benzanthracene derivative and organic electroluminescence device using the same |
US20070252517A1 (en) | 2006-04-27 | 2007-11-01 | Eastman Kodak Company | Electroluminescent device including an anthracene derivative |
KR100805038B1 (en) | 2006-05-04 | 2008-02-20 | 주식회사 엘지화학 | Organic Light Emitting Diode And Method For Preparing Thereof |
EP2018674A1 (en) | 2006-05-12 | 2009-01-28 | Merck Patent GmbH | Indenofluorene polymer based organic semiconductor materials |
DE102006025777A1 (en) | 2006-05-31 | 2007-12-06 | Merck Patent Gmbh | New materials for organic electroluminescent devices |
US7582508B2 (en) | 2006-05-31 | 2009-09-01 | Byoung-Choo Park | Method for manufacturing an organic semiconductor device that utilizes ionic salt |
DE102006025846A1 (en) | 2006-06-02 | 2007-12-06 | Merck Patent Gmbh | New materials for organic electroluminescent devices |
DE102006031990A1 (en) | 2006-07-11 | 2008-01-17 | Merck Patent Gmbh | New materials for organic electroluminescent devices |
JP2009544772A (en) | 2006-07-21 | 2009-12-17 | メルク パテント ゲーエムベーハー | Copolymer of indenofluorene and thiophene |
JPWO2008016018A1 (en) | 2006-08-04 | 2009-12-24 | 出光興産株式会社 | Material for organic electroluminescence device and organic electroluminescence device using the same |
US8062769B2 (en) | 2006-11-09 | 2011-11-22 | Nippon Steel Chemical Co., Ltd. | Indolocarbazole compound for use in organic electroluminescent device and organic electroluminescent device |
JP4478166B2 (en) | 2006-11-09 | 2010-06-09 | 三星モバイルディスプレイ株式會社 | Organic light-emitting device provided with organic film containing organometallic complex |
JP2008124156A (en) | 2006-11-09 | 2008-05-29 | Idemitsu Kosan Co Ltd | Organic el material-containing solution, method for forming thin film of organic el material, thin film of organic el material, and organic el device |
JP5294872B2 (en) | 2006-11-20 | 2013-09-18 | 出光興産株式会社 | Organic electroluminescence device |
CN101198233A (en) * | 2006-12-08 | 2008-06-11 | 奥斯兰姆奥普托半导体有限责任公司 | Electric appliance |
DE102007002714A1 (en) | 2007-01-18 | 2008-07-31 | Merck Patent Gmbh | New materials for organic electroluminescent devices |
US8168963B2 (en) * | 2007-01-19 | 2012-05-01 | Ratcliffe William R | System and methods for self-decontaminating a surface |
JP4902381B2 (en) | 2007-02-07 | 2012-03-21 | 昭和電工株式会社 | Polymer of polymerizable compound |
US7687678B2 (en) * | 2007-05-10 | 2010-03-30 | Cisco Technology, Inc. | Electronic bandage with flexible electronic controller |
TWI468489B (en) | 2007-05-29 | 2015-01-11 | Nippon Steel & Sumikin Chem Co | Organic electroluminescent element compounds and organic electroluminescent elements |
DE102007024850A1 (en) | 2007-05-29 | 2008-12-04 | Merck Patent Gmbh | New materials for organic electroluminescent devices |
JP4519946B2 (en) | 2007-05-30 | 2010-08-04 | 新日鐵化学株式会社 | Compound for organic electroluminescent device and organic electroluminescent device |
US7645142B2 (en) | 2007-09-05 | 2010-01-12 | Vivant Medical, Inc. | Electrical receptacle assembly |
EP2202818B1 (en) | 2007-09-28 | 2014-11-12 | Idemitsu Kosan Co., Ltd. | Organic el device |
DE102008017591A1 (en) | 2008-04-07 | 2009-10-08 | Merck Patent Gmbh | New materials for organic electroluminescent devices |
US20100016844A1 (en) | 2008-07-21 | 2010-01-21 | Patel Jr Manoj B | Transilluminating foley catheter to facilitate prostate and bladder surgery |
US20100123385A1 (en) * | 2008-11-18 | 2010-05-20 | Willorage Rathna Perera | Electroluminescent fibers, methods for their production, and products made using them |
US8404273B2 (en) * | 2009-04-24 | 2013-03-26 | Old Dominion University Research Foundation | Wound care system and bactericidal methods and devices |
-
2011
- 2011-02-15 EP EP11704723A patent/EP2544765A1/en not_active Withdrawn
- 2011-02-15 JP JP2012556400A patent/JP6246468B2/en not_active Expired - Fee Related
- 2011-02-15 US US13/634,101 patent/US9539438B2/en not_active Expired - Fee Related
- 2011-02-15 KR KR1020127026665A patent/KR20130020883A/en not_active Application Discontinuation
- 2011-02-15 WO PCT/EP2011/000707 patent/WO2011110277A1/en active Application Filing
-
2016
- 2016-06-01 JP JP2016110275A patent/JP2016193208A/en active Pending
- 2016-12-23 US US15/389,655 patent/US20170100607A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4234907A (en) * | 1979-01-29 | 1980-11-18 | Maurice Daniel | Light emitting fabric |
US20060012294A1 (en) * | 1998-12-22 | 2006-01-19 | Christensen Alton O Sr | Electroluminescent devices and displays with integrally fabricated address and logic devices fabricated by printing or weaving |
US6538375B1 (en) * | 2000-08-17 | 2003-03-25 | General Electric Company | Oled fiber light source |
US7144249B2 (en) * | 2000-11-15 | 2006-12-05 | Biolase Technology, Inc. | Device for dental care and whitening |
US20030099858A1 (en) * | 2001-11-27 | 2003-05-29 | General Electric Company One Research Circle | Environmentally-stable organic electroluminescent fibers |
US7304201B2 (en) * | 2002-06-12 | 2007-12-04 | University Of Florida Research Foundation, Inc. | Phototherapy bandage |
US20060149342A1 (en) * | 2004-12-30 | 2006-07-06 | Industrial Technology Research Institute | Light therapeutic device |
US20070251526A1 (en) * | 2006-04-28 | 2007-11-01 | Marc Alan Zocher | Treatment of airflow |
US20100010593A1 (en) * | 2006-08-07 | 2010-01-14 | Koninklijke Philips Electronics N.V. | System of plaster and radiation device |
US20100114263A1 (en) * | 2008-11-04 | 2010-05-06 | Pressler Tiffany J | Phototherapy garment |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10753575B2 (en) | 2015-07-30 | 2020-08-25 | Vital Vio, Inc. | Single diode disinfection |
US11713851B2 (en) | 2015-07-30 | 2023-08-01 | Vyv, Inc. | Single diode disinfection |
US12018801B2 (en) | 2015-07-30 | 2024-06-25 | Vyv, Inc. | Single diode disinfection |
US10918747B2 (en) | 2015-07-30 | 2021-02-16 | Vital Vio, Inc. | Disinfecting lighting device |
US12069939B2 (en) | 2017-04-26 | 2024-08-20 | Oti Lumionics Inc. | Method for patterning a coating on a surface and device including a patterned coating |
US11581487B2 (en) | 2017-04-26 | 2023-02-14 | Oti Lumionics Inc. | Patterned conductive coating for surface of an opto-electronic device |
US10617774B2 (en) | 2017-12-01 | 2020-04-14 | Vital Vio, Inc. | Cover with disinfecting illuminated surface |
US10835627B2 (en) | 2017-12-01 | 2020-11-17 | Vital Vio, Inc. | Devices using flexible light emitting layer for creating disinfecting illuminated surface, and related method |
WO2019108432A1 (en) * | 2017-12-01 | 2019-06-06 | Vital Vio, Inc. | Cover with disinfecting illuminated surface |
US11426474B2 (en) | 2017-12-01 | 2022-08-30 | Vyv, Inc. | Devices using flexible light emitting layer for creating disinfecting illuminated surface, and related methods |
WO2019108431A1 (en) * | 2017-12-01 | 2019-06-06 | Vital Vio, Inc. | Devices using flexible light emitting layer for creating disinfecting illuminated surface, and related method |
US10309614B1 (en) | 2017-12-05 | 2019-06-04 | Vital Vivo, Inc. | Light directing element |
US11751415B2 (en) | 2018-02-02 | 2023-09-05 | Oti Lumionics Inc. | Materials for forming a nucleation-inhibiting coating and devices incorporating same |
US10806812B2 (en) | 2018-03-29 | 2020-10-20 | Vital Vio, Inc. | Multiple light emitter for inactivating microorganisms |
US11395858B2 (en) | 2018-03-29 | 2022-07-26 | Vyv, Inc. | Multiple light emitter for inactivating microorganisms |
US10413626B1 (en) | 2018-03-29 | 2019-09-17 | Vital Vio, Inc. | Multiple light emitter for inactivating microorganisms |
US11730012B2 (en) | 2019-03-07 | 2023-08-15 | Oti Lumionics Inc. | Materials for forming a nucleation-inhibiting coating and devices incorporating same |
US11639897B2 (en) | 2019-03-29 | 2023-05-02 | Vyv, Inc. | Contamination load sensing device |
US12101987B2 (en) | 2019-04-18 | 2024-09-24 | Oti Lumionics Inc. | Materials for forming a nucleation-inhibiting coating and devices incorporating same |
US12069938B2 (en) | 2019-05-08 | 2024-08-20 | Oti Lumionics Inc. | Materials for forming a nucleation-inhibiting coating and devices incorporating same |
US11541135B2 (en) | 2019-06-28 | 2023-01-03 | Vyv, Inc. | Multiple band visible light disinfection |
US11717583B2 (en) | 2019-08-15 | 2023-08-08 | Vyv, Inc. | Devices configured to disinfect interiors |
US11369704B2 (en) | 2019-08-15 | 2022-06-28 | Vyv, Inc. | Devices configured to disinfect interiors |
US12115267B2 (en) | 2019-08-15 | 2024-10-15 | Vyv, Inc. | Devices configured to disinfect interiors |
US11878084B2 (en) | 2019-09-20 | 2024-01-23 | Vyv, Inc. | Disinfecting light emitting subcomponent |
US11985841B2 (en) | 2020-12-07 | 2024-05-14 | Oti Lumionics Inc. | Patterning a conductive deposited layer using a nucleation inhibiting coating and an underlying metallic coating |
Also Published As
Publication number | Publication date |
---|---|
US9539438B2 (en) | 2017-01-10 |
JP2016193208A (en) | 2016-11-17 |
KR20130020883A (en) | 2013-03-04 |
JP6246468B2 (en) | 2017-12-13 |
WO2011110277A1 (en) | 2011-09-15 |
EP2544765A1 (en) | 2013-01-16 |
US20130006119A1 (en) | 2013-01-03 |
JP2013524864A (en) | 2013-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170100607A1 (en) | Fibers in therapy and cosmetics | |
US9373807B2 (en) | Radiative fibers | |
EP2510072B1 (en) | Therapeutic and cosmetic electroluminescent compositions | |
EP2675524B1 (en) | Device and method for treatment of cells and cell tissue | |
US9385337B2 (en) | Nanocrystals on fibers | |
KR101720828B1 (en) | Nanocrystals in devices |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MERCK PATENT GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BUCHHOLZ, HERWIG;PAN, JUNYOU;AYDT, EWALD;SIGNING DATES FROM 20170307 TO 20170328;REEL/FRAME:041881/0843 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |